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Abstract 
Live, attenuated measles virus (MV) has demonstrated tumour-specific replication 
and anti-tumour activity in murine models of hematological and non-hematological 
malignancy, leading to a number of published or on-going clinical trials. However, 
the potentially overriding issue of how to achieve successful administration of 
oncolytic measles virotherapy in patients with intact humoral immunity remains.  
 
I have examined mechanisms for optimizing delivery of oncolytic MV to acute 
lymphoblastic leukaemia (ALL) – a disseminated haematological malignancy. Anti 
MV antibody titres in adult patients with ALL were evaluated before and after 
leukaemia treatment regimens including high dose corticosteroids, cyclophosphamide 
and anti-B cell monoclonal antibodies. Antibody titres were unaffected by induction 
and intensification treatment protocols, suggesting the need for consideration of 
optimal virotherapy delivery strategies to achieve therapeutic success. Here, I 
demonstrate that human bone marrow-derived mesenchymal stromal cells (BM-
MSCs) can be used effectively as virus delivery vehicles, permitting ex-vivo cellular 
virus loading and intracellular virus amplification, delivery of virus to distant sites of 
disease following systemic infusion, and virus hand-off to precursor B lineage ALL 
cell targets in the presence of pre-existing anti-MV antibodies. In vivo modelling 
using SCID mice bearing disseminated pre-B ALL xenografts demonstrated enhanced 
survival of passively immunized animals following IV treatment with BM-MSC-
delivered MV versus naked MV or BM-MSCs alone.  
 
In order for vaccine MV to be safely and rationally utilized as a novel therapeutic for 
ALL, a detailed mechanistic understanding of how the virus exerts its oncolytic effect 
is paramount. In this thesis, I have utilized a previously characterized model of 
cellular transformation generated using human BM-MSCs to characterize the 
phenomenon of relative tumour cell specificity by oncolytic MV, in terms of 
infectivity, productivity and cell killing. Furthermore, this thesis begins to explore 
some of the potential mechanisms that confer vaccine MV its tumour-tropic and anti-
cancer properties.
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Chapter 1:  Introduction 
1.1 Cancer therapy landscape 
1.1.1 Conventional therapies 
Since early attempts at chemotherapy over half a century ago, the progress that has 
been made in the development of chemotherapy drugs and cancer treatment protocols 
cannot be denied. Whilst this fact remains, chemotherapy regimens are frequently 
accompanied by unavoidable toxicities, and initial successes can be hampered by the 
development of potential chemoresistance and subsequent disease relapse. In the last 
2 decades, heralded by the successes of the tyrosine kinase inhibitor (TKI) imatinib as 
an effective targeted treatment for chronic myeloid leukaemia (CML), the advances in 
our understanding of the molecular basis of cancer biology has paved the way for the 
development of other rationally designed targeted cancer therapies. However, the 
revolutionary successes of imatinib and CML treatment have not been replicated in 
other diseases. Although targeted therapies have shown modest responses in certain 
diseases, efficacy is often hampered by the complexity of molecular cancer biology 
pathways in the majority of both haematological and non-haematological 
malignancies, and the ability of tumours to evolve and develop resistance to highly 
specific anti-cancer mechanisms. The developments of monoclonal antibodies - such 
as the anti-CD20 targeted compound Rituximab – has led to improvements in cancer 
outcomes for a number of haematological diseases when used in combination with 
existing chemotherapies, but despite such successes, there undoubtedly remains a 
need to develop novel non-cross reactive cytotoxic treatments showing multi-pronged 
mechanisms of action, efficacy in a number of different cancer types, amenability to 
administration by desired routes, and favourable side effect profiles when used either 
alone or in combination with existing treatments.  
1.1.2 Oncolytic virotherapies 
Using viruses to treat cancer is not a novel concept. Viruses have attracted interest as 
anti-cancer therapeutics since the beginning of the 20
th
 century, when cases of viruses 
causing spontaneous tumour regressions were first reported
1,2
. Remissions were most 
often seen in the context of haematological malignancies, but were usually short-
 21 
lived. Interest in using different live viruses to treat cancer patients waned in the 
1970-80’s following safety concerns regarding the use of wild-type viruses in the 
clinical setting
3
, the anticipation of potential technical limitations to virus 
manufacture, and the prioritization of the development of other treatment strategies 
such as monoclonal antibodies or molecularly targeted treatments
4
. However, the last 
30 years has seen a resurgence of interest in cancer virotherapy paralleling our 
increased understanding of the nature of viruses, their mechanisms of oncolytic 
activity, and their potential for genetic manipulation and exploitation in order to 
achieve desired aims.  
 
Oncolytic viruses are characterized by their ability to preferentially infect and lyse 
transformed cells whilst leaving normal cells relatively unharmed. Their attraction as 
novel therapeutics is several-fold and includes their lack of cross resistance with 
existing therapies, their likely multi-pronged mechanisms of action, and their relative 
specificity for target cells, lending them favourable side effect profiles. Whilst 
considerable academic progress has been made in the field of cancer virotherapy, the 
pace of clinical progress has been dictated by an initial paucity of activity in early 
phase clinical trials. The complex biological interactions between viruses and 
humans, and difficulties in modeling such interactions in pre-clinical studies, have 
provided challenges to the rapid development of virotherapy agents. Despite these 
challenges, the recent years have seen a concerted effort by the oncolytic virotherapy 
community to push promising pre-clinical products through phase I and early phase II 
clinical trials, with a shortlist of candidates - having demonstrated safety and efficacy 
- being taken forward by biotherapeutic companies into pivotal phase III trials.
  
 
2
2
 
Table 1-1: Overview of oncolytic virotherapy clinical trial activity. 
Virus Trial phase Tumour type 
Adenovirus 1-3 Squamous cell carcinoma of head and neck (SCCHN); Lung metastases; 
glioma; sarcoma; ovarian/pancreatic/colorectal/hepatobiliary cancers 
Coxsackie 1-2 Melanoma; SCCHN; solid tumours 
Herpes simplex virus 1-3 Solid tumours; melanoma; SCCHN; glioma; melanoma; mesothelioma; 
breast cancer; colorectal cancer + liver metastases 
Measles virus (Edmonston strain) 1 Cutaneous T-cell lymphoma; ovarian cancer; glioma; myeloma; 
mesothelioma; SCCHN 
Newcastle disease virus 1-2 Glioma; solid tumours 
Parvovirus 1-2 Glioma 
Poliovirus 1 Glioma 
Reovirus 1-3 Glioma; peritoneal cancer; solid tumours; colorectal cancer; sarcoma; 
melanoma; SCCHN; pancreatic cancer; lung cancer 
Seneca valley virus 2 Small cell lung cancer 
Retrovirus 1-2 Glioma  
Vaccinia virus 1-3 Colorectal cancer; hepatocellular carcinoma; melanoma 
Vesicular stomatitis virus 1-2 Solid tumours; SCCHN; hepatocellular carcinoma 
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1.1.2.1 Advanced phase clinical trial activity 
A handful of promising oncolytic virotherapy candidates have now reached advanced 
phase clinical trial status. Talimogene laherparepvec (T-VEC) was the first oncolytic 
virus to demonstrate proven efficacy in a phase III clinical trial. Based on a strain of 
herpes simplex virus 1 (HSV-1), T-VEC has been modified to enhance tumour 
specificity, and promote anti-tumour immune responses (by insertion of the human 
granulocyte/monocyte – colony stimulating factor (GM-CSF) gene). In a phase II 
trial, using intralesional T-VEC in a cohort of heavily pre-treated patients with 
advanced malignant melanoma, overall response rates of 26% (with 16% complete 
responses) were seen, with survival rates of 52% at 2 years (medial overall survival 
16 months)
5
. Following on from this success, the US Food and Drug Administration 
(FDA) approved a special protocol assessment using this drug for patients with stage 
III and IV malignant melanoma. Interim phase III trial data in over 400 patients has 
showed a significant improvement in objective response and durable response rates 
over the control arm (GM-CSF alone), with a trend toward improved overall 
survival
6
. Reolysin – an oncolytic agent based on wild-type Reovirus (serotype 3 
Dearing strain) is being developed as a novel treatment for a number of different 
cancers. Published phase II data using intravenously administered Reolysin in patients 
with metastatic melanoma showed good tolerability. Whilst no objective responses 
were seen, 75-90% tumour necrosis – consistent with clinical effect – was seen in one 
patient with lesions surgically removed, and future phase II trials in this disease are 
targeted towards combination therapy with virus and standard cytotoxic compounds
7
. 
Phase II trials have also shown efficacy in head and neck cancers, and as with T-VEC, 
Reolysin has a US FDA special protocol assessment for an ongoing phase III clinical 
trial of intravenously delivered Reolysin in combination with paclitaxel and 
carboplatin for head and neck cancer. JX-594 (Pexa-Vec) is another promising 
oncolytic agent based on a Vaccinia poxvirus with a deleted thymidine kinase gene 
(improving tumour cell targeting), and modulated to express the human GM-CSF 
gene (improving anti-tumour immune responses). Published phase I data in primary 
hepatocellular carcinoma (HCC) demonstrated safety and tolerability. Early phase II 
trial results showing enhanced survival benefit for patients with heavily pre-treated, 
advanced HCC when treated with high doses of intratumoural Pexa-Vec
8
 have paved 
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the way for a phase III trial in this disease, and have led to Pexa-Vec being assigned 
‘orphan drug’ designation by the US FDA in 2013 for the treatment of HCC.  
1.1.2.2 Measles virus (MV) clinical trial activity 
The first case reports alluding to the oncolytic potential of MV were published in 
1971 and detailed transient tumour regressions in patients with leukaemia, Hodgkin 
lymphoma or Burkitt’s lymphoma9-13.  Since this time, there has been considerable 
academic progress in the field of oncolytic measles virotherapy, but as with many 
other oncolytics, clinical trial activity has lagged behind. Despite vaccine MV 
showing tumour-specific replication and anti-tumour activity in pre-clinical models of 
lymphoma
14-16
, myeloma
17,18
, acute lymphoblastic leukaemia (ALL)
19
, ovarian 
cancer
20,21
, glioma
22-25
 and breast cancer
26,27
, the early challenges in ensuring the 
appropriateness of pre-clinical animal models for a virus with humans as its only 
natural host, and our relatively limited mechanistic understanding of what confers 
vaccine MV its oncolytic capabilities, have undoubtedly contributed to the slow pace 
of clinical development for this complex biological agent. Despite these challenges, 
early phase clinical trial data shows great promise. As well as demonstrating little in 
the way of toxicity, published phase I data has demonstrated efficacy of 
intratumourally-injected vaccine MV in patients with cutaneous T cell lymphoma
28
, 
and favourable median survival rates (12.15 months compared to expected 6 months) 
following intraperitoneal injection of MV (modified to express the marker peptide 
carcinoembryonic antigen (CEA) to aid real-time monitoring of viral gene expression) 
to patients with recurrent ovarian cancer
29
. More recently, systemically administered 
MV (engineered to express the human iodide symporter gene (MV-NIS) - to allow for 
noninvasive radioiodine imaging) has been used in a phase I clinical trial to treat 
patients with relapsed, drug-refractory multiple myeloma. Early reports detail clinical 
responses with a reduction in paraprotein and resolution of bone marrow (BM) 
plasmacytosis in 2 patients treated at the highest dose of 10
11 
TCID50  (50% tissue 
culture infectious dose) infectious units of MV-NIS, with one patient showing durable 
complete remission at all disease sites. Toxicities were mild and self-limiting, and 
tumour targeting was elegantly demonstrated by NIS-mediated radioiodine uptake in 
virally infected tumours. Of note in this study, the initial 2 responders were measles-
seronegative, alluding to the potential role of anti-measles antibodies in abrogating 
efficacy of this otherwise promising new therapeutic
30
. 
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Table 1-2: MV clinical trials. 
Author/year Trial  
design 
No. of 
patients 
Patient population Protocol Side effects Efficacy  
Galanis et al.  2010 Phase I 21 Platinum refractory 
recurrent ovarian cancer; 
normal CEA. 
MV-CEA (derived 
from MV-NSe) 
(intraperitoneal) every 
4 weeks; max. 6 cycles; 
(10
3
 to 10
9
 TCID50). 
Grade 1-2 
only. 
Median survival:  2.15 
months (1.3-38.4).  
 
Heinzerling et al. 
2005 
Phase I 5 (6 lesions) Histologically 
demonstrated cutaneous 
T cell lymphoma stage 
IIb or higher; resistant or 
relapsed after 
conventional treatment; 
pre-existing MV 
immunity. 
MV- Edmonston-
Zagreb x16 injections 
(intratumoural) upto 2 
cycles (10
2
 to 10
3
 
TCID50); pre-treatment 
with Interferon alpha.  
Grade 1 only. 5/6 lesions treated 
showed clear regressions 
within 28 days of initial 
treatment; one 
disappearance; distant 
non-injected lesions 
improved in 2 patients. 
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NCT00390299  Phase I Recruiting Patients with recurrent 
glioblastoma multiforme 
(GBM), pre-existing 
immunity to MV and 
candidates for gross total 
or subtotal tumour 
resection. 
MV-CEA (derived 
from MV-NSe) (10
5
 to 
2x10
7
 TCID50). Group 
A: direct MV-CEA 
into resection cavity; 
Group B: direct tumour 
admin. followed by 
resection and second 
intra-cavity dose. 
No dose 
limiting 
toxicities 
observed thus 
far.  
Awaited. 
NCT00450814 
Interim report: 
Russell et al. 2014 
Phase I Recruiting Patients with recurrent or 
refractory multiple 
myeloma.  
MV-NIS (derived from 
MV-NSe) (10
6
 to 10
11
 
TCID50). Group A: 
Single intravenous 
injection. Group B: 
Pre-treatment with 
cyclophosphamide 
10mg/kg 2 days prior 
to intravenous MV-NIS 
single dose. 
Systemic 
response to 
virus infusion 
at highest 
dose, 
resolving 
within 1 week 
of treatment. 
2 x good responses, one 
being a complete 
response at highest dose.  
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1.2 MV overview 
MV is a highly pathogenic morbillivirus from the Paramyxoviridae family. 
Predominantly a childhood infection (although occurring at any age), cases in general 
are rare in the UK as a result of immunization programmes. However, vaccination 
rates in the UK were severely affected after, now discredited, claims of a link between 
the MMR (Measles-Mumps-Rubella) vaccine and autism, with MMR uptake reaching 
its lowest levels in 2003-4 and subsequent outbreaks seen in England and Wales in 
2012-2014. Measles infection is characterized by a period of latency (10-14 days) 
followed by symptoms including cough, fever, Koplik’s spots and a maculopapular 
rash. Whilst complications are more likely in children with defects in cell mediated 
immunity, MV itself causes a characteristic suppression of cell-mediated immunity in 
the infected host that can contribute to serious secondary infections even after 
resolution of viraemia. Rare but serious complications of Measles involve the central 
nervous system and include include acute disseminated encephalomyelitis (ADEM) – 
an autoimmune demyelinating disease usually occurring within weeks of infection in 
children over the age of 4 years, Measles inclusion body encephalitis (MIBE) – a 
progressive infection occurring in immunocompromised individuals who cannot clear 
the virus, and the rare brain disease – subacute sclerosing panencephalitis (SSPE), 
which can occur in immunologically normal children several years after contracting 
wild-type measles infection.  
1.2.1 MV strains 
Wild-type MV was first isolated by Enders and Peebles in 1954, from a patient - 
David Edmonston - using cultured human embryonic kidney cells
31
. Further 
attenuated of this strain was achieved by serial tissue culture passage in human kidney 
cells, human amnion cells, embryonated hens’ eggs, and chicken embryonic fibroblast 
cells in tissue culture. The resultant MV-Edm strain, now in widespread laboratory 
use, has mutated in order to replicate efficiently in cell culture, and is immunogenic 
without causing viraemia or clinical symptoms of disease. MV-Edm became the 
progenitor virus of many commonly utilized vaccine strains
32
. Naniche et al. showed 
that in contrast to wild type MV strains, vaccine strains induced high levels of 
interferon (IFN) in peripheral blood mononuclear cells, and were more sensitive to 
exogenous IFN
33
. Subsequently, changes primarily in the MV P/V/C (and M, H and 
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L) genes have been implicated in the mechanisms conferring attenuation of virus 
virulence
34-37
. MV remains a single serotype (monotypic), with serum samples from 
patients naturally infected with measles decades ago still containing antibodies that 
can neutralize currently circulating wild type strains
38
, and vaccination conferring 
lifelong immunity. Despite the expected inherent error rate in RNA synthesis, and the 
lack of proof-reading capacity of the viral RNA-dependent RNA polymerase (RdRp), 
there is minimal genomic variability between existing MV strains. Sequencing of 
many virus strains has been accomplished, and has identified 23 different viral 
genotypes distributed over 8 clades
39
.  Sequence analysis of genes encoding for the F, 
H, N and M proteins of Edmonston-derived and non-Edmonston-derived vaccine MV 
strains has shown remarkable sequence similarity amongst coding and non-coding 
regions
40
. 
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Figure 1-1: Edmonston vaccine lineage (adapted from Rota et al. 1994). Schematic representation of the 
Edmonston vaccine strains. Moraten (blue box) is the currently used UK vaccine strain of virus. MV-NSe (pink 
box) is the laboratory-adapted strain used for all experiments detailed in this thesis.  
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1.2.2 Virion structure 
MV is a negative sense single-stranded RNA virus. Within the lipid bilayer envelope 
(derived from the host cell) is the viral ribonucleoprotein complex (RNP), consisting 
of viral proteins (N, P and L) and viral genome essential for virus propagation
41
. The 
viral genome is 15894 nucleotides in length, and follows the ‘rule of six’42, whereby 
to form a proper nucleocapsid template for efficient replication, genomic RNA must 
contain a total number of nucleotides which is a multiple of six, to allow complete 
encapsidation by the N protein. The viral genome encodes for 6 genes, separated by 
trinucleotide intergenic sequences. Genes are preceded by a Leader (Le) sequence at 
the 3’ end, and a Trailer (Tr) sequence at the 5’ end. The MV genome is encapsidated 
by the phosphorylated protein N (nucleocapsid), and is closely associated with L 
protein (large protein) responsible for providing the enzymatic activity of the RNA 
polymerase complex, and the viral protein P (phosphoprotein) - a polymerase cofactor 
associating with the RNP complex. The RNP complex is surrounded by the M protein 
(matrix protein), which serves to anchor overlying envelope proteins and regulate 
viral transcription. Proteins V and C are non-structural proteins encoded by the P 
gene. V protein prevents interferon (IFN)-induced transcriptional responses and 
signaling. C protein also prevents type 1 IFN transcriptional responses, acts as an 
infectivity factor, and plays a role in the regulation of replication and transcription. 
The type 2 and type 1 transmembrane glycoproteins H (haemagglutinin) and F 
(fusion) are responsible for virus attachment and fusion respectively. 
  
      
3
1
 
Figure 1-2: MV structure. (A) Schematic diagram of virion structure, with colours of MV genes (B) corresponding to viral 
proteins. MV haemagglutinin (H) and fusion (F) are embedded in the lipid envelope, anchored by the matrix protein (M). 
The RNA genome is encapsidated by nucleoprotein (N), with phosphoprotein (P) and large protein (L) forming the RNA 
dependent RNA polymerase complex (RdRp). (B) Organisation of the MV genome. Transcription gradient is generated by 
detachment of viral RdRp at the intergenic sites. 
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1.2.3 MV replication cycle 
1.2.3.1 Entry 
Target cell entry is mediated by MV cell surface glycoproteins H and F. The F 
glycoprotein is initially in a biologically inactive state (F0), but becomes activated 
upon proteolytic cleavage by ubiquitously expressed furin-like proteases, to form an 
F1-F2 complex held together by a disulfide bridge between 2 cysteine residues (a 
feature of all Paramyxoviruses). The interaction between H and F leads to alterations 
in protein structure and creates fusion complexes
43
 that permit entry of viral RNPs 
into the cytoplasm upon interaction with cellular receptors
44
 (see below).  
1.2.3.2 Viral RNA synthesis 
Once viral nucleocapsid is released into the cytoplasm, primary transcription can 
occur. The viral polymerase transcribes the genomic template starting at the 3’ end, in 
order to generate a positive Leader sequence, and successive capped and 
polyadenylated mRNAs, by stopping and starting at each intergenic region. Because 
of this, there exists a ‘gradient of transcription’, whereby mRNAs are generated in 
decreasing molar abundance from the N to the L position.  
1.2.3.3 Genome replication 
Once primary transcription (and translation) has generated sufficient viral proteins, 
MV-N (along with viral P) starts to assemble the nascent Leader chain. By the 
coordinated assembly and synthesis of the RNA, the polymerase is prompted to 
ignore the junctions between individual genes, with eventual yield of the full-length 
antigenomic nucleocapsid. The viral antigenomic structure serves as an intermediate 
template in genomic replication, and is also though to potentially play a role in 
preventing the host cell from undergoing apoptosis
45
.  
1.2.3.4 Virion assembly and release 
MV components assemble in the cytoplasm, and virion budding takes place from sites 
on the plasma membrane of the host cell where viral components have accumulated. 
Budding and release of virions (with lipid envelopes derived from the host cell 
surface membrane) requires the coordination of multiple viral components is achieved 
via complex interactions between proteins (including MV-M protein), lipids and the 
host cell machinery.  
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For replication to be a success, RNA viruses utilize their intimate relationship with 
host cell and cellular machinery. A number of interactions between MV and host 
factors have been described that bind and influence MV replication (including heat 
shock protein 72 (HSP72)
46-48
, casein kinase II
49
, and peroxiredoxin 1 (Prdx 1))
50
. 
However, a comprehensive understanding of the involvement of such host factors in 
MV RNA synthesis is lacking. 
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Figure 1-3: The MV replication cycle (adapted from Griffin et al. 2007). 
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1.2.4 MV receptors 
MV causes a productive infection in humans and certain non-human primates only, 
with tropism and pathogenicity being determined by virus receptor specificity. Until 
recently, there were only two well-characterized viral receptors. Whilst signaling 
lymphocyte activation molecule (SLAM, or CD150) is known to act as the primary 
receptor for wild-type virus strains, vaccine and laboratory-adapted strains show a 
wider cell specificity, with the ability to utilize both SLAM and more efficiently the 
membrane cofactor protein, CD46
51
. The discovery of a third receptor – Nectin 4 - 
has led to a further advance in our understanding of MV entry and dissemination 
during infection.  
1.2.4.1 CD46 
CD46 – a C3b/C4b-binding type I transmembrane glycoprotein that acts as an 
inhibitor of complement-mediated lysis - is ubiquitously expressed on all human 
nucleated cells, and was the first receptor identified for the attenuated strain MV-Edm 
in 1993
52,53
. A number of different isoforms of the receptor exist, but all of the four 
primary isoforms of CD46 are able to serve as MV receptors - permitting infection, 
cell fusion, and virus cell-to-cell transmission when expressed in rodent cell lines
54
. 
The ability of MV strains to utilize CD46 as a cellular receptor is determined by a 
single amino acid substitution in the haemagglutinin (H) protein at position 481 
(asparagine to tyrosine) (H481NY)
55-58
. Furthermore, serial passage of MV strains on 
human HEp-2 or Vero cells results in selection of viruses with tyrosine substitutions 
at position 481, and adaption to CD46 receptor usage
59
, suggesting that this may be an 
in vitro phenomenon. The structure of CD46 consists of four short consensus repeats 
(SCR1-4), a serine-threonine-proline (STP) rich region, a transmembrane domain and 
a cytoplasmic tail. Binding of the MV-H glycoprotein to SCR1 and 2 is crucial for 
viral entry via this receptor
60,61
. Following cellular infection via CD46, vaccine and 
attenuated strains induce contact-mediated downregualtion of this receptor – making 
cells more sensitive to complement mediated lysis and potentially promoting virus 
clearance. This may in part explain the observation that attenuated MV strains which 
utilize CD46 as the primary entry receptor in vitro, do not preferentially target this 
receptor in vivo
62
. 
  
      36 
1.2.4.2 SLAM (CD150) 
SLAM is a membrane glycoprotein expressed on immune cells, which acts as the 
primary cellular receptor for wild-type MV strains
55,63,64
. As a member of the 
immunoglobulin superfamily, SLAM was initially identified as a co-stimulatory 
receptor for T cells. It has a role in enhancing T cell proliferation, cytotoxicity and 
IFNγ production65. Activated T cells, immature thymocytes, memory T cells and a 
fraction of B cells all express high levels of SLAM
66,67
 with moderate expression seen 
on dendritic cells (DCs)
68,69
 and monocytes
70
. The tissue distribution of SLAM is in 
keeping with the lymphotropic nature of wild-type MV, and contributes to our 
understanding of measles disease progression. Wild-type H glycoprotein-expressing 
virus strains can enter cells through SLAM 2-3 times more efficiently than they do 
Vero cells expressing CD46. Conversely, virus strains possessing the H protein of 
attenuated MV-Edm enter CD46-expressing cells twice as efficiently as SLAM-
expressing cells in vitro
58
. In addition to MV, the importance of SLAM as a virus 
entry receptor for morbilliviruses is evidenced by conserved usage throughout the 
genus, with canine distemper virus (CDV) and rinderpest using canine and bovine 
SLAM respectively. SLAM consists of an extracellular domain with variable (V) and 
constant (C2) regions, and a cytoplasmic tail with three tyrosine-based motif repeats. 
Three residues (I60, H61, V63) have been identified on the V domain of SLAM as 
being required for binding to MV-H
71
, with at least ten other residues being involved 
in SLAM-dependent fusion, and one of these – I194, being critical for receptor 
binding
72
. As with CD46, receptor downregulation on host cells occurs following 
cellular infection, and may play a role in the suppression of cell-mediated immunity 
seen during active measles infection
73-75
. 
1.2.4.3 Nectin-4 
Whilst experimental infections of non-human primates with enhanced green 
fluorescent protein (eGFP)-expressing strains of MV showed infection of SLAM 
positive lymphocytes and DCs during the peak of virus replication
76
, infection of 
CD46 and CD150 negative cells was also evident in vitro and in vivo
77-79
 . By 
comparing microarray data of upregulated membrane-associated genes in wild-type 
MV-susceptible and non-susceptible cell lines, the search for an additional MV 
receptor - allowing wild-type virus entry into SLAM-negative epithelial cells - led to 
the discovery of Nectin 4 (PVRL4) by two independent groups
80,81
. Nectin 4 is 
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exclusively localized on the basolateral epithelial surface, and acts as an adherens 
junction protein that interacts with the MV-H protein via its membrane distal domain. 
The location of Nectin 4 on the basolateral surface is in keeping with the observation 
that epithelial cells cannot be infected via their apical surface
77-79,82,83
. Discovery of 
this receptor has progressed our understanding of measles pathogenesis. It is now 
thought that initial MV infection in the respiratory tract is SLAM-dependent. MV-H 
attaches to alveolar macrophages or DCs
84,85
 via DC-SIGN, a C-type lectin found on 
the surface of these cells
86,87
. Attachment subsequently results in upregulation of 
intracellular SLAM to the cell surface
88
, and infected cells can then transmit the virus 
to draining lymph nodes. MV infection of activated B and T cells within the lymph 
nodes can occur via SLAM, leading to virus propagation and primary viraemia. 
Dissemination of virus to secondary lymphoid organs (including spleen, thymus and 
tonsils) leads to a secondary viraemia and acute immunosuppression. Spread of virus 
within lymphocytes or DCs to distal sites including liver, skin, gastrointestinal tract, 
genital and respiratory mucosal surfaces leads to virus shedding. Transmission of 
virus via the submucosa to epithelial cells within the respiratory tract takes place via 
basolateral Nectin 4
83
, and virus is shed from the apical epithelial cell surface 
resulting in respiratory transmission to the next host
80,81,89
.  
1.2.4.4 Cell-to-cell spread in subacute sclerosing pan-encephalitis (SSPE) 
Although MV is known to infect cells of the human central nervous system (CNS), 
the mechanisms utilized by MV to gain neuronal cell entry and spread from cell to 
cell remain unclear. It has been suggested that infection may occur via endothelial 
cells at the blood-brain barrier (BBB)
90
, or via infected lymphocytes within the 
CNS
91
. Whilst strong CD46 expression can be seen on cerebral endothelial cells, 
weaker CD46 expression is detectible on subsets of neurons and oligodendrocytes 
within normal brain tissue, and is not detectible in MV-positive tissues in SSPE 
brains. In SSPE brains only a small subset of SLAM-positive lymphocytes can be 
detected, and no SLAM is found on cells commonly infected by MV
92
. Whilst the 
role of Nectin 4 in endothelial cell and neuronal cell infection is not clear, the 
possibility of an additional neuronal receptor for MV that facilitates neuronal 
infection remains. Non-permissive differentiated human neurons have been shown to 
become susceptible to MV following contact and fusion with permissive 
neuroepithelial cells in vitro, suggesting a requirement for contact and trans-synaptic 
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passage of virus
93
, and a possible role for the substance P receptor neurokinin-1
94
. 
Attenuated transcription and translation of viral RNA within neurons is thought to 
allow low level virus persistence but very low levels of virus protein production
93
, 
and may contribute to the pathogenesis of SSPE, where little infectious virus or viral 
antigen can be recovered, whilst viral RNA has been detected
95,96
. 
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Figure 1-4: MV receptors (adapted from Dhiman et al. 2004). Schematic representation of CD46, 
SLAM and Nectin 4. STP domain: serine-threonine-proline-rich domain; V: variable domain; C: constant 
domain. Numbers 1-4 represent CD46 short consensus repeats (SCR). 
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1.2.5 Host immune responses to MV 
1.2.5.1 Detection of RNA viruses by the host cell 
Cellular antiviral innate immune responses, and counteracting virus strategies 
ultimately mediate the outcome of cellular MV infection. Pathogen-associated 
molecular patterns (PAMPs) (including the presence of viral RNA or protein) are 
detected by cellular pattern recognition receptors (PRRs) that influence cellular 
antiviral inflammatory and type 1 IFN responses. Cytosolic pattern-recognition 
receptors and transmembrane toll-like receptors (TLRs) are two classes of PRRs 
described in the detection of MV
97
.  
1.2.5.1.1 RIG-I like receptors 
The RIG-I like receptors (RLRs) are cytosolic receptors expressed at low levels by 
most resting human cells, that are upregulated upon the detection of RNA viruses
98-
100
. Family members of known importance in RNA viral signaling include retinoic 
acid-inducible gene I (RIG-I), melanoma differentiation-associated antigen 5 (MDA-
5) and laboratory of genetics and physiology 2 (LGP-2). Both RIG-I and MDA-5 
contribute to the recognition of MV. Whilst MDA-5 is generally thought to bind 
double stranded RNA (dsRNA) fragments
101
, there is evidence of its involvement in 
the generation of IFN responses by MV
102,103
. RIG-I can detect both single-stranded 
(ssRNA) or short dsRNA
104. Upon cellular entry and virus replication, viral 5’-
triphosphate ssRNA structures bind to the C-terminal domain of RIG-I, triggering 
exposure of the caspase recruiting domain (CARDs)-like regions at the N-terminus. 
CARD domains are then able to interact with other CARD-containing proteins and 
initiate signaling via the IFN β promoter stimulator 1 (IPS-1), otherwise known as 
mitochondrial anti-viral signaling protein (MAVS)
105
. Signaling via IPS-1 (by both 
MDA-5 and RIG-I) on the outer mitochondrial membrane influences the induction of 
proinflammatory cytokines and type 1 IFN responses via IFN response family 3 
(IRF3) and nuclear factor kappa beta (NF-κβ) activation106, with IPS-1-deficient mice 
showing impaired production of proinflammatory cytokines and defective type 1 IFN 
responses upon RNA virus stimulation
107
. The recently identified adapter molecule – 
stimulator of IFN genes (STING) – also found on the mitochondrial membrane, is 
also thought to interact with RIG-I and IPS-1, although its role in antiviral immune 
signaling has yet to be fully elucidated
108
. IRF3 and NF-κβ activation lead to IFNβ 
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production, induction of IFN response factor 7 (IRF7) gene expression, and the 
subsequent enhancement of cellular type 1 IFN responses. LGP-2, another member of 
the RLR family, does not directly initiate antiviral gene expression, but is known to 
have negative regulatory functions on RIG-I signaling and cellular antiviral responses 
to RNA viruses
109
.  
1.2.5.1.2 Toll-like receptors 
TLRs are transmembrane glycoproteins consisting of an extracellular N-terminal 
PAMP-binding region and a C-terminal intracellular signaling moiety. Of the 10 
family members, TLR-2, 3, 4, 7 and 8 are known to be involved in detection of RNA 
viruses with TLR-2 being the best described example utilized by MV
110
. TLR-2 is 
known to recognize viral glycoproteins (such as the MV-H glycoprotein) rather than 
viral nucleic acids, and is expressed on the surface of immune cells including 
macrophages and DCs. Downstream signaling via this receptor ultimately leads to 
stimulation of a proinflammatory cytokine response
111
, and potentially additional type 
1 IFN responses via the transcription factor NF-κβ112. TLR-7 and 8, present in the 
endosomal compartment, are also known to be involved in the detection of ssRNA 
from virions internalized and digested within endosomes
113,114
. As MV enters the cell 
via direct membrane fusion rather than by utilizing endosomes, this pathway is likely 
to play less of a predominant role here.  
1.2.5.2 Host innate immune responses 
As described above, one of the early non-specific innate immune responses to MV 
infection is the induction of a type 1 IFN antiviral response. Following measles 
immunization, elevated levels of IFN and IFN-induced proteins can be detected in the 
blood
115
. IFNs act in either an autocrine or paracrine manner, binding to their cognate 
receptors on infected and neighbouring uninfected cells, and leading to 
phosphorylation and activation of signal transducers and activators of transcription 1 
and 2 (STAT1 and 2) via janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2)
116
. 
Phosphorylated STAT 1 and 2 heterodimers then translocate to the nucleus to form 
IFN-stimulated gene factor 3 (ISGF3) that binds to IFN-stimulated response elements 
(ISREs) and drives the expression of multiple interferon-stimulated genes (ISGs), and 
production of proteins with a role in establishing an antiviral state (including MxA, 
PKR, and ADAR1)
117-121
. Type 1 IFNs also stimulate DC maturation, natural killer 
(NK) cell cytotoxicity, and maturation of virus-specific cytotoxic T cells
122
, reflecting 
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the influence that initial innate antiviral immune responses have on lasting adaptive 
immunity. 
1.2.5.3 Host adaptive immune responses 
Whilst MV infection is associated with host immunosuppression, strong and specific 
cellular and humoral immune responses against MV are induced that are crucial for 
virus clearance and longterm protection from infection respectively. The onset of the 
maculopapular rash in measles-infected individuals heralds the development of MV-
specific CD8+ T-cell responses, and the detection of anti-MV antibodies
123,124
. 
Production of IFNβ has been shown to result in upregulation of MHC class I 
expression on infected cells in vitro
125
, and is thought to contribute to the recognition 
of MV-infected cells by CD8+ T lymphocytes in vivo. Spontaneous proliferation of 
MHC class II restricted CD4+ T cells also occurs in response to MV infection, with 
elevated levels of soluble CD4 in the plasma of infected individuals
74
. Whilst early 
stages of MV infection result in the generation of a Th1 cytokine profile designed to 
promote clearance of virally infected cells (with production of IFNγ and IL-2 leading 
to activation of macrophages and proliferation of T cells respectively)
126
, Th2 
responses (with production of IL-4 and IL-10) that favour the generation of anti-MV 
antibodies and immunological memory predominate in later infection
73
. The 
preferential activation of type 2 CD4+ T cells in later infection is also thought to 
contribute to the generalized suppression of cellular immune responses seen with 
measles infection, with IL-4 contributing to suppressed in vitro lymphoproliferative 
responses to mitogens, and potentially inhibiting NK cell induction, decreasing 
delayed-type hypersensitivity, and decreasing macrophage activation
74
. Initial anti-
MV antibody responses are in the form of IgM, but are ultimately overtaken by 
production of MV-specific IgG1 and IgG3 – mediators of virus neutralisation124. 
Antibodies against MV-N, H, F and M have all been detected
127
, but the N protein is 
most abundantly expressed during infection, and therefore antibodies against MV-N 
predominate. Despite this, it is thought that anti-MV-N antibodies have limited 
biological function, and antibodies directed against the H and F glycoproteins are 
more important for virus neutralization
128
.  
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1.2.6 MV mechanisms to combat host immunity 
Wild-type MV strains have devised mechanisms to evade the host IFN responses, and 
are therefore much less efficient in their triggering of type 1 IFN production than 
vaccine strains
33
. MV proteins P, V and C have all been implicated in the negative 
regulation of viral PRRs. Wild-type V protein is known to interact with and inhibit 
MDA-5 signaling
129,130
, and via its interaction with LGP-2, the V protein can inhibit 
signaling through RIG-I
131
. Downstream, the V protein has been shown to interact 
with IRF3 and IRF7 to inhibit their transcriptional activities
132,133
, wild-type MV-C 
protein can accumulate in the nucleus of the host cell and directly downregulate IFNβ 
transcription
134
, and MV proteins P, V and C have all been shown to bind and block 
NF-κβ signaling135. Virus proteins can also inhibit antiviral signaling via JAK/STAT 
by preventing nuclear import of activated STAT
136,137
 (N and V proteins), promoting 
degradation of STAT1 (P protein)
138
, and blocking JAK phosphorylation (V and P 
proteins)
139
. ADAR1 – a dsRNA-specific adenosine deaminase - was previously 
thought to have antiviral properties and limit MV cytotoxicity by causing mutations in 
the M protein gene
140
. However, recent evidence suggests that ADAR1 may also play 
a paradoxical role in suppressing antiviral IFN responses, and suppressing the 
activation of dsRNA-dependent protein kinase (PKR) triggering by MV
141
. 
Conversely, PKR has antiviral activity via the amplification of IFNβ induction by 
MV. These effects are counteracted by the MV C protein
142
. Further work is required 
for an elaborate understanding of how MV fights other antiviral effects.  
 
In contrast to wild-type MV, vaccine strains have been shown to contain C proteins 
with disrupted nuclear localization signals (NLS), allowing triggering of more robust 
antiviral responses, and contributing to their attenuated pathogenicity
134
. Mutations in 
vaccine MV-V protein genes result in a lack of MDA-5 suppression and more robust 
IFN responses
143,144
. Vaccine strains of MV are also known to induce stronger IFN 
responses via enhanced production of defective interfering (DI) RNA particles
145
. 
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1.3 MV as an oncolytic virotherapy agent 
As previously described, evidence of the oncolytic capability of MV emerged with 
early case reports detailing transient but significant tumour regressions following 
wild-type measles infection. Whilst wild-type MV is a serious pathogen – responsible 
for millions of deaths worldwide
146
, vaccine strains of the virus have a number of 
properties making them well suited to therapeutic use in anticancer strategies. 
1.3.1 Vaccine MV therapeutic suitability 
1.3.1.1 Specificity and efficacy in haematological malignancies 
Live, attenuated Edmonston B vaccine strain MV (MV-Edm) and its derivatives are 
the most commonly used virus strains in experimental models of oncolysis. In 
haematological malignancies, MV-Edm has demonstrated selective replication in 
myeloma cell lines in vitro, with pre-infected cell lines showing reduced ability to 
form tumours in severe combined immunodeficient (SCID) mouse models in vivo, 
and regression of pre-formed tumours upon intratumoural injection. Partial tumour 
regressions were also seen when virus was administered systemically to established 
myeloma xenografts
147
. Successful pre-clinical modeling of MV oncolysis in 
myeloma led to the currently active phase I clinical trial, where promising responses 
are being seen. Using MV-Edm and MVlacZ (a strain of MV-Edm genetically 
modified by the addition of a beta-galactosidase reporter gene) in SCID mouse 
models of both aggressive (Raji) and indolent (DoHH2) B-cell lymphoma, tumour 
regressions proportional to tumour size, were seen with intratumoural virus 
administration (in contrast to ultraviolet inactivated (UV)-MV treated tumours) even 
in the presence of passively transferred anti-MV antibodies, whilst systemic 
administration of virus also slowed the growth of established tumours
14
. In the case of 
acute lymphoblastic leukaemia (ALL), large multinucleate syncytia were seen 
following MV-NSe infection of primary ALL cell cultures, with rapid cell death in 
vitro. In vivo, intratumoural MV-NSe treatment of established subcutaneous NALM-6 
precursor B-ALL SCID mouse xenografts demonstrated striking antitumour activity 
in all cases, with antitumour activity also being evident in disseminated xenografts 
following intravenous virus delivery
19
.   
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1.3.1.2 Safety 
Vaccine strains of MV have been administered to more than a billion people in the 
last 40 years, as part of a worldwide immunization programme, and have 
demonstrated an excellent safety record
148
. Immunity in the majority of individuals in 
the developed world, and the limited tropism of MV, results in the absence of an 
existing human or animal reservoir for this pathogen, and reduces the likelihood of 
recombination events with other environmental organisms. Furthermore, the negative 
sense, non-segmented genomic RNA structure of MV results in a non-integrating, 
highly genetically stable pathogen with limited capacity for recombination between 
virus strains
149
.  
1.3.1.3 Ability to manipulate the MV genome 
In addition to the above, there are a number of virus considerations that make MV a 
sensible choice as an oncolytic agent. In 1995, the first reverse genetics system was 
used to successfully rescue MV from cloned cDNA
150
, and the possibility of 
engineering the MV genome was introduced. Methodology will be described in more 
detail in Chapter 4. Pleiomorphic and tolerant of manipulation, the MV genome has 
been extensively engineered allowing for insertion of therapeutic transgenes or 
traceable markers as additional transcription units, to aid efficacy and traceability. 
Genetic engineering has also allowed for manipulation of virus entry to specific cell 
types.  
1.3.1.3.1 Enhancing oncolytic efficacy and virus surveillance 
Oncolytic MV has been ‘armed’ by the expression of prodrug convertases to enhance 
efficacy when used in combination with chemotherapeutics
16,151
. It has been 
manipulated to express therapeutic proteins such as GM-CSF and G-CSF with 
favourable effects on therapeutic outcome being demonstrable in vivo
152
. MV has also 
been engineered to exploit cancer-specific proteases, by introducing proteases 
expressed at high levels, or preferentially expressed in cancer cells such as matrix 
metalloproteases (MMPs) into the virus glycoprotein cleavage domains
153
. In addition 
to such strategies, MV has been manipulated to express proteins such as 
carcinoembryonic antigen (CEA) or β-human chorionic gonadotrophin (β-hCG) 
upstream of MV-N to allow for measurement of concentration of virally encoded 
marker peptides in culture supernatants or serum20,154. The introduction of NIS 
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– the sodium iodide symporter gene – has allowed for effective tracking of virus 
replication, and enhancement of its therapeutic effect when administered in 
conjunction with radioiodine (
131
I)
18
. 
1.3.1.3.2 Targeting MV tropism 
The ability to target MV entry to specific cell types has meant that evermore 
sophisticated and specific viruses have been generated with the aim of enhancing MV 
oncolytic efficacy, reducing off-target side effects, and at the same time addressing 
some of the potential safety concerns of systemically administering a replicating virus 
with a ubiquitously expressed native receptor.  Early targeting attempts were focused 
on creating viruses that could enter non-permissive cells via the creation of hybrid 
proteins consisting of growth factors such as epidermal-derived growth factor (EGF) 
or insulin-like growth factor-1 (IGF-1) linked to the extracellular (carboxyl) terminus 
of the MV-Edm attachment glycoprotein H. Such viruses were successfully rescued, 
propagated, and shown to be able to enter CD46-negative rodent cells expressing EGF 
or IGF-1 receptors respectively
155
.  Following on from these early experiments, 
successful targeting was achieved by creating similar hybrid H proteins using single 
chain antibodies against a range of different receptors including CEA
156
, CD20
157
 and 
CD38
158
, targeting tumour vasculature by the expression of disintegrin M28L 
echistatin
159
, or targeting specific MHC ligands by the expression of high affinity 
single chain T-cell receptors (scTCR)
160
. With the discovery of the residues in the 
MV-H glycoprotein important for CD46 and SLAM receptor binding, ablation of the 
natural virus binding to CD46 or SLAM followed
161
. This was closely succeeded by 
the development of viruses blind to both CD46 and SLAM, that could gain cellular 
entry via non-native receptors due to additional ligands (EGF) or single chain 
antibodies (scFVantiCD38) on the mutated MV-H glycoprotein
162
. Such viruses could 
be rescued and propagated on Vero-α-His cells expressing a single chain antibody 
recognizing a 6-histidine peptide expressed by the receptor blind viruses at the C 
terminus of their ablated H protein. 
1.3.2 Mechanisms of MV-mediated oncolysis 
Multiple mechanisms have been proposed for the action of oncolytic viruses. Primary 
mechanisms inducing tumour regression (including direct viral cytolysis of tumour 
cells, and induction of tumour cell apoptosis) have been proposed for vaccine MV
163-
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165
, alongside secondary mechanisms of action such as immune-mediated anti-tumour 
responses, resulting in tumour regressions in murine xenograft models in the face of 
limited viral intratumoural spread
14
. However, there is little evidence to suggest why 
vaccine MV may exert such effects in tumour cells but not in healthy normal cells. 
Cellular differences between malignant and non-malignant cells exploited by vaccine 
MV have historically extended only as far as differences in CD46 receptor density. 
CD46 was shown to be overexpressed in certain malignant cells, as compared to their 
non-transformed counterparts
166
, with cell-cell fusion being minimal at low receptor 
densities, and increasing significantly above a threshold in vitro
167
. Whist 
undoubtedly of influence upon experimental in vitro and pre-clinical modeling 
systems, the role of tumour cell CD46 upregulation in the clinical successes seen in 
early phase trials is unclear. As previously described, attenuated MV strains known to 
utilize CD46 as the primary entry receptor in vitro, do not preferentially target this 
receptor in vivo
62
. An additional potential mechanism for the tumour cell-selectivity 
of MV vaccine strains results from defective type 1 IFN pathways in neoplastic cells. 
A recent study examining antiviral responses in MV susceptible and non-susceptible 
sarcoma cell lines, demonstrated an inhibition of viral replication and strong 
upregulation of the cytoplasmic PRR molecule RIG-I, and the IFN-stimulated gene 
(ISG) IFIT1, with enhanced and persistent phosphorylation of IFN-stimulated STAT1 
in the MV-resistant cell lines. In contrast, MV-susceptible cell lines demonstrated 
weaker, delayed, or absent expression of IFIT1 and phosphorylation of STAT1, that 
was corrected with exogenous IFNβ administration, suggesting that differences in 
innate immune responses (cytoplasmic pathogen receptors and ISGs) may account for 
differential susceptibility of cells to vaccine MV-mediated killing in this model
168
.   
 
In contrast to vaccine MV, cellular mechanisms exploited by other oncolytic viruses 
are better characterized. Studies of Reovirus and HSV1 have revealed target 
specificity for cells with activated RAS signaling pathways
169,170
, a feature in up to 
30% of cancers
171
. Myxoma virus, a rabbit -specific poxvirus with oncolytic activity 
in humans, has been shown to exploit dysregualted Akt signaling pathways in a 
variety of cancer cells
172
. In addition, cellular susceptibility is thought to be further 
modulated by tumour suppressor pathways, with defects in p53, ATM and pRB all 
having being implicated in cancer cell specificity
173
. Defects in tumour suppressor 
function have also been linked to anti-cancer activity of the EB1 gene knockout 
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oncolytic adenovirus (ONYX-015), demonstrating replication and killing in p53 
dysfunctional human tumour cells, but not cells with an intact p53 pathway
174
. 
Subsequent reports have however challenged p53-selectivity as a mechanism, and as 
such the progression of this oncolytic virus through phase III clinical trials has 
slowed
175
.  
1.3.3 Immune barriers to oncolytic virotherapy 
Although genetic engineering approaches have allowed sophisticated manipulations 
of the MV genome to be undertaken, there remains the real and potentially overriding 
issue of how such viruses can be delivered successfully to distant or widespread sites 
of tumour in patients with intact immunity. The importance of immune shielding may 
be underestimated when viruses are initially tested against human tumours in 
immunodeficient animal models. MV replication is specific to primates, with its only 
natural host being humans. Studies using human tumour xenografts established in 
immune deficient rodents are limited to looking at MV distribution or replication 
within the tumour tissue itself. Although CD46 transgenic rodent models have been 
generated, vaccine strains of MV only replicate well in such models if another 
immune defect (such as defects in the IFN receptor
176
, or RAG-1 knockout
177
) is also 
present. Hence accurate evaluation of the impact of the immune system on systemic 
virotherapy delivery is a challenge.  
1.3.3.1 Reticuloendothelial system 
Off-target binding or sequestration is likely to limit the efficacy of systemically 
administered oncolytic virotherapy, by reducing the circulatory half-life (t/2) and 
bioavailability of the virus concerned. In a recent publication, intravenously delivered 
oncolytic MV was sequestered by the mononuclear phagocytic system (MPS) of the 
liver and the spleen in vaccine MV-receptor CD46-positive and CD46-negative mice. 
Virus elimination from the systemic circulation was rapid, with a t/2 of only 1 
minute
178
. With respect to another oncolytic virus, the administration of vesicular 
stomatitis virus (VSV) via the intravenous route to immunocompetent, virus naïve 
mice with hind flank tumours led to successful tumour cell delivery and intratumoural 
virus amplification. However, examination of virus biodistribution showed that 
systemic virus delivery was far from efficient, with <0.001% of virions reaching 
tumour, and the vast majority being taken up from the circulation by the liver and 
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spleen. Despite this, barriers posed by the reticuloendothelial system were overcome 
when virus was administered in sufficient doses
179
. 
1.3.3.2 T-cell immunity 
As previously described, evidence of T cell activation occurs during the prodromal 
phase of measles infection, and full expression of the response coincides with the 
appearance of the classical MV exanthem. CD8+ and CD4+ MV-specific T cell 
responses are generated, with both playing a role in elimination of infected cells, 
either by class 1-restricted cytotoxic mechanisms (CD8+), or by local cytokine 
secretion resulting in attraction, activation or deactivation of macrophages, and in 
proliferation and differentiation of B and T cells (CD4+). There is evidence that 
replication of vaccine viruses can be prolonged in persons who are 
immunosuppressed or immunodeficient, with case reports linking measles vaccine 
virus infection to subsequent death in at least six severely immunocompromised 
persons. Whilst the importance of cell-mediated immunity in virus clearance has been 
unequivocally demonstrated
123
, children infected with asymptomatic human 
immunodeficiency virus (HIV) have been shown to have no increase in adverse 
events following vaccination, as compared with controls
180
, and patients with 
leukaemia in remission who have not received chemotherapy for at least 3 months 
may be vaccinated against the disease. Following vaccination with live, attenuated 
MV strains, cytotoxic T-cell responses elicited after re-challenge with MV are less 
robust than after natural infection
181
, and although T cell-mediated immune responses 
are likely to play a role in the clearance of oncolytic measles virotherapy, these 
cellular defense mechanisms are often defective in the setting of malignancy. The 
implications of this, and the true limitations that vaccine generated, MV-specific 
cytotoxic T-cell responses pose to the efficacy of oncolytic measles virotherapy 
treatment are at present unknown, and require further elucidation. Potential 
mechanisms for this include adoptive transfer of T cells engineered to express MV-
specific T cell receptors, into immunocompromised xenograft hosts.  
1.3.3.3 Humoral immunity 
Oncolytic viruses can be neutralized in the bloodstream by pre-existing antiviral 
antibodies. With each virus exposure, anamnestic responses result in augmentation of 
antibody titres, an increased likelihood of virus inactivation, and reduction in 
therapeutic efficacy. Anti-MV neutralising antibodies are likely to inhibit the delivery 
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of MV to target sites, prevent target cell infection, and prevent spread of virus within 
tumour cells. In pre-clinical models, SCID mice bearing disseminated KAS 6/1 
myeloma xenografts showed an inferior survival following passive immunization with 
anti-measles antibody, before treatment with MV-NIS as compared to those without 
passive immunization before therapy (50 days vs. 72 days; p<0.0001)
182
. In athymic 
mice bearing established SKOV3ip.1 ovarian tumour xenografts, a significant 
difference in survival was seen when using naked MV-NIS in measles-naïve mice 
versus measles immune mice (P<0.0001)
183
. From these and other pre-clinical 
examples, it is clear that neutralizing antibodies pose a real and significant barrier to 
effective systemic measles virotherapy, and ways to overcome such barriers are 
required. One potential mechanism would be ablation of the epitopes for antibody 
binding. However, clinically relevant neutralizing anti-measles antibodies are directed 
against multiple epitopes on MV H and F – and it is therefore inconceivable that 
mutations could be introduced to ablate all such epitopes. Early clinical trial data 
regarding the significance of anti-MV antibodies is conflicting, with no correlation 
seen between clinical responses and humoral immune status for patients receiving 
intraperitoneally-delivered MV on the phase I ovarian cancer trial, but robust 
responses to intravenously-delivered MV seen only in seronegative phase I myeloma 
patients. 
1.3.4 Overcoming the immune response to MV 
Investigating strategies that can be employed to enable viruses to overcome the 
barriers posed by an intact immune system will potentially enhance their therapeutic 
applicability and efficacy. 
1.3.4.1 Immunosuppression 
Temporary immunosuppression, such as with the co-administration of virotherapy 
and chemotherapy, has been used in attempt to improve therapeutic efficacy of a 
number of oncolytic viruses, including MV
15,184
. In virus-susceptible mice, primary 
antibody responses to intravenously administered oncolytic MV or VSV were 
partially or completely suppressed by multidose regimens of oral or systemic 
cyclophosphamide (CPA) initiated 1 day before virus delivery. However, in the case 
of MV, the majority of individuals requiring treatment will have pre-existing 
antibodies following vaccination. It is of note therefore, that when MV-immune or 
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VSV-immune mice were re-challenged and concurrently treated with multiple doses 
of systemically delivered CPA, anamnestic antibody responses were completely 
suppressed, with titres falling below clinically significant levels
185
. Although such 
strategies may facilitate repeat virotherapy dosing, they raise issues in terms of the 
type, level and duration of immunosuppression that can be safely delivered whilst 
ensuring that viral proliferation is not allowed to proceed in an uncontrolled and 
potentially dangerous manner. Furthermore, there is a growing body of evidence 
alluding to the potential contributory role of both innate and cellular immune 
responses in the mechanism of viral oncolysis that may be abrogated by utilizing such 
strategies.  
1.3.4.2 Envelope-chimeric MVs 
By exchanging the MV envelope with that of the closely related virus CDV, Miest 
and colleagues
186
 were able to generate a chimeric virus capable of escaping 
neutralization by sera from both MV-immunized mice and measles immune humans, 
whilst retaining its oncolytic efficacy. Although this strategy is appealing and appears 
to allow for successful virus delivery for initial injections, it is likely that neutralizing 
antibodies generated towards the novel virus envelope would quickly develop, and 
anamnestic responses would preclude repeat administration.  
1.3.4.3 Carrier cell strategies 
In order to circumvent humoral immunity there has been increasing interest in the use 
of cell-based delivery systems as a novel platform for the targeted delivery or 
‘chaperoning’ of oncolytic viruses to sites of tumour. Success of this strategy is 
dependent on successful ex-vivo carrier cell loading with oncolytic virus, effective 
cellular targeting of tumour sites following systemic administration, and successful 
virus hand-off at tumour site. All of this must take place whilst evading immune 
attack. As well as being susceptible to viral infection, the ideal cell based vector 
would act as a miniature factory within which virus amplification can take place.  
A number of different cell types have undergone evaluation for this purpose with 
varying degrees of therapeutic success. Although a number show promise in pre-
clinical studies, in reality many of the potential candidates are technically difficult to 
isolate and either expensive or difficult to expand ex-vivo, making their use in the 
clinical setting logistically difficult. 
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Table 1-3: Cell-carrier-based systemic virotherapy (adapted from Power et al. 2007). 
Cell type Advantages Disadvantages 
 
PRIMARY LEUCOCYTES 
  
 
Tumour-specific CD8+ T cells 
 
 Trafficking to tumour antigen 
 Activation at tumour site 
 Additional antitumour cell cytotoxicity 
 
 Difficult to isolate and expand 
 Low infection efficiency 
 
Activated T cells  
 
 More readily infected than unstimulated 
cells 
 Antitumour cell cytotoxicity  
 
 Difficult isolation and activation procedure 
 
Cytokine-induced-killer cells 
(CIK) 
 
 Traffic to tumours 
 Tumour cell cytotoxicity  
 
 Difficult isolation and expansion 
 
Dendritic cells 
 
 Additional antitumour activity  
 
 Difficult isolation and expansion 
 
IMMORTALISED CELL LINES 
  
 
Solid tumour 
 
 Easily propagated in vitro 
 Support productive infection 
 
 Requires ablation of proliferative capacity 
due to risk of malignant growth 
 
Haematological  
 
 Support productive infection 
 Can disseminate systemically 
 
 Requires ablation of proliferative capacity 
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PROGENITOR CELLS 
  
 
Outgrowth endothelial cells  
 
 Engraftment in tumour vasculature 
 Easily propagated in vitro 
 
 Requires intermittent re-isolation from 
clinical samples 
 
Mesenchymal stromal cells 
 
 Easily isolated and expanded ex-vivo 
 Tumour homing potential  
 Can engraft in tumour stroma for targeted 
delivery  
 
 Intermittent re-isolation required 
 Infection efficiency less than that of 
transformed cells 
 
Neuronal stem cells 
 
 Targeted delivery in GBM  
 
 Increased virus productivity and superior 
efficacy when compared to MSCs in glioma 
model 
  
      54 
Activated T cells
188
, monocytes
189
, tumour associated macrophages
190
, and 
mesenchymal stromal cells (MSCs)
183
 have all been investigated as cellular vectors 
for oncolytic measles virotherapy. Ong et al.
188
 used activated T cells to deliver 
oncolytic MV to NOD/SCID mice bearing myeloma xenografts. They successfully 
demonstrated cellular trafficking to tumour cells, cell-cell heterofusion and tumour 
cell infection with MV. The extent of tumour infection correlated inversely with the 
level of neutralizing antibody present regardless of the mode of virus delivery. 
However, when using cell-based delivery systems, infection of tumour cells was 
demonstrated over a range of antibody titres non-permissive to infection when using 
naked virions. Iankov et al. used MV-infected monocytic cells and outgrowth 
endothelial cells to demonstrate successful in-vitro transfer of infection to lymphoma, 
myeloma and ovarian cancer cells by cell-cell fusion even in the presence of 
neutralizing antibodies, whereas cell free virions were completely neutralized by 
antibody
189
. Furthermore, in NOD/SCID murine models they used a dual colour 
model to show heterofusion of intraperitoneally injected MV-infected cell carriers and 
tumour cells. Enhanced tumour cell infectivity and therapeutic activity was 
demonstrated when using MV-infected cell carriers as compared to cell free virus in 
the presence of neutralizing antibody.  
1.4 MSCs 
MSCs are an essential component of the BM microenvironment with a critical role in 
supporting haematopoiesis
191
. They can be isolated from a number of different 
sources including BM, adipose tissue
192
, dental pulp
193
, cord blood
194
, placental 
tissues, fetal and amniotic tissues
195
. MSCs have several inherent characteristics that 
make them ideally suited to a role as delivery vehicles for the systemic administration 
of virotherapeutics. 
1.4.1 MSC processing 
MSCs can be obtained from a wide variety of tissues by simple isolation methods. 
They can be cultured and expanded ex-vivo in cellular therapy laboratories under 
good manufacturing process (GMP) conditions, and can be produced in sufficient 
quantities for therapy. The culture conditions employed and the source from which 
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MSCs are obtained is likely to have a significant impact on their biological 
phenotype, and needs to be taken into account.  
1.4.2 MSCs in the clinic 
There is a wealth of existing data for the use of MSCs in the clinical setting. The 
safety of administering third-party MSCs to humans via the intravenous route has 
been extensively demonstrated in studies using MSCs as immunomodulators in acute 
graft versus host disease post haematopoietic cell transplantation
196-200
. Although 
known to have immunomodulatory properties, thus far there is no clinical evidence to 
suggest that the administration of third party MSCs increases rates of disease relapse 
when used in the setting of haematological malignancies.  
1.4.3 MSC homing 
The ability of virus-loaded cells to localize to and be retained in the appropriate tissue 
is a pre-requisite for success in cell-based virotherapeutic delivery systems.  
Mechanisms implicated in tissue localization of systemically infused MSCs include 
MSC rolling along the endothelium in a P-selectin dependent manner
201
, chemokine-
mediated MSC activation and migration
202
, and integrin-mediated adhesion and 
transendothelial migration
201
. MSC homing is most convincing in models of tissue 
injury
203-205
, with poor localization demonstrated in the absence of tissue damage and 
cytokine release
206,207
. Numerous cytokines and growth factors have been implicated 
in MSC trafficking, including amongst others vasculoendothelial growth factor 
(VEGF), fibroblast growth factor 2 (FGF2), IL-6, hepatocyte growth factor (HGF), 
monocyte chemotactic protein 1 (MCP1), and stromal-derived growth factor 1 alpha 
(SDF-1α)208. Mechanisms of MSC homing and the role of SDF-1α will be discussed 
in more detail in Chapter 4.  
1.4.4 MSCs as virotherapeutic cell carriers 
In order for MSCs to function as effective cellular vehicles for virotherapy, their 
ability to support efficient and productive virus infection, retain viability, traffic to 
tumour sites, and effectively ‘hand-off’ virus to target cell needs to be demonstrated. 
Furthermore, the optimal timescale of ex-vivo loading and cellular administration post 
infection is likely to be a critical determinant to therapeutic success. MSCs support 
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productive viral infection with varying efficiencies. Komarova et al
209
 successfully 
demonstrated the ability of BM-MSCs to support replicating adenovirus, and in vitro 
adenovirus-loaded MSCs caused cell killing when co-cultured with cancer cell lines. 
In-vivo, adenovirus-infected MSCs increased the survival of NOD/SCID mice 
bearing ovarian cancer xenografts as compared to cell free adenoviral injection. In 
relation to measles virotherapy, Mader et al
183
 showed that adipose-derived MSCs 
could transfer MV infection to target cells via cell-cell heterofusion, and induce 
syncytia formation in the presence of high-titre anti-MV antibodies that completely 
inactivated naked virions in vitro. In athymic mice bearing ovarian cancer xenografts, 
they demonstrated cell-carrier trafficking and virus hand-off to peritoneal tumours, 
and were able to show enhanced survival of xenografted mice that were passively 
immunized with anti-MV antibodies when treated with MV-loaded MSCs versus 
those animals given treatment with naked MV or uninfected MSCs. In an 
orthotopically implanted SCID mouse model of human HCC, intravenously delivered 
MV-infected BM-MSCs were shown to home to sites of disease, transfer virus to 
tumour cells, and inhibit tumour growth in both measles naïve and passively 
immunized SCID mice
210
. In preparation for clinical use, adipose-derived MSCs 
obtained from healthy donors or ovarian cancer patients have been characterized for 
their susceptibility to virus infection, and tumour homing properties. Phenotype and 
doubling times of both healthy donor and patient MSCs were similar, with no tumours 
seen in SCID beige mice following administration of up to 1.6x10
9
 MSC/kg. 
Furthermore, MSCs did not promote the growth of SKOV3 human ovarian cancer cell 
lines. Rapid co-localisation of intraperitoneally-administered MV-infected MSCs to 
established ovarian tumours in athymic mice was demonstrated, with MV-infected 
MSC treatment, but not naked virus treatment significantly prolonging the survival of 
measles immune animals
211
. Such data is promising, but demonstration of the use of 
MSCs as cellular virotherapy delivery vehicles to treat a disseminated haematological 
malignancy has yet to be achieved. 
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1.5 Project aims 
1.5.1 Improving therapeutic outcomes of systemic oncolytic measles 
virotherapy in pre-clinical models of ALL 
This project explores the use of measles virotherapy as a novel treatment strategy for 
ALL. Adult ALL is an aggressive haematological malignancy with complete 
remission rates following initial “induction” therapy of 85-95%212-219. Therapy 
consists of combination chemotherapy with numerous immunosuppressive and 
myelosuppressive chemotherapeutics, in cycles. However, long-term survival is 
achieved in fewer than half of adults
220
, and few patients with relapsed disease 
survive
221
. The ability to quantify and monitor minimal residual disease (MRD) in the 
majority of patients with ALL, provides a basis  - already recognised by the 
regulatory authorities - for early intervention with novel therapeutics prior to overt 
disease relapse
222
 which would be the optimal setting for novel biological therapies. 
With this in mind, there is a need to develop effective, non-cross resistant, rationally 
designed treatments in this disease that could be used alone or in combination with 
existing therapeutics. Using lymphotropic oncolytic MV as a novel therapy in an 
aggressive lymphoid malignancy should enhance tumour cell specificity. The efficacy 
of oncolytic MV in pre-clinical models of precursor B-lineage ALL has already been 
established
19
, however, mechanisms to shield MV from antibody neutralization during 
systemic delivery need to be addressed, and this project aims to do so by investigating 
the use of BM-MSCs as a cell-based delivery system in this disseminated 
haematological malignancy. Using primary human BM-MSCs to deliver MV to a 
BM-based disorder is a rational choice, with such cells ideally being more likely to 
demonstrate desirable properties such as homing back to the BM following systemic 
administration. Furthermore, in ALL stromal cells are recognized as playing a 
significant role in maintaining leukaemia cells and affording chemoprotection
191
. 
Therefore, MV infection of MSCs is likely to enhance virotherapeutic success.  
1.5.2 Probing mechanisms of tumour specificity and virus-initiated cell death.  
As previously detailed, the oncolytic capacity of vaccine MV is unquestionable. In 
addition to optimizing MV delivery systems, our group has been interested in gaining 
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further understanding of the mechanisms that lend MV its oncolytic properties. An 
additional aim of this project was to probe the mechanisms conferring primary 
healthy cells and malignant cells their differential susceptibilities to oncolytic MV-
mediated killing. To undertake this aim, I utilized a model of cellular transformation 
generated from primary BM-MSCs (gifted by Boshoff laboratory, UCL, UK), adapted 
to represent different stages of the malignant transformation process
223
. Reasons for 
chosing this model, and details of the model itself can be found within Chapter 5.  
1.5.3 Hypotheses 
The central hypothesis of this thesis, is that BM-MSCs can be effectively utilized, 
firstly as virotherapeutic cellular carriers - enhancing delivery and therapeutic 
efficacy of oncolytic MV in pre-clinical models of disseminated ALL - and secondly, 
as a model of cellular transformation to gain insight into the differential cellular 
effects of oncolytic MV in primary untransformed, and malignant cell counterparts. 
Specific hypotheses are detailed at the start of each data chapter, and are outlined 
here: 
 
Chapter 3: Feasibility of BM-MSCs as biological delivery vehicles for systemic 
oncolytic measles virotherapy to ALL targets 
a. A proportion of adult ALL patients will have clinically significant anti-
measles antibody levels pre and post treatment that have the potential to 
impact on the success of systemic oncolytic measles virotherapy.  
b. Human BM-MSCs will be successfully infected by oncolytic MV, sustain 
viral replication without cellular toxicity, target distant tumour cell niches, and 
hand off virus to tumour targets in the presence of anti-measles antibodies.  
c. The systemic delivery of oncolytic measles virotherapy within BM-MSC cell 
carriers will result in enhanced therapeutic outcomes in pre-clinical models of 
ALL in the presence of anti-measles humoral immunity.  
 
Chapter 4: Manipulating the MV genome to enhance localization of infected carrier 
cells 
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a. MV-infected BM-MSCs will show sub-optimal localization to tumour targets 
within the murine BM, due to downregulation of chemokine receptors during 
ex-vivo culture.  
b. MSCs infected with a hCXCR4-expressing oncolytic MV may upregulate 
trafficking to tumour sites and enhance tumour killing.  
 
Chapter 5: Characterising MV kinetics in a stromal cell model of transformation 
a. There will be a difference in the permissiveness of fully transformed MSCs to 
oncolytic MV versus that of primary MSCs.  
b. Differences in infectivity, productivity, and cytotoxicity will not be accounted 
for solely by MV receptor expression profile.  
c. Transformation of BM-MSCs will result in cellular functional defects in innate 
immune signaling or translational regulation in response to MV infection, 
which may contribute to differential viral kinetics. 
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Chapter 2:  Methods 
Except where indicated in the Statement of work undertaken, I myself performed all 
experiments.  Specific materials and methods are described in the relevant results 
chapters. 
2.1 General cell line culture 
Unless otherwise stated, suspension cells were grown in RPMI-1640 medium 
supplemented with 10% foetal bovine serum (FBS), penicillin-streptomycin (100u/ml 
and 100μg/ml respectively) and L-glutamine (2mM) in a humidified incubator with 
5% CO2 at 37°C (HERAcell, ThermoScientific, Surrey, UK). The MCF-7 cell line 
was further supplemented with 10mg/ml human insulin. Vero cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS, 
penicillin-streptomycin and L-glutamine under the same conditions. Vero-Slam cells 
required the addition of 0.5mg/ml Geneticin® G418. The 293T cell line and 
PhoenixAMPHO cell line required 10% FBS. In general, cell lines were passaged at 
sub-confluency. All the cell lines used were growth factor independent. Specific 
techniques used for the isolation and culture of primary human BM-MSCs are given 
later in this chapter.  
2.1.1 Cell lines 
 293T – human embryonal kidney cell line, adherent (CRL-11268; ATCC) 
 Jurkat – human T-cell ALL cell line, non-adherent (TIB-152; ATCC) 
 MCF-7 – human breast adenocarcinoma cell line, adherent (ACC-128; 
DSMZ) 
 NALM-6 – human B-cell acute lymphoblastic leukaemia cell line, non-
adherent  (ACC-128; DSMZ) 
 Phoenix AMPHO – human embryonic kidney cell line, adherent (CRL-3213; 
ATCC) 
 Vero – african green monkey kidney cell line, adherent (CLL-81; ATCC) 
 Vero-Slam – Vero cells expressing the SLAM receptor, adherent (gifted by 
Mayo Clinic, MN, USA) 
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2.1.2 Cell culture reagents 
 Bovine serum albumin (BSA) (Sigma Aldrich, Poole, UK) 
 Dimethyl sulfoxide (DMSO) (Sigma Aldrich, Poole, UK) 
 Dulbecco’s Modified Eagle Medium (DMEM) – high glucose 4.5g/l 
(Invitrogen, Paisley, UK) 
 Foetal bovine serum (FBS), heat inactivated (Invitrogen, Paisley, UK) 
 Geneticin® G418, used at 0.5mg/ml (Invitrogen, Paisley, UK) 
 HBSS (Invitrogen, Paisley, UK) 
 Human insulin, added at 10mg/ml (RFH Pharmacy) 
 L-glutamine 200mM, added to media to achieve 2mM concentration 
(Invitrogen, Paisley, UK) 
 OptiMEM® medium (Invitrogen, Paisley, UK) 
 Penicillin-Streptomycin containing 10,000units/ml penicillin and 10,000μg/ml 
streptomycin, used at 100units/ml and 100μg/ml respectively (Sigma Aldrich, 
Poole, UK) 
 Phosphate buffered saline (PBS) (Invitrogen, Paisley, UK) 
 RPMI-1640 medium (Invitrogen, Paisley, UK) 
 TrypLE™ Express (Invitrogen, Paisley, UK) 
2.1.3 Cell culture plastics 
 1.8ml cryovials (VWR International, Merck, UK) 
 24-well transwell plates, polycarbonate membrane 8.0mm (Corning, UK) 
 0.4μm cell strainer for 50ml BD Falcon (Becton Dickinson LTD, UK) 
 6, 12, 24 and 96 well tissue culture plates (Nunc, NY, USA) 
 Sterile syringe filters 25mm SFCA membrane, 0.2μm pore (VWR 
International, Merck, UK) 
 T25, T75 and T175 flasks (VWR International, Merck, UK) 
 10cm and 14cm petri dishes (Nunc, NY, USA) 
2.1.4 Active compounds used in cell culture 
 AMD3100 (Sigma Aldrich, Poole, UK) 
 SDF-1α, recombinant human (Peprotech, London, UK) 
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 Z-D-Phe-Phe-Gly-OH - fusion inhibitory peptide (FIP), used at 40μg/ml 
(Bachem, Swizerland) 
2.1.5 Cell counts and viability 
Cells were enumerated utilizing a haematocytometer.  Cell viability was measured by 
Trypan blue (Sigma Aldrich, Poole, UK) dye exclusion and viability of cell lines 
maintained at >95%. 
2.1.6 MTS colorimetric assay 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega,UK) is 
a colorimetric assay for determining viable cells in proliferation, or cytotoxicity. Cells 
cultured in 96 well plates were infected with MV-NSe at the appropriate multiplicity 
of infection (MOI) under standard conditions for the desired duration before 
performing the assay. For each well, 20μl of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent was added and 
the plate incubated at 37°C for 4 hours. The resulting absorbance was read at 490nm 
on a Tecan Sunrise absorbance reader (Jencons-PLS, UK).   
2.2 Human BM-MSCs 
The study received ethical approval from the National Research Ethics Committee 
(NREC number: 11/NW/0216).  Healthy BM donors recruited during admission for 
BM harvesting gave written consent for participation in this project. The patient 
information leaflet, consent form and ethics approval can be found in the Appendix 
section of this document. 
2.2.1 Primary MSC isolation and expansion 
BM samples were filtered through a 40μM cell strainer (Becton Dickinson LTD, UK) 
and BM mononuclear cells were isolated by density gradient centrifugation using 
Ficoll-Paque™ (Amersham Biosciences, Bucks, UK). The resultant cell population 
was resuspended in MesenCult MSC basal medium supplemented with 
MesenCult stimulatory supplements (StemCell technologies, Grenoble, France), 
100u/ml penicillin, 100g/ml streptomycin, 2mM L-glutamine, and 1ng/ml 
recombinant basic human FGF (bFGF) (R&D systems, MN, USA). Cells were plated 
in T175 tissue culture flasks at a concentration of 1x10
7
 per 25ml of medium and 
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cultured in a 37C, 5% CO2 incubator. After 1-2 days, non-adherent cells were 
removed and adherent cells were washed using phosphate buffer saline (PBS) 
(Invitrogen, Paisley, UK) and fresh medium was added. Medium was replaced every 
5-7 days thereafter. Following approximately 14 days in culture, cells were washed 
with PBS and incubated at 37C with 5ml TrypLE™ Express (Invitrogen, Paisley, UK) 
for 3-5 minutes. The detached cells were collected in 10mls of fresh medium, 
centrifuged at 1200rpm for 5 minutes, enumerated in a haemocytometer chamber, and 
either frozen as described below for future propagation, or passaged into new T75 
tissue culture flasks at a concentration of 3x10
5
 cells per 10mls of medium. Cells were 
passaged when they reached sub-confluency (80-90%). Passage 3-5 MSCs were used 
for experiments. For immortalized MSCs (hTERT, 3H, 4+V and 5H), cells were 
cultured in MesenCult MSC basal medium supplemented with MesenCult 
stimulatory supplements, 100u/ml penicillin, 100g/ml streptomycin, 2mM L-
glutamine, and 1ng/ml recombinant basic human FGF (bFGF). Cell culture passage 
was performed when reaching sub-confluency (80-90%).  
2.2.2 MSC cryopreservation 
MSCs were cryopreserved by resuspending the live cell pellet in a freezing mix 
consisting of 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, Poole, UK) and 90% 
FBS to a concentration of 1x10
6
 cells/ml. The cell suspension was aliquoted into 
polypropylene cryogenic vials and placed at -80ºC overnight in a freezing container 
(Nelgene, Rochester, US) filled with 100% isopropyl alcohol to achieve a cooling rate 
of 1ºC/minute. On the following day, the frozen cells were transferred to liquid 
nitrogen for long-term storage. When required, cells were thawed in a 37ºC water 
bath for 2~3 minutes. As soon as the cells were thawed, 10 ml of pre-warmed FBS 
was added dropwise to resuspend them. After centrifugation at 1200rpm for 5 minutes 
without brake, the cell pellet obtained was washed again with the appropriate cell 
medium supplemented with 50% FBS to remove any residual DMSO. Finally, cells 
were resuspended in supplemented medium and kept initially in a T25 flask at 37ºC, 
passaging to a T75 flask when reaching sub-confluency, at concentrations as before. 
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2.2.3 MSC characterization 
Cells were assessed at the time of tissue culture passage (P1-3) to confirm success of 
the isolation procedure, and purity of the product obtained. Criteria set out by the 
International Society for Cellular Therapy (ISCT) were used to guide the definition of 
MSCs
224
.  
 
Table 2-1: Minimal criteria for human MSC definition (ISCT). 
 
Adherent to tissue culture plastic when maintained in standard tissue culture 
conditions. 
 
Cell surface positivity (>90%) for CD105, CD73 and CD90 expression.  
 
Lack of (<2%) cell surface CD45, CD34, CD14 or CD11b, CD79a or CD19 and 
HLA-DR. 
 
Multipotent differentiation in vitro: osteoblasts, adipocytes, chondroblasts. 
 
2.2.3.1 Microscopic evaluation 
Cells were monitored microscopically and identified by their adherence to tissue 
culture plastic and their distinctive spindle-shaped appearance in vitro. 
2.2.3.2 Flow cytometric classification 
For immunophenotypic characterization, MSCs were analyzed for the appropriate 
markers either in combinations or as single stains after harvesting by trypsinisation, 
resuspending in PBS and incubating with the appropriate primary antibody/antibodies 
at 4°C in the dark for 30 minutes before being washed and re-suspended in PBS. 
Corresponding isotype controls were used to account for non-specific background 
staining. Live cells were gated according to their forward scatter (FSC)/side scatter 
(SSC) characteristics or identified by using TO-PRO-3 (Invitrogen, Paisley, UK) or 
Propidium Iodide (PI) (Invitrogen, Paisley, UK) to exclude dead cell population. Ten 
thousand live events were collected on a BD FACSAria instrument (Becton 
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Dickinson, Oxford, UK). Data was analyzed using FlowJo (Tree Star) (software 
version 7.4.1). A full list of antibodies is provided in the flow cytometry section of 
these methods. 
2.2.3.3 Multipotent differentiation 
Adipogenic and osteogenic differentiation of primary MSCs was demonstrated using 
the Human Mesenchymal Stem Cell Functional Identification Kit (R&D Systems, 
MN, USA). In addition, differentiation was further confirmed using Oil Red O and 
Alizaran red staining techniques on fixed cells. Briefly, MSCs plated into 24 well 
tissue culture plates were fixed at room temperature (RT) for 30-60 minutes with 2 
mls of 10% formalin after being washed with PBS. Three parts Oil Red O stock 
solution (gifted by RFH histopathology department) was mixed with 2 parts distilled 
(DI) water and incubated at RT for 10 minutes. The working solution was then 
filtered through fine filter paper. Formalin was removed from each well and cells 
were gently rinsed with 2ml DI water, followed by incubation with 2mls 60% 
isopropyl alcohol for 5 minutes. Isopropanol was then removed and 2mls of Oil Red 
O working solution was added to each well, and left at RT for a further 5 minutes. 
The stain was then removed and cells were rinsed with DI water until the water was 
rinsing clear, then counterstained for 1 minute at RT with 2mls Carrazi’s 
haematoxylin stain (gifted by RFH histopathology department) and visualized under a 
light microscope (Nikon Eclipse TS100). For the Alizarin Red staining, cells were 
fixed in ice cold 70% ethanol for 1 hour at RT. Alcohol was then aspirated and cells 
were rinsed twice with 2mls DI water per well. 2mls Alizarin Red S (Sigma Aldrich, 
Poole, UK) working stock was then added to each well and cells incubated for 30 
minutes at RT before being washed with DI water and visualizing under a light 
microscope. 
2.3 Flow cytometry 
2.3.1 General flow cytometry method 
Monoclonal antibodies were used as direct conjugates with fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), phycoerythrin-Cy7 (PE-Cy7), peridinin-chlorophyll-
protein complex (PerCP), allophycocyanin (APC), allophycocyanin-H7 (APC-H7), 
and Alexafluor® V450.  1-10x10
5
 cells per aliquot were incubated at 4°C in the dark 
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with the designated panel of antibodies for 30mins before being washed and re-
suspended in PBS.  Samples were acquired on a BD FACSAria or LSR II flow 
cytometer (Becton Dickinson, Oxford, UK) with 5000-10 000 events being recorded 
and analysed with FlowJo (Tree Star) (software version 7.4.1).  
 
Table 2-2: Antibodies used in flow cytometry 
Target Reactivity Species Ig class Product 
code 
Company 
 
Clone Conjugate 
CD73 Human Mouse IgG1, k 550257 BD  AD2 PE 
CD73 Human Mouse IgG1, k 561258 BD AD2 PE-Cy7 
CD105 Human Mouse IgG1, k MCA1557 AbD Serotec SN6 FITC 
CD105 Human Mouse IgG1, k 561447 BD  266 V450 
CD105 Human Mouse IgG1, k 9811-11 SouthernBiotech SN6 APC 
CD90 Human Mouse IgG1, k 555595 BD 5E10 FITC 
CD34 Human Mouse IgG1, k 555824 BD  581 APC 
CD45 Human Mouse IgG1, k 641399 BD  APC-H7 
CD45 Human Mouse IgG1, k 555482 BD  H130 FITC 
CD150 Human Mouse IgG1, k 559592 BD A12 PE 
Nectin 
4 
Human Mouse IgG2b, 
k 
FAB2659P R&D systems 337516 PE 
CD147 Human Mouse IgG1, k 555962 BD HIM6 FITC 
CD46 Human Mouse IgG2a, 
k 
555949 BD E4.3 FITC 
CD184 Human Rat IgG2a, 
k 
551413 BD 1D9  
CD10 Human Mouse IgG1, k MCA1556F AbD Serotec SN5c FITC 
CD10 Human Mouse IgG2a, 
k 
347503 BD W8E7 FITC 
CD19 Human Mouse IgG1, k 345777 BD 4G7 PE 
2.3.2 Fluorescent activated cell sorting 
Cell sorting was performed on a MoFlo XDP (Beckman Coulter, Fullerton, Ca, USA) 
fitted with three lasers: 350, 488, and 647 nm. The enhanced blue fluorescent protein 
(eBFP) marker was excited by the 350 UV laser (100mW) and its emission was 
collected using a 450/65 filter. The GFP and mCherry markers were excited using the 
488 blue laser. GFP emission was collected using a 653/40 filter, and mCherry using 
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a 613/20 filter. 
2.4 Measles virus 
2.4.1 MV strains 
For the purposes of all experiments, the Edmonston strain vaccine virus, MV-NSe, 
was used unless otherwise stated. To visualize MV infection and aid infected cell 
tracking, MV-NSe-GFP or MV-NSe-Luc were utilized. For both of these modified 
vaccine strains, reporter genes were cloned into the MV genome upstream of the MV-
N gene. 
2.4.2 MV propagation 
Attenuated vaccine strain virus - MV-NSe (or the derivatives MV-NSe-GFP, MV-
NSe-Luc or MV-NSe-hCXCR4) - was used for the purposes of the experiments 
outlined in this document. MV strains were generated from the infectious cDNA of 
the Edmonston vaccine lineage Seed B. MV was propagated on Vero cells by 
inoculating with virus in OptiMEM® at a multiplicity of infection (MOI) of 0.01, and 
incubating at 37C, 5% CO2 for 2 hours. Following this the inoculum was removed 
and replaced with DMEM medium, supplemented with 5% FBS, 100 units/ml 
penicillin G + 100μg/ml streptomycin and 2mM L-glutamine. When the maximum 
cytopathic effect was observed, cells were scraped into small volumes of OptiMEM®, 
and exposed to two freeze-thaw cycles to release cell associated viral particles. The 
titer of propagated MV was determined by an end-point infectivity assay. 
Approximately 5 103 Vero cells were seeded in each well of a 96-well tissue culture 
plate. Ten-fold serial dilutions of MV stock were made and for each dilution, 50μl 
was dispensed per well for the 8 wells in one column of the 96-well plate. The plate 
was incubated at 37 °C, 5% CO2 and read on day 4 post inoculation. The 50% tissue 
culture infectious dose (TCID50) of MV stock was calculated using the modified 
Kärber formula
225
 as shown below:  
 
Log10 TCID50 = - [Log10x – d (p - 0.5)] + Log10 (1/v) 
 
x = highest dilution that gives 100% of wells positive for infection 
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d = Log10 of dilution interval (e.g. for 10-fold dilution, d=1) 
p = sum of values of the proportion of wells positive for infection at all dilutions 
v = volume of viral inoculum for each well in milliliters. 
 
The plaque forming units (pfu) in 1ml of viral stock was estimated by multiplying 
TCID50 value with 0.7 (a factor derived from Poisson distribution).  
 
All viral stocks were frozen in small aliquots at -80°C. Repeated freeze and thaw 
cycles were avoided.  
2.4.3 Cellular infection 
MV stocks were thawed briskly in a water bath at 37°C and placed on ice before use. 
For MV infection of adherent human tumour cell lines or MSCs, cells were washed 
once with PBS and inoculated with virus in OptiMEM® at the required multiplicity of 
infection (MOI) for that particular experiment. Mock-infected cells were washed and 
‘inoculated’ with OptiMEM® only. Cells were incubated at 37°C in 5% CO2 for 2 
hours before removal of the inoculum and replacement with fresh medium. For cells 
cultured in the presence of FIP, 40μg/ml was added to the fresh medium at this stage. 
2.5 Molecular biology 
2.5.1 Reagents for molecular biology 
 0.1M DTT (Invitrogen, Paisley, UK) 
 10mM dNTPs (Promega, Southampton, UK) 
 5 x first strand buffer (Invitrogen, Paisley, UK) 
 Agar (Calbiochem, UK) 
 Chloroform (VWR International, Lutterworth, UK) 
 DNase/RNase free water (Invitrogen, Paisley, UK) 
 Ethanol 100% (VWR International, Lutterworth, UK) 
 Glycerol (VWR International, Lutterworth, UK) 
 HiSpeed Plasmid Midi Kit (Qiagen, Crawley, UK) 
 Isopropanol (VWR International, Lutterworth, UK) 
 LB broth (Invitrogen, Paisley, UK) 
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 One Shot® TOP10 competent cells (Invitrogen, Paisley, UK) 
 pCRII-TOPO TA cloning kit (Invitrogen, Paisley, UK) 
 QIAex II gel purification kit (Qiagen, Crawley, UK) 
 Random hexamers (Promega, Southampton, UK) 
 Restriction enzymes (New England Biolabs, Hitchin, UK) 
 RNasin® Plus RNase Inhibitor (Promega, Southampton, UK) 
 SuperScript™ III reverse transcriptase (Invitrogen, Paisley, UK) 
 T4 DNA Ligase (New England Biolabs, Hitchin, UK) 
 TRIzol® (Invitrogen, Paisley, UK) 
2.5.2 DNA extraction 
DNA extraction was performed using the HiSpeed Plasmid Midi Kit. Resultant DNA 
concentration and purity was determined by measuring UV-light absorbance of 
samples at 260nm (A260) and 280nm (A280) with NanoDrop1000 
spectrophotometer (Thermo Scientific, Essex, UK). Samples with A260/A280 ratio of 
1.75~2.0 were used for the purposes of the experiments outlined. DNA was stored at -
20°C until use.  
2.5.3 RNA extraction 
Total RNA was extracted from cells at the appropriate time points using TRIzol
®
. 
Cell pellets (typically 1.5105 cells) were lysed in 500μl TRIzol®. After five minutes 
incubation at RT, 100μl of chloroform was added to each sample, mixed well and 
incubated at RT for a further 2 minutes before being centrifuged at 12,000g for 15 
minutes at 4°C. The aqueous layer was removed and mixed with 250μl of isopropanol 
to encourage RNA precipitation, before pelleting the RNA by centrifugation at 
12,000g for 10 minutes. The RNA pellet was washed once with 75% ethanol, air-
dried, and re-suspended in 20μl of RNase/DNase-free water. Concentration and purity 
of RNA was determined by measuring UV-light absorbance of the samples at 260nm 
(A260) and 280nm (A280) with NanoDrop1000 spectrophotometer (Thermo 
Scientific, Essex, UK). Samples with A260/A280 ratio of 1.75~2.0 were used for the 
purposes of the experiments outlined. RNA stocks were stored at -80°C in aliquots of 
10~15μl. Once thawed, any un-used RNA in an aliquot was not re-frozen. A fresh 
aliquot was taken from -80°C if any other use was required.   
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2.5.4 First-strand cDNA synthesis 
To each 0.4-1μg sample of total RNA, 2μl (334ng) of random hexamer, 1μl of 0.1M 
DTT and 2μl of 10mM dNTPs were added and mixed. Samples were then heat 
blocked at 65°C for 5 minutes and then incubated on ice for a further 10-15 minutes. 
Following this 4μl of 5  first strand buffer, 1μl (40 units) of RNasin® Plus RNase 
Inhibitor and 1μl (200 units) of SuperScript III reverse transcriptase were added to 
each sample, and the reaction mixtures were incubated at 25°C for 10 minutes, 50°C 
for 50 minutes and 70°C for 15 minutes. The product containing 1
st
 strand cDNA was 
then used for PCR immediately or stored at -20°C for future use. 
2.5.5 MV-nucleocapsid (MV-N) mRNA relative quantification 
Expression of MV-N mRNA was quantified by a customized TaqMan gene 
expression Real-time PCR assay (Applied Biosystems, California, US) in reactions of 
25μl volume. cDNA was mixed with 0.9mM forward and reverse primers and 0.25 
mM TaqMan® probe labelled with FAM reporter dye. To each reaction, 12.5μl of 
TaqMan® Universal Master Mix (Applied Biosystems, California, US) was added, 
and the remaining volume was made up with RNase/DNase-free water. The PCR 
conditions for the assay are as follows: 
 Step 1: 50°C for 2 mins 
 Step 2: 95°C for 10 mins 
 Step 3: 40 cycles of 95°C for 15 seconds, 60°C for 1 minute 
 (Data collection was performed during step 3, stage 2) 
 
Primer sequences for MV-N are shown below: 
MV-N s 5′-GTATCCTGCTCTTGGACTGCAT-3′  
MV-N a  5′-GTTCATCAAGGACTCAAGTGTGGAT-3′   
 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the housekeeping 
gene for all assays. All PCR reactions were carried out on an ABI 7500 system 
(Applied Biosystems, California, US). Samples were run in triplicates for each gene. 
Non-template controls (NTC) using RNase/DNase-free water instead of cDNA were 
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included in each plate. PCR cycle number at threshold is represented as Ct. Relative 
expression level of genes of interest was calculated using the following formula
226
:  
ΔCt=Ct(experiment) – Ct(GAPDH) 
ΔΔCt=ΔCt – Ct(calibrator) 
RQ=2
(-ΔΔCt) 
2.5.6 Plasmid preparation 
Plasmid preparation for lentiviral and retroviral vectors used 5-20ng plasmid DNA 
was added directly to a vial of One shot® TOP10 competent cells and incubated on 
ice for 30 minutes, heat-shocked at 42°C for 30 seconds before adding 250μl of pre-
warmed SOC medium. Vials were then placed in a shaking incubator at 37°C for 1 
hour at 225 rpm. LB agar plates containing 100μg/ml ampicillin were spread with 20-
200μl of each transformation reaction, inverted and stored in a bacterial incubator at 
37°C overnight. One colony was picked with a sterile pipette tip and transferred to 
2mls LB broth containing 100μg/ml ampicillin to form a starter culture, and placed in 
the shaking incubator at 37°C for 3-4 hours, before being transferred to 50mls of 
media and leaving in the shaking incubator overnight. The following morning, 
glycerol stocks were made from the culture by mixing 500μl bacterial culture with 
500μl 50% sterile glycerol, and freezing at -80C. The remaining liquid culture 
medium was decanted and centrifuged at 4000rpm for 20 minutes at 4°C (no brake). 
Supernatant was discarded and bacterial pellet was used for DNA extraction using the 
HiSpeed Plasmid Midi Kit according to manufacturer’s instructions. Plasmid DNA 
concentration was quantified using a NanoDrop1000 spectrophotometer (Thermo 
Scientific, Essex, UK). Samples with A260/A280 ratio of 1.75~2.0 were used for the 
purposes of the experiments outlined. DNA was stored at -20°C until use. 
2.6 Immunostaining 
2.6.1 MV-H glycoprotein 
For MV-H glycoprotein staining, cells were grown at appropriate density in 12 or 24 
well tissue culture plates. At the desired time points post infection, medium was 
removed and cells were fixed at RT for 30-60 minutes with 10% formalin. After 
washing with DI water, cells were then incubated with anti-H antibody (clone MS-X; 
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1:100 dilution, Chemicon, Merck, UK) or mouse IgG1 κ (clone MOPC21; 1μg/ml; 
Sigma Aldrich, Poole, UK) for 45 minutes, washed x 2, incubated with polyclonal 
goat anti-mouse biotin IgG (1:400 dilution; Dako, Cambridgeshire, UK) for 30 
minutes, washed again x 2, and then incubated with Streptavidin/HRP (1:500 dilution; 
Dako, Cambridgeshire, UK) for 30 minutes. Following this, cells were incubated with 
AEC+ High Sensitivity Substrate Chromogen (Dako, Cambridgeshire, UK) for 5 
minutes, washed with DI water x 3 and counterstained with Carrazi’s haematoxylin 
for 30 seconds. After a final wash step with DI water, cells were visualized under a 
light microscope (Nikon Eclipse TS100). 
2.6.2 Human CXCR4 (hCXCR4) 
Cells were grown at appropriate density in 12 or 24 well tissue culture plates. At the 
desired time points post MV-NSe-hCXCR4 infection, medium was removed and cells 
were fixed at RT for 30-60 minutes with 10% formalin. After washing with DI water, 
cells were incubated with human CXCR4 monoclonal antibody (clone 44716; 
15μg/ml; R&D systems, UK) overnight at 4°C. Cells were stained with the anti-
mouse HRP-AEC Cell and Tissue Staining Kit (R&D systems, UK) according to 
manufacturer’s instructions, and counterstained with Carrazi’s haematoxylin for 30 
seconds. After a final wash step with DI water, cells were visualized under a light 
microscope (Nikon Eclipse TS100). 
2.7 Enzyme-linked immunosorbent assay (ELISA) 
MV IgG antibody quantification was performed using solid phase ELISA based on 
the sandwich principle (IBL international, Hamburg, Germany). Patient ALL serum 
samples were obtained and preserved at -80 C at the time of specimen collection. 
Each sample was undiluted and analyzed in duplicate alongside standard samples and 
controls. Optical density (OD) was measured at 450 nm (reference wavelength 650 
nm) using Tecan Sunrise absorbance reader (Jencons-PLS, UK). OD of standards was 
plotted against their concentration (x-axis; logarithmic) and concentration of samples 
was determined directly from the standard curve. Titers of 200mIU/ml or higher were 
deemed MV immune 
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2.8 Animal methods 
2.8.1 Murine strains 
Six to eight week old CB17 severe combined immunodeficient (SCID) mice (Charles 
River Laboratories, Margate, UK) were housed in a barrier facility and cared for in 
accordance with UK home office approved protocol.  
 
2.8.2 Xenograft models 
To establish disseminated ALL xenografts, 1x10
6
 viable NALM-6 cells (either un-
manipulated (MV-NSe) or firefly luciferase-expressing (MV-NSe-Luc) (see chapter 
specific methods)) were injected intravenously in a volume of 200μl via the lateral tail 
vein. Mice were regularly observed and euthanized when pre-defined humane 
endpoints were reached. MSC localization experiments and MV-loaded carrier cell 
therapeutic experiments are described in chapter-specific methods (Chapter 3). 
2.8.3 Bioluminescent imaging 
Bioluminescent imaging was performed using an IVIS® 100 Lumina (Caliper Life 
Sciences, Cheshire, UK). Prior to imaging, shaved animals were given 200μl D-
Luciferin (Caliper Life Sciences, Cheshire, UK) intraperitoneally and then 
anaesthetized using 1.5-2% isofluorane. Data was analysed using Living Image® 3.2 
software.   
2.9 Statistical analysis 
Graphs were plotted using Prism 5.0 (GraphPad software) and Microsoft Excel. Data 
are presented as mean  SEM (standard error mean) where appropriate. Statistical 
analysis was performed by unpaired student’s t test or Mann Whitney U test as 
appropriate. For pre-clinical virotherapy animal experiments, Kaplan-Meier curves 
were used to assess survival, and differences between groups were compared using 
the log-rank test. P value ≤ 0.05 is considered statistically significant. All p values 
quoted are two-sided.  
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Chapter 3:  Feasibility of BM-MSCs as biological 
delivery vehicles for systemic oncolytic measles 
virotherapy to ALL targets 
3.1 Background 
3.1.1 Cellular carriers as systemic virotherapy delivery units 
Although standard chemotherapy regimes would be presumed to have an impact on 
levels of antibodies against vaccine-preventable diseases, in unselected cohorts of 
children treated with intensive chemotherapy regimes for a range of malignancies, a 
decline in anti-measles antibody levels below the clinically protective level was seen 
in only 6%-25% of cases with established pre-treatment immunity
227,228
. Furthermore, 
in successfully treated paediatric ALL cases, only 35-40% of children were deemed 
non-measles immune on completion of therapy
229,230
. It is therefore reasonable to 
presume that even in heavily treated adults with ALL, a proportion of patients will 
have clinically significant anti-measles antibodies that will prevent successful 
systemic delivery of naked measles virotherapy. It is worth noting however, that the 
effect upon neutralizing antibody levels, of the recent introduction of the targeted 
anti-CD20 monoclonal antibody treatment (Rituximab) to induction regimes for adult 
ALL patients on the UKALL14 trial, is unknown, but it would be expected to ablate 
memory B cells tasked with the production of anti-measles antibodies on rechallenge.      
In order to circumvent humoral immunity, cell-based delivery systems have been 
developed for the ‘chaperoning’ of oncolytic viruses to sites of tumour. Success 
requires ex-vivo carrier cell loading with oncolytic virus, cellular targeting of tumour 
sites following systemic administration, and virus hand-off by carrier cells to the 
tumour site, whilst going unnoticed by the immune system. The advantages and 
disadvantages of the commonly utilized cell carriers have been detailed in Chapter 1 
(see Table 1-3).  
3.1.2 MSC carriers 
I chose to investigate the potential of human BM-MSCs to act as virotherapeutic 
delivery vehicles in this study for a number of reasons. Firstly, as outlined in the 
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introduction, MSCs are a highly clinically relevant commodity, with a wealth of data 
detailing the safe use of intravenously delivered allogeneic or autologous BM-MSCs 
as a therapeutic strategy in several diseases including acute graft-versus-host disease 
following hematopoietic cell transplantation for hematological malignancy
196,197,200
. 
Secondly, MSCs are hypoimmunogenic
231
, permitting safe administration without 
pre-conditioning. Thus, allogeneic, donor-mismatched BM-MSCs can potentially be 
an “off the shelf” commodity, allowing their use as virotherapeutic delivery vehicles 
but without themselves representing a target for elimination of the therapeutic 
element. Thirdly, evidence suggests that MSCs co-locate and interact with ALL in the 
BM microenvironment
191
. Finally, based on preclinical studies investigating the 
migratory capacity of MSCs
232
, I hypothesized that BM-MSCs would be likely to 
‘home’ to BM targets upon systemic infusion. It is worth mentioning, however, that 
there is ongoing debate about the use of allogeneic versus autologous MSCs. The 
majority of in vivo studies of MSC therapies have utilized allogeneic or syngeneic 
donor cells because of the difficulty of extracting cells in a survival surgery in small 
animals. It has been proposed, that each individuals MSCs and the specific responses 
that they elicit, are determined by their genotype. Minor differences between host and 
donor cells may therefore have an impact on trophic (and other) effects. Furthermore, 
although MSCs are generally considered immune-privileged, they do express 
detectable levels of HLA class I antigens, and if allowed to differentiate in vivo, their 
HLA expression will be altered, making them potentially more recognizable by the 
host. In a mouse study comparing immune response with syngeneic versus allogeneic 
MSCs, allogeneic cells triggered a significant increase in CD8+, natural killer, and 
natural killer T cells compared with animals receiving syngeneic cells
233
, and in 
clinical trials, anti-HLA antibody responses have been detected against allogeneic 
MSCs
234
.  
 
In vivo studies have shown both BM-derived and adipose-derived MSCs to be 
effectively utilized as MV carriers in pre-clinical models of ovarian carcinoma, and 
HCC respectively
183,210
. Whilst the ovarian carcinoma model required delivery of 
cellular virotherapy units via the intraperitoneal route, localization at sites of HCC 
was seen when BM-MSCs were delivered intravenously. In both studies, therapeutic 
outcomes demonstrated superiority when using MSCs as cellular virotherapy units as 
compared to delivery of naked virus in the presence of anti-measles humoral 
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immunity. So far, there has been no pre-clinical demonstration of the success of this 
approach following intravenous cell carrier delivery to a disseminated model of 
haematological malignancy.  
 
MSCs can be isolated from a number of alternative sources in addition to BM, and 
subtle differences in their in vitro immunophenotype, differentiation capacity and 
gene expression profile have been seen. However, the extent to which these features 
lead to biological differences in vivo remains unknown but MSC lineage needs to be 
carefully and rationally considered for each particular tumor type. On this point it is 
noteworthy to mention, that authors have drawn our attention to the consistency and 
reproducibility of gene expression profiles for MSCs derived from different donors 
using the same culture procedure, in contrast to the diversity of gene expression seen 
when comparing MSCs from different ontogenetic sources, or grown using different 
culture conditions
110
. Using intravenously administered BM-MSCs for the targeted 
delivery of an oncolytic virus to a BM-based malignancy such as ALL is rapidly 
translatable, since it is fully compatible with current investigational and therapeutic 
approaches.  
3.2 Purpose of this chapter 
In this chapter, I initially investigated the existing MV immune status in a cohort of 
heavily treated adult patients with ALL. Following this, the potential of human BM-
MSCs to be successfully infected by oncolytic MV, and the feasibility of utilizing 
such cells as viable virus producing units will be addressed.  A prerequisite to 
therapeutic success is the ability of biological carriers to target and ‘off-load’ virus to 
tumour cells upon systemic infusion. In addition to investigating the ability of human 
BM-MSCs to target and hand off virus to distant tumour targets, this chapter also 
explores therapeutic outcomes of this approach to virotherapy delivery in pre-clinical 
models of ALL.  
3.3 Hypotheses 
a. A proportion of adult ALL patients will have clinically significant anti-
measles antibody levels pre and post treatment, which have the potential to 
impact on the success of systemic oncolytic measles virotherapy.  
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b. Human BM-MSCs will be successfully infected by oncolytic MV, sustain 
viral replication without cellular toxicity, target distant tumour cell niches, 
and hand off virus to tumour targets in the presence of anti-measles 
antibodies.  
c. The systemic delivery of oncolytic measles virotherapy within BM-MSC 
cell carriers will result in enhanced therapeutic outcomes in pre-clinical 
models of ALL in the presence of anti-measles humoral immunity.  
3.4 Methods 
3.4.1 Lentiviral vector production 
For the preparation of lentiviral particles, 293T cells were co-transfected with the 
appropriate plasmids using a Fugene® high-density transfection reagent (Roche, 
Sussex, UK) method. Briefly, on the day of transfection, 4 x confluent T75 tissue 
culture flasks of 293T cells were passaged 1:2 into 8 x T75 flasks. The cells were 
transfected in suspension. Plasmids used (per 2 flasks) were as follows: 
 
 3μg gal-pol expressor plasmid (pCMV-ΔRp8.91) 
 3μg envelope plasmid (pCAGGS-VSV-G; gifted by Dr Martin Pule, UCL, 
UK) or for MV-pseudotyped vectors truncated H and F constructs were used 
(pCGHcΔ18 and pCGFcΔ30) at a ratio of 1:7 totaling 3μg DNA.235 
 5μg vector construct (pSIN-GFP or pSIN-mCherry; gifted by Dr Eric Poeshla, 
Mayo Clinic, MN, USA). 
 
A final volume of 100μl was made with H20, and the DNA mix was incubated at 55ºC 
for 5 minutes to sterilize. Fugene® was diluted in a cryotube by adding 40μl to 200μl 
OptiMEM. DNA mix was then added to the Fugene® solution (ratio 1:3.6 (DNA 
(μg):Fugene®(μl)), mixed by gentle pipetting and then incubated at room temperature 
for 15 mins. The liposomal complexes were then divided between and directly added 
to 2 x T75 tissue culture flasks (150μl/flask) of 293T cells that had been previously 
trypsinised, washed and resuspended in 10mls fresh medium to obtain a cell 
suspension. Lentiviral vector supernatant was collected after 24, 48 and 72 hours and 
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stored at 4°C. When all supernatants were obtained they were pooled and frozen with 
10% glycerol (filter sterilized) at -80, or concentrated immediately. 
3.4.2 Lentiviral vector titration 
For lentiviral vector titration, healthy 293T cells growing in log phase were harvested 
using TrypLE
™ 
express as before, washed, resuspended and enumerated. 
Subsequently 2x10
5
 cells were plated per well of a 6 well culture plate on the first 
morning of the procedure. On the same afternoon, serial dilutions of virus supernatant 
were made in a 24 well plate according to the anticipated viral titres. Medium was 
aspirated from the plated target cells and 5 dilutions of supernatant were added to the 
wells (plain medium in the first well; 1ml per well). Additional medium was made 
with 8μg/ml Polybrene (Millipore, Hertfordshire, UK) and a further 1ml of this 
medium was added to each well. Plates were then incubated at 37°C at 5% CO2 until 
day 3 when the cells were harvested by trypsinisation, washed, resuspended and 
transferred to flow cytometry tubes for analysis on the BD FACSAria for detectable 
marker expression. Virus titrations were calculated as follows: 
 
Transducing units/ml = [2x10
5
 seeded cells x % positive cells x 1000]/μl of vector 
3.4.3 Lentiviral vector ultracentrifugation 
Where required, lentiviral vector supernatants were concentration by 
ultracentrifugation through a 20% sucrose cushion (20% sucrose in HBSS 
(Invitrogen, Paisley, UK), filter sterilized). Three mls of the sucrose solution was 
placed at the bottom of a Beckmann centrifuge tube (Beckmann Coulter, High 
Wycombe, UK), and the lentiviral vector supernatant was carefully layered on top. 
Tubes were then placed in the ultracentrifuge buckets, positioned on the rotor and 
spun at 25000g for 2 hours. Supernatant was then discarded and the lentiviral vector 
pellet was resuspended in HBSS with 10% glycerol (filter sterilized) at a volume 
according to the anticipated titre. Virus was then aliquoted and stored at -80°C. A 
10μl aliquot was reserved for virus titration on 293T cells.  
3.4.4 Retroviral vector production 
For the preparation of retroviral vector particles, Phoenix AMPHO cell line (CRL-
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3213; ATCC) was co-transfected with the appropriate plasmids using a Fugene® 
high-density transfection reagent (Roche, Sussex, UK) method. Briefly, on the day of 
the procedure (day 1), Phoenix AMPHO cells were harvested by trypsinisation, 
washed, resuspended and enumerated. A cell suspension was made with 2x10
6
 cells in 
8mls of fresh medium and cells were plated into 10cm petri dishes and incubated at 
37°C and 5% CO2 overnight. On day 2 the transfection mix was prepared as follows: 
 
Solution A    
10μl Fugene®  
150μl OptiMEM® 
 
Solution B 
1.5μg pCL-ampho retrovirus packaging vector (Imgenex, CA, USA) 
2.6μg vector construct (SFG.Fluc_opt_2A_eBFP2; gifted by Dr Martin Pule, UCL, 
UK) 
Adjust volume to 50μl with H20 
 
The DNA mix was then added to the Fugene® solution, mixed by gentle pipetting, 
and incubated at room temperature for 15-20 minutes. The liposomal complexes were 
added directly to the Phoenix AMPHO cells and then returned to the incubator. On 
day 3, medium was removed from the Phoenix AMPHO cells, and replaced with 5mls 
of fresh RPMI (+10% FBS; 1% P/S and 1% L-glutamine). Virus supernatant was 
ready to be used for transduction on day 4. 
3.4.5 Lentiviral/retroviral vector transduction of NALM-6 cell line 
For lentiviral and retroviral vector transduction, 6 well tissue culture plates were 
coated with 2.5ml/well of Retronectin (Clontech, France) at a concentration of 
30ng/ml, and incubated at room temperature for 2-3 hours. Retronectin was then 
removed and the wells were blocked for 30 minutes at room temperature with 2ml per 
well of 2% bovine serum albumin (BSA) (Sigma Aldrich; Poole, UK) that had been 
filter sterilized. The blocking solution was then removed and wells were washed twice 
with PBS (3mls per well). NALM-6 cells that had been kept in culture prior to this 
procedure were adjusted to a concentration of 1x10
6
 cells/ml in RPMI complete 
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medium, and 2.5mls of cell suspension was added to each well of the pre-prepared 6 
well plates and incubated at 37°C for 30 minutes to allow cellular attachment. Virus 
supernatant was added to each well of a 6 well plate at the desired multiplicity of 
infection (MOI). Plates were returned to the tissue culture incubator at 37°C and 5% 
CO2 overnight. The following day, viral supernatant was removed from the wells and 
replaced with fresh RPMI complete medium (5ml/well) and further cultured at 37°C 
and 5% CO2 for 3 days, at which time cells were harvested, washed, resuspended and 
transferred into tubes for flow cytometric analysis to determine transgene expression. 
Once transgene expression was confirmed, cell sorting was performed as previously 
described in Chapter 2: Methods. 
3.4.6 Confocal microscopy 
5x10
3
 MSCs were infected with MV-NSe-GFP (MOI 1.0) for 2 hours and cultured in 
Lab-Tek™ eight-well chambered borosilicate coverglasses (Nunc, NY, USA). After 
48 hours, 75x10
3
 NALM-6 cells expressing mCherry were added and directly imaged 
by resonance laser scanning confocal microscopy (TCS SP5 RS) (Leica, UK) using 
excitation wavelengths of 488 and 594nm with 20x dry and 63x water immersion 
objectives (N.A.=1.2) and analyzed by using Volocity software (National Institutes of 
Health, USA).  
3.4.7 Xenograft models 
For assessment of MV-infected BM-MSC localization to established ALL xenografts, 
1x10
6 
viable NALM-6 cells (in 200l PBS) were injected intravenously. After 3 
weeks, intra-BM (IBM) sampling was performed to confirm leukemia engraftment 
(see below). Ten days later, animals received 1x10
6
 MV-NSe-Luc-loaded BM-MSCs 
(or PBS control) intravenously. Fate of infected BM-MSCs was determined by 
bioluminescent imaging. Shaved animals were given 200l D-Luciferin (Caliper Life 
Sciences, Cheshire, UK) intraperitoneally, and imaged under anaesthetic using an 
IVIS® 100 Lumina (Caliper Life Sciences, Cheshire, UK). Analysis was with Living 
Image® 3.2 software. To assess therapeutic efficacy, disseminated ALL xenografts 
were established by intravenous injection of 1x10
6
 viable NALM-6-Luc cells (in 
200l PBS). Weekly bioluminescent imaging was performed from week 3 onwards. 
As treatment, six consecutive weekly intravenous injections of either 1x10
6
 pfu MV-
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NSe, 1x10
6
 BM-MSCs pre-loaded with MV-NSe at an MOI of 1.0, or 1x10
6
 BM-
MSCs alone were given, starting 3 days after tumor administration. Passively 
immunized mice received 50IU anti-MV IgG intraperitoneally, 3 hours before each 
MV injection. Primary end-point was survival to humane end-point, with secondary 
end-point being disease burden (assessed by bioluminescence imaging or by flow 
cytometric quantification).  
3.4.8 IBM sampling 
Briefly, following isofluorane (Forene, Germany) induction, anesthesia was 
maintained using 1.5-2% isofluorane delivered via nose cone. The right leg/knee joint 
area of each animal was sprayed locally with 70% ethanol. Access to the BM cavity 
was obtained by flexing the right knee to 90°, drawing the proximal side of the tibia 
to the anterior, and inserting a 25-gauge needle into the joint surface of the tibia and 
into the BM cavity. BM was aspirated into a syringe containing preservative free 
heparin, and mononuclear preparations were assessed for human CD19 and CD10 
positive populations by flow cytometry. Perioperatively, animals received 
buprenorphine analgesia. 
3.5 Results 
3.5.1 Optimization of MSC and ALL cell populations 
3.5.1.1 Characterization of BM-MSCs 
BM-derived MSCs were isolated from freshly obtained healthy BM donor samples as 
detailed in Chapter 2: Methods. Following a period of expansion, passage 1-3 MSCs 
underwent cellular characterization to confirm successful isolation and ensure purity 
of the product, prior to use in future experiments. All MSCs were shown to be 
adherent to tissue culture plastic under standard growth conditions. MSC samples 
were selected at random to undergo multipotent differentiation experiments. All 
samples chosen successfully demonstrated adipocytic and osteocytic differentiation 
under required experimental conditions. Representative photographs of multipotent 
differentiation are shown in Figure 3-1. Flow cytometric analysis of cell surface 
markers demonstrated >90% positivity for CD105, CD73 and CD90 in all cases, with 
<2% of cells demonstrating CD45, CD34, and CD19 positivity – confirming low 
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levels of haematopoietic cell contamination in the product (see Figure 3-2). MSCs 
were frozen in -80°C until required. Passage 3-5 MSCs were used for all experiments 
unless otherwise stated. 
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Figure 3-1: MSC differentiation. Representative photographs demonstrating adipocytic and osteocytic differentiation of BM-MSCs, using the 
Human Mesenchymal Stem Cell Functional Identification Kit (R&D Systems, MN, USA). In addition, Oil Red O (staining triglycerides and 
lipids) and Alizarin Red (staining free calcium and calcium compounds) techniques were performed on fixed cells to demonstrate adipocytic and 
osteogenic differentiation respectively. α-FABP-4: alpha-fatty acid binding protein 4.
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Figure 3-2: MSC phenotype. (A) Live MSC populations were gated according to 
their FSC and SSC characteristics, or using PI staining where required. MSC 
populations were shown to co-express CD73, CD105 and CD90 in >95% of cells. 
Corresponding isotypes were used as negative controls. (B) On the same cell 
populations, haematopoietic markers (CD34, CD45) and B cell markers (CD19) were 
demonstrated to be negative in >95% of cells. 
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3.5.1.2 ALL cell labeling 
In order to aid both in vitro ALL cell imaging, and in vivo tumour burden monitoring, 
NALM-6 cells were used to generate stably labeled pre-B ALL cell lines by two 
methods. Firstly, lentiviral vector transduction of NALM-6 cells was performed to 
obtain cells stably expressing mCherry or GFP, and secondly retroviral vector 
transduction of NALM-6 cells was performed to obtain cells stably expressing both 
eBFP and firefly luciferase.  
3.5.1.2.1 Lentiviral transduction 
For initial labeling of NALM-6 with mCherry or eGFP, lentiviral vectors expressing 
the chosen traceable marker gene were generated as detailed in the chapter-specific 
methods. Vectors were pseudotyped with the VSV-G envelope, to confer broad 
cellular tropism, or vaccine strain MV envelope glycoproteins. In the context of 
SSPE, truncations of the cytoplasmic F protein domains have been shown to allow 
measles virus to spread more rapidly
236
. It is interesting therefore, that efficient 
retargeting of lentiviral vector entry using MV pseudotyping has been shown to 
require truncation of both cytoplasmic tails
235
. Representative photographs of 293T 
cells co-transfected with lentiviral vector constructs, the appropriate envelope 
plasmid, and p8.91 carrying the accessory proteins required for viral particle assembly 
are shown in Figure 3-3. Where cytoplasmic tail-truncated MV-H and F envelope 
glycoproteins were used, 293T cells show the presence of giant multinucleate 
syncytia – the cytopathological hallmark for MV infection. VSV-G-pseudotyped 
vector particles generated were concentrated by ultracentrifugation. Attempted 
ultracentrifugation of MV-pseudotyped lentiviral particles was undertaken (see Table 
3-1), however inadequate titres were obtained after concentration, suggesting particle 
fragility and sensitivity to rapid high velocity ultracentrifugation protocols. For this 
reason, VSV-G-pseudotyped vectors were used for NALM-6 transduction. Post 
transduction, cells were FACS-sorted according to their traceable marker, obtaining a 
population of cells with post-sort purity of >95% in all cases. Following this, cells 
were either propagated in tissue culture, or frozen in aliquots for use in future 
experiments. Only short-term co-culture experiments were performed using mCherry 
transduced NALM-6 cells (maximum co-culture period 48 hours), and for this reason 
long-term stability of transgene expression was not determined here.  
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3.5.1.2.2 Retroviral vector transduction 
NALM-6 cells stably transduced to express firefly luciferase were generated for the 
purposes of in vivo tumour burden monitoring. Vector particles were generated, and 
NALM-6 cells transduced and FACS-sorted as detailed in chapter-specific methods. 
As luciferase-expressing NALM-6 cells (NALM-6-Luc) were to be used to for pre-B 
ALL murine xenograft modeling, stability of transgene expression was characterized 
over a 6-week period (the timescale over which unmanipulated NALM-6 
disseminated murine xenografts will succumb to leukaemia if left untreated). A shows 
in vitro characterization of eBFP expression (and corresponding mean fluorescent 
intensity (MFI)) in transduced NALM-6 cells as compared to mock-transduced cells 
over time. Both the percentage expression and MFI remain relatively stable over a 6-
week period. Correlation between amount of luciferase activity and number of 
transduced NALM-6 cells is shown in Figure 3-4C, whilst Figure 3-4D shows 
luciferase activity in transduced NALM-6 cells (minus background luminescence) 
over 6 weeks. In order to evaluate the ability of the NALM-6-Luc cell line to be used 
for tumour burden monitoring in vivo, 6-8 week old SCID mice were injected with 
1x10
6 
NALM-6-Luc cells via the lateral tail vein (or PBS control) and underwent 
weekly bioluminescent imaging to assess relative tumour burden. Tumour 
engraftment was evidenced by a steady increase in the amount of luminescence 
activity detectable in all mice receiving the NALM-6-Luc cell line. Luminescent 
activity was generally detectable from week 3 post-inoculation onwards, with all 
animals (except control) succumbing to their humane endpoint at 6 weeks post-
inoculation (see Figure 3-5). 
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Figure 3-3: mCherry and eGFP lentiviral vector generation on 293T cells. Representative photographs of 293T cells at 24 hours post-
transfection with SIN lentiviral vectors carrying mCherry and eGFP and the gag/pol expressor plasmid pCMV-ΔRp8.91. Lentiviral vector 
particles are pseudotyped with either tail-truncated MV-H and F glycoproteins (pCGHcΔ18+pCGFcΔ30) or VSV-G envelope glycoprotein 
(pCAGGS-VSV-G).  
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Table 3-1: Lentiviral vector titration. 
Lentiviral vector particles Lentiviral vector titration (transducing units per ml) 
 
VSV-G-pseudotyped lentivirus expressing eGFP 
 
5.9x10
8
 (post ultracentrifugation) 
 
VSV-G-pseudotyped lentivirus expressing mCherry 
 
1.4x10
8
 (post ultracentrifugation) 
 
MV-pseudotyped lentivirus expressing eGFP 
 
3.2x10
6 
 
MV-pseudotyped lentivirus expressing mCherry 
 
6.4x10
5 
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Figure 3-4: NALM-6-Luc characterisation. (A) % eBFP cell surface expression for transduced and 
mock-transduced NALM-6 cells as assessed by flow cytometry. Live cell population was gated according 
to FSC and SSC characteristics. (B) Corresponding MFI of transduced and mock-transduced cells. (C) 
Linear regression of luminescent activity (photons/second) for NALM-6-Luc cells at differing 
concentrations, performed immediately post sorting. (D) Luciferase activity (photons/second) for equivalent 
numbers of NALM-6-Luc cells kept in continuous cell culture for the duration of the experiment.   
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Figure 3-5: NALM-6-Luc disseminated xenograft model. SCID mice were injected with 1x10
6 
NALM-6-Luc 
cells via the lateral tail vein, or PBS as a control. Bioluminescent imaging was performed on a weekly basis. 
Representative images are shown at 3 and 5 weeks post tumour inoculation. 
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3.5.2 Anti-measles antibody titres persist in ALL patients following treatment 
In order to contextualize the issue of humoral immunity and systemic measles 
virotherapy in ALL, quantification of anti-MV IgG antibody levels was performed in 
a cohort of 16 adult patients undergoing intensive immunosuppressive chemotherapy 
as participants in the UKALL14 trial (NCT01085617) – an international randomized 
trial for newly diagnosed adult ALL patients. Biobanked sera samples used for the 
purposes of this study were prior obtained following informed consent, in accordance 
with the UKALL14 ethically approved study protocol (REC reference: 09/H0711/90). 
All patients had been treated according to an intensive chemotherapy regime 
including high dose steroids, vincristine, daunorubicin, L-asparaginase, anti-B cell 
monoclonal antibodies, 6-mercaptopurine, cytarabine and cyclophosphamide. Day 3 
of phase 1 induction is the earliest timepoint that sera was obtained following 
treatment initiation, with post-intensification samples being obtained following a 
minimum of 3 months of almost continuous, potentially immunosuppressive 
chemotherapy. Paired sera samples taken at a minimum of 2 different time points 
during phase 1 induction and post intensification were examined initially. A single 
patient had anti-MV IgG titres deemed insufficient for protective immunity against 
MV at the start of induction treatment, with sub-optimal titres persisting post 
intensification. One further patient had IgG titres just above the level at which they 
would be deemed MV immune at the start of treatment, which fell to just below MV-
immune levels (<200mIU/ml, IBL international) post-intensification. All other 
patients with paired samples from phase 1 induction and post intensification showed 
anti-MV IgG titres persisting at clinically significant levels during this time, despite 
the immunosuppressive chemotherapy that they received, with no significant 
difference between titres at these timepoints (D3 phase 1 induction: 2340 +/- 360.8 
IU/ml; D18 phase 1 induction: 2531 +/- 71.50 IU/ml; D2 post-intensification: 2293 
+/- 415.0 IU/ml; D16 post-intensification: 2046 +/- 516.6 IU/ml) (see Figure 3-6A 
and B). This data clearly demonstrates the potential significance of anti-measles 
antibody levels in adult ALL patients when systemic measles virotherapy is being 
considered as a novel treatment strategy, and suggests that innovative ways in which 
humoral immunity can be overcome to promote therapeutic success of this approach 
need to be closely considered. 
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Figure 3-6: Intensive immunosuppressive therapy for ALL does not suppress anti-MV IgG production in patients on the UKALL14 
trial. (A) Graph showing anti-MV IgG titres as quantified by ELISA. Paired sera from 16 patients participating in the UKALL14 trial were 
evaluated at a minimum of 2 time points (x-axis). Each dot represents a value, with a line connecting each patient’s individual values. The dotted 
line represents the level at which a human is considered immune to MV infection. (B) Graph showing individual values with mean (horizontal 
line) and SEM of anti-MV IgG for the 12 patients with samples from the earliest (day 3 phase 1 induction) and latest time points (post 
intensification). There is no statistical difference between the two time points.
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3.5.3 BM-MSCs support MV infection ex-vivo 
Next, MSCs were prepared from normal human BM and their appropriate 
characteristics were demonstrated. To confirm the susceptibility of BM-MSCs to MV 
infection ex-vivo, we evaluated cell surface expression of the known MV receptors 
CD46, SLAM and Nectin 4 by flow cytometry (see Figure 3-7A-D). Positive controls 
for CD46, SLAM and Nectin 4 were Raji, Vero-SLAM and MCF7 cell lines 
respectively. BM-MSCs consistently expressed CD46 – the receptor for oncolytic 
vaccine strain MV, whilst the MV wild-type receptor SLAM, and the epithelial 
receptor Nectin 4 were negative. 
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Figure 3-7: MV receptor expression profile of BM-MSCs. (A) Representative plots 
showing negative (isotype) and positive controls for Nectin 4, CD150/SLAM and CD46 
using MCF7, Vero-SLAM and Raji cells respectively. (B) Representative plots showing 
MSCs stained with IgG1 FITC or CD46 FITC. (C) Bar chart showing mean percentage MV 
receptor expression on BM-MSCs and (D) mean fluorescent intensity (MFI) of antibody 
stained cells (minus isotype MFI). For CD46 N=5 and data is shown as mean +/- SEM. For 
CD150 and Nectin 4, N=1. 
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3.5.4 BM-MSCs can act as viable MV producing units  
Next, I determined the optimum multiplicity of infection (MOI) and time-point post-
infection, at which maximal virus productivity occurs with minimum BM-MSC death. 
BM-MSCs were infected with MV-NSe-GFP at MOI 0.1, 1.0, 2.0, and 5.0 and 
visually compared for the extent of GFP positivity in cells at 24-hourly timepoints 
post infection. GFP positivity consistently showed a peak in intensity at 48 hours post 
infection (hpi). In addition, MV-H glycoprotein immunostaining was performed to 
demonstrate cell surface MV-H envelope glycoprotein expression. Cell surface MV-H 
glycoprotein expression correlated closely with cellular GFP expression, reaching 
maximal intensity at 48 hpi. Photomicrographs of representative experiments at 48 
hpi with MOI 1.0 are shown in Figure 3-8 demonstrating MV cytopathy, with 
widespread multinucleate syncytia formation and GFP expression. After 48 hours, 
morphological evidence of cell death ensued. The viability of BM-MSCs was 
formally assessed by MTS assay. Figure 3-9A shows cell proliferation (relative to 
uninfected control cells) at each timepoint for each MOI. At MOI of 1.0 there was no 
significant difference in cell viability between timepoints, with relative cell 
proliferation remaining above 100%.  
 
Assessment of viral genome, by RQ-PCR for MV-N mRNA was also performed 
using RNA extracted from MSCs infected with a range of MOIs, at 24-hourly 
timepoints post infection. Whilst there was a clear increase in MV-N mRNA with 
MOI 1.0 versus MOI 0.1 (see Figure 3-9B), increasing the MOI beyond this provides 
no additional benefit. Using MOI 1.0, there was a demonstrable peak in MV-N 
mRNA productivity at 48 hours post infection (see Figure 3-9C), which does not 
improve at later timepoints. 
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Figure 3-8: MV infectivity of BM-MSCs. (A) Representative photographs (standard 
and fluorescent) of MSCs infected with MV-NSe-GFP at an MOI of 1.0, taken at 48 
hours post infection. Corresponding photographs for mock-infected cells are shown 
below. (B) Representative photographs of MSCs infected with MV-NSe at MOI 1.0 
(48 hours post infection) and stained for MV-H glycoprotein. To account for non-
specific staining, infected cells stained with isotype only are represented below.
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Figure 3-9: MSC viability and MV-N mRNA productivity post infection. (A) MSCs were infected, or mock-infected, at a range of 
multiplicities of infection (MOI) and cell proliferation of infected cells relative to their mock-infected counterparts was assessed using MTS 
assay, at 24-hourly intervals post infection. (B) MV-N mRNA levels were assessed by RQ-PCR performed using RNA extracted from MV-
infected MSCs for a range of MOIs (data shown is for 48 hours post infection) and (C) at 24-hourly intervals post infection (data shown is for 
MOI 1.0). N=3 independent experiments performed in triplicate. GAPDH was used as the housekeeping gene in all cases, with equivalent mock-
infected cells used as the calibrator. Data shown is mean +/- SEM.
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For further assessment of MSC virus productivity, cell-associated and supernatant 
virus output was quantified on MSCs infected using MV-NSe at MOI 1.0, by TCID50. 
In line with previous data, virus titrations confirmed a peak in cell-associated virus 
productivity at 48 hpi (see Figure 3-10A). Notably, there was almost no virus shed 
into the supernatant. Finally, I demonstrated that upon reducing virus-mediated cell-
cell fusion and multinucleate syncytia formation by the post-infection addition of FIP 
to cell culture medium, cell-associated virus titres were higher at all timepoints post 
infection (Figure 3-10B), with a trend towards statistical significance at later 
timepoints. Trypan blue viability assay confirmed a reduction in MV-specific cell 
death for cells cultured with FIP as compared to those cultured without (Figure 3-11). 
Taken together, these data confirmed optimal conditions for ex-vivo BM-MSC 
loading using an MOI of 1.0 for cellular MV infection, and utilizing the post-infection 
addition of FIP to tissue culture media to improve cell viability and productivity. For 
in vivo experiments, cellular harvest was performed at 24 hours post ex-vivo loading, 
prior to optimal virus production at the 48 hour time point.  
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Figure 3-10: MSC cell-associated and released virus titres. (A) At 24-hourly timepoints, TCID50 virus titrations were performed on MSC cell 
lysates (black) and tissue culture supernatants (red) from cells infected using a range of MOIs. (B) The effect of FIP on cell-associated TCID50 
virus titrations is shown using cells infected with MOI 1.0, taken at 48 hours post infection. N=3 independent experiments performed in 
duplicate. Mean +/- SEM are shown. The effect of FIP has been analyzed using an unpaired t-test. For 72 hpi *p=0.05.
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Figure 3-11: The effect of FIP on viability of MV-infected MSCs. MSCs 
were infected at MOI 1.0 and trypan blue viability assessment was performed 
every 24 hours for 3 days. Mock-infected cells were also assessed and data is 
expressed as the amount of MV-specific cell death by subtracting the number 
of non-viable mock-infected cells from non-viable MV-infected cells, and 
expressing as a percentage of the total cell number. Data shown is mean +/- 
SEM. N=3 independent experiments.  
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3.5.5 In vivo localisation of MV-infected BM-MSCs 
To evaluate the ability of ex-vivo loaded BM-MSCs to localize to established sites of 
ALL we used a previously characterized model of disseminated precursor B lineage 
ALL
19
. 6-8 week old SCID mice were injected with 1x10
6
 NALM-6 cells 
intravenously. After 3 weeks IBM sampling from the right femur in each animal 
confirmed co-expression of human CD19 and CD10, indicating tumor cell 
engraftment in all mice. Representative flow cytometry plots are shown in Figure 3-
12A. Injection of MV-loaded carrier cells was performed 10 days later, to minimize 
the potentially confounding issue of BM-MSC homing towards injured tissues 
resultant upon the sampling method.  Passage 3 BM-MSCs were loaded ex-vivo with 
a firefly luciferase expressing MV (MV-NSe-Luc) at MOI 1.0, and 24 hours post 
inoculation, cells (1x10
6
 cells per mouse) were harvested and injected intravenously, 
with control mice receiving PBS alone. The fate of infected cells was tracked using 
bioluminescent imaging performed at 24-hourly timepoints for 10 days. Figure 3-12B 
shows representative images confirming early localization of MV-infected BM-MSCs 
to lung parenchyma, consistent with first pass entrapment as detailed by other 
groups
237,238
. However, by day two following BM-MSC infusion, there was re-
localization of bioluminescence signal to the ALL-containing BM. As we know from 
previous experiments, that virus production was essentially confined to the 
intracellular compartment (with amounts of released virus being negligible), this data 
confirms the ability of MV-NSe-Luc to reach distant tumor targets when delivered 
intravenously within BM-MSC. Furthermore in 2/3 animals, bioluminescent activity 
co-localized within the contralateral BM from that used for IBM sampling, proving 
that homing was not solely related to bony injury resultant upon sampling methods. 
Attempts to directly demonstrate the presence of human MSCs within the murine BM 
by flow cytometry were unsuccessful, due to low input cell doses, and lack of long-
term engraftment of systemically delivered MSCs as shown by others
239
. 
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Figure 3-12: In vivo MV-NSe-Luc-infected MSC localisation. (A) Representative flow cytometry plots of murine BM 
confirming the presence of human CD19 (X axis) and CD10 (Y axis) - expressing leukaemia populations. Gating was of 
live cells based on FSC and SSC characteristics, with appropriate isotypes used as negative controls. (B) Representative 
bioluminescence images of SCID mice following systemic injection with MV-NSe-Luc-infected BM-MSCs. Mice 
receiving PBS only were used as controls to account for background luminescence. For treatment group N=3. 
A B 
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3.5.6 BM-MSCs allow successful hand-off of virus to tumour cell targets in the 
presence of humoral immunity 
Next, the ability of BM-MSCs to deliver MV to ALL cells in the presence of pre-
existing neutralising antibodies was assessed. Human anti-MV antisera (obtained 
from discard clinical samples identified as having high titre anti-MV antibodies 
present) were obtained. Anti-MV IgG was titrated in pooled, heat-inactivated sera 
using ELISA (see Methods – Chapter 2) and quantified at 490IU/ml. MV-loaded BM-
MSCs or naked MV was treated with serial dilutions of high titre anti-MV antibody 
serum ex-vivo, before being overlaid onto the standard MV culture cell line, Vero. 
MV hand-off from BM-MSC to Vero was quantified by syncytia formation at 48 
hours post overlay (Figure 3-13). Naked MV was very effectively neutralised by anti-
MV IgG – with syncytia being evident only at very low concentrations of antibody  
(1:256 or higher dilution). When Vero cells were overlaid with MV-infected BM-
MSCs, greater numbers of syncytia were seen at all antibody concentrations. 
Statistically significant differences were seen in numbers of syncytia for 1:256 and 
1:1024 antibody dilutions. MV-infected BM-MSCs permitted MV ‘hand-off’, at high 
antibody concentrations (1:8 dilution), a five-fold higher concentration than the 
minimum concentration (1:256 dilution) permissive to infection when naked MV was 
used. These data confirm the ability of BM-MSCs to protect MV against antibody 
neutralisation in-vitro. 
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A. Figure 3-13: In vitro virus neutralisation in the presence of anti-MV antibody. Vero cell syncytia quantification at 48 hours post overlay 
with MV-NSe-loaded BM-MSCs or naked MV-NSe pre-treated with dilutions of high titre anti-MV antibody. Total numbers of syncytia 
from each well of a 96 well plate were counted. Data is represented as a percentage of virus control (MV or MV-infected cells with no serum 
pre-treatment; X axis) in relation to serum dilution (Y axis) for naked MV and MV-infected BM-MSCs, and shown as mean +/- SEM. N=6 
from 3 independent experiments. Analysis uses the unpaired t-test. For 1:256 dilution, **p=0.047; for 1:1024 dilution, **p=0.0051.  
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Following this, I used a dual colour system to perform live-cell confocal microscopy, 
and allow for direct visualisation of virus ‘hand-off’ between NALM-6 ALL cells – 
stably transduced to express mCherry (see Chapter 3: Methods), and green MV-NSe-
GFP-infected BM-MSCs.  Representative still images are shown in Figures 3-14A 
and B, and demonstrate the different stages of heterofusion events between red 
NALM-6 cells and green MV-NSe-GFP-infected BM-MSCs. Figure 3-14A shows a 
series of images taking place over 20 minutes of co-culture (for full video see 
Appendix), with the diagrammatic representation of heterofusion shown in figure 3-
14B. Figure 3-14C shows multiple episodes of the same process over a 3 minute 
timescale. In Figure 3-14A, a single NALM-6 cell is seen to transition from red, 
becoming yellow as heterofusion takes place, and subsequently green as MV-NSe-
GFP hand-off occurs. Corresponding grey-scale images are shown beneath each 
fluorescent image here. In rare events, ALL cells were seen to turn green without 
evidence of fusion, and the presence of cell to cell nanotubule formation was 
identified. The live-cell imaging approach was used to probe the role of anti-MV 
antibodies in the BM-MSC-to-ALL cell fusion/hand-off process. As indicated in 
Figure 3-15A, cells were pre-incubated with anti-MV antibody containing serum, 
diluted either 1:4 (positive control, expected from data in Figure 3-13 to block fusion 
in both conditions) or 1:128 (the highest antibody dilution expected to clearly 
discriminate between the two conditions), or with FIP as an additional positive 
control. Figure 3-15A and B show the percentage of NALM-6 cells fusing with 
infected BM-MSCs, or ratio of mCherry:GFP respectively, following 80 minutes of 
co-culture. When anti-MV antibodies are absent, up to 40% of cells in contact 
demonstrated heterofusion within this time frame. Whilst fusion was predictably and 
significantly ablated in the presence of 1:4 serum dilution, or with FIP (positive 
control), no significant difference in heterofusion was observed in the presence of 
1:128 serum dilution, with just over 20% of cell-cell heterofusion events remaining 
i.e. half the level of the negative control condition. To be certain that anti-MV 
antibody did not affect contact time between cells rather than prevent fusion, BM-
MSC-to-ALL cell contact time in the presence of 1:128 serum dilution was quantified 
for at least n=125 events. The majority of heterofusion events were rapid, occurring 
within 20 minutes of co-culture (see Figure 3-15C) indicating that contact time 
between ALL and BM-MSC did not significantly change with the addition of anti-
MV antibody. Taken together these data illustrate the ability of MV-infected BM-
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MSCs to readily ‘hand off’ viable replicating MV to non-infected ALL cell targets, 
with BM-MSCs affording MV significant protection against neutralising antibodies 
in-vitro. A proportion of the virus ‘hand-off’ occurs via the rapid process of carrier 
cell-to-tumour cell heterofusion.  
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B. Figure 3-14: Carrier cell to tumour cell heterofusion and virus hand-off. (A) Representative live-cell confocal images 
of BM-MSCs at 48 hpi with MV-NSe-GFP (MOI 1.0), co-cultured with NALM-6 cells transduced with mCherry. Images 
show the different stages of a fusion event between a NALM-6 cell (red) and an infected BM-MSC (green). Scale bar 
represents 10 m. (B) Representative diagram of heterofusion process (adapted from Horwiz et al. Blood 2014). (C) 
White arrows represent NALM-6 to MSC heterofusion events taking place over a 3-minute time period.  
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C. Figure 3-15: Quantification of heterofusion events. (A) Percentage of NALM-6 cells fusing (dark grey bars) or not (light grey bars) 
after establishing contact with infected BM-MSCs within 80 minutes of co-culture (first column). Columns 2-4 represent the test and 
control conditions, with dilutions of serum or FIP, as indicated. ** p<0.01; * p<0.05. (B) Ratio of red fluorescence in green syncytia over 
80 minutes of co-culture. Columns are as for (A). (C) Contact time between NALM-6 cells and BM-MSC before fusion occurs, within 
80 minutes of co-culture. When indicated, cells were also pre-incubated with anti-MV antibody serum 1:128. For each of the above 
conditions, n>125 cells were counted, data are from 6 independent experiments, with mean +/- SEM shown. 
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3.5.7 Therapeutic efficacy of BM-MSC-delivered oncolytic measles virotherapy 
in a disseminated precursor-B lineage ALL murine xenograft model 
We then determined whether the in vitro findings could be translated into therapeutic 
efficacy in a SCID murine model of precursor B-lineage ALL. 6-8 week old SCID 
mice received intravenous injection with 1x10
6
 NALM-6 cells stably transduced to 
express firefly luciferase. On day 2, mice received intravenous injections of either 
1x10
6
 plaque forming units (pfu) MV-NSe, 1x10
6
 BM-MSCs loaded ex-vivo (24 
hours prior) with MV-NSe at an MOI of 1.0, or 1x10
6
 uninfected BM-MSCs. 
Treatments continued weekly, for a total of 6 weeks. Treatment groups were further 
divided into mice receiving passive immunization with 50IU anti-measles IgG, 
delivered intraperitoneally 3 hours before each therapy injection, or those receiving 
PBS as a control. Tumor burden was quantified by bioluminescent imaging. Overall 
survival (OS) was plotted using the method of Kaplan-Meier. Figure 3-16 shows the 
OS of all mice by treatment allocation. As expected, mice receiving BM-MSCs alone 
rapidly succumbed to ALL (median survival 53 days; range 42-62 days) Mice treated 
with naked MV had a significantly enhanced OS, consistent with our previously 
published data (median survival 91 days; range 69-96 days).  When anti-MV antibody 
was administered to mice treated with naked MV, the therapeutic effect was 
abrogated (median survival 64 days; range 53-81 days). The difference between these 
groups was statistically significant (P=0.0013). Mice who received MV delivered 
within BM-MSCs had the best anti-tumor response (median survival >100 days) with 
all mice surviving to the end of the experiment, significantly superior to those 
receiving MV alone (P=0.0022). The administration of anti-MV antibody to mice 
receiving MV within BM-MSC did not abrogate the therapeutic effect at all. 
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Figure 3-16: Therapeutic efficacy of cell carrier-delivered oncolytic measles virotherapy in a NALM-6 disseminated model of precursor 
B cell ALL. Kaplan Meier survival curves of mice bearing disseminated NALM-6 xenografts treated intravenously with a total of either 1x10
6
 
pfu MV-NSe; 1x10
6
 BM-MSCs loaded with MV-NSe at MOI 1.0, or 1x10
6
 uninfected BM-MSCs. Mice in the relevant groups also received 
50IU (100μl) of anti-MV IgG antibody (or 100μl PBS control) via the intraperitoneal route 3 hours before each MV injection. Data represent 
results from 3 independent experiments. N=2-5 per group. 
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Figure 3-17 shows representative bioluminescent imaging performed at equivalent 
timepoints, pictorially representing the relative tumor burdens for animals in the 
different treatment groups. Luminescent activity (relative light units (photons/second) 
is shown for all animals at week 6 as a scatter plot in Figure 3-18. Data for each 
animal is shown minus the mean average background luminescence values for control 
animals. The data in Figure 3-16 and Figure 3-18 confirm a statistically significant 
therapeutic benefit of delivering MV within BM-MSCs, in the presence of anti-MV 
humoral immunity. To ensure that any technical problems with ALL engraftment had 
not biased the results, flow cytometric evidence of ALL was sought at experiment 
termination in the BM of every animal in which bioluminescence did not show overt 
disease.  Every mouse, even the long-term survivors, had some flow cytometric 
evidence of leukemia within the BM at termination. These data confirm our previous 
finding that systemically administered MV can successfully treat mice with 
aggressive disseminated ALL. We have shown that anti MV antibody abrogates this 
therapeutic potential. However, administration of MV inside BM-MSC carriers 
‘protects’ the virus against antibody neutralization allowing an on-going therapeutic 
effect of systemically administered virus against disseminated tumor in the presence 
of high titre antibody. 
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Figure 3-17: In vivo bioluminescent imaging. Representative bioluminescence images of SCID mice treated with naked 
MV, MV-infected BM-MSCs or BM-MSCs alone in the presence or absence of anti-measles antibody containing serum. 
The images demonstrate disease burden post ALL cell injection at 6, 9 and 12 weeks. Where no image is shown, this 
indicates that no mice remained in the relevant treatment group.  
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Figure 3-18: Quantification of tumour burden using bioluminescence. Scatter dot plot showing individual values for luminescence 
(photons/second) performed on each surviving animal in each treatment group at week 6. Values are represented minus background activity. 
Data shown are mean +/- SEM. To ensure data for all surviving animals could be plotted, zero or negative values were arbitrarily assigned a 
value of 1.0. **p=0.0051. 
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3.5.8 Discussion 
We have previously shown that disseminated pre-B ALL xenografts in SCID mice are 
highly sensitive to MV-mediated oncolysis
19
. For our planned phase 1 trial in patients 
with relapsed ALL, the co-administration of various immunosuppressive anti-ALL 
agents such as cyclophosphamide, steroid or anti-B cell monoclonal antibodies 
alongside MV therapy is under consideration, with the aim of suppressing an anti-MV 
response. This rationale is based on murine data suggesting that clinically approved 
cyclophosphamide regimens can suppress humoral anti-MV and anti-VSV 
responses
185
. However, data here shows, on sera samples taken from a subset of 
UKALL14 trial participants before and after intensive immunosuppressive and 
myelosuppressive chemotherapy (including dexamethasone, anthracycline, 
vincristine, asparaginase, cyclophosphamide, and cytarabine) that clinically 
significant anti-MV antibodies persist, confirming the need for an alternative but 
clinically relevant strategy for circumvention. It is worth mentioning, that ELISA-
based methods of detecting and quantifying anti-measles IgG levels were used here, 
and the neutralizing capabilities of these antibodies were assumed. However, in order 
to determine the neutralizing capabilities of such antibodies, functional assessment 
(eg. plaque reduction neutralization assay or TCID50 assessment) would be required.  
 
In contrast to primary ALL tumor cells, that typically die soon after MV infection
19
, 
BM-MSCs are readily infectable by MV, retain viability at 48 hours post infection, 
and continue to produce virus. Attempts to accurately quantitate the level of cellular 
MV infection by using flow-cytometric based methods to assess extent of GFP 
positivity were challenging, due to autofluorescence of infected MSCs, and syncytia 
formation post infection (resulting in underestimation of values). Performing accurate 
quantification at very early timepoints post infection (in the presence of fusion 
inhibitory peptide to minimize syncytia effect) may be required in order to extrapolate 
more accurately the likely infectious burden at the time of cell harvest. Quantitative 
data in terms of the extent of plaque formation could also be obtained using image J 
(or equivalent) software. In MSC ex-vivo virus loading experiments detailed in this 
chapter, I used FIP to block cell-cell fusion and enhance viability and productivity of 
carrier cells until delivery to SCID mice. Alternatively, by introducing anti-F siRNA 
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into the carrier cells, MSCs could be infected with virus, but prevented from 
undergoing fusion before hand-off at distant tumour targets occurs.  
 
MV-loaded BM-MSCs localized to sites of ALL in the BM of mice following 
intravenous infusion. Before moving to therapeutic studies in mice, I was keen to 
quantify the interaction between BM-MSCs and target ALL cells precisely. The 
timescale over which virus ‘hand-off’ occurs, and whether this process occurs by 
fusion or by cellular infection from released virus are important questions, as both 
parameters are likely to influence the potential success of this delivery approach in 
clinical trials. Live cell confocal imaging confirmed that the majority of ‘hand-off’ 
occurs via a process of cell-cell heterofusion, and occurs rapidly (within 20 minutes 
of co-culture), suggesting that virus delivery to tumor would take place in vivo long 
before BM-MSC viability is compromised and prior to any anamnestic response is 
generated. Live cell confocal imaging was also used to visualize the impact of 
antiviral antibodies on this process. Heterofusion events – impossible unless MV-H 
and F glycoproteins are both displayed at the surface of the BM-MSC - were 
predictably ablated in the presence of very high antibody concentrations and FIP, 
whilst at lower antibody concentrations heterofusion events remained plentiful.  
In vivo, passive immunization of animals prior to each MV administration was 
provided with injection of high titre anti-MV antiserum (50IU anti-MV IgG) – 
equating to an ultimate anti-MV antibody concentration several logs higher than the 
300mIU/ml deemed ‘high titre’ in the clinical setting. This was sufficient to almost 
completely abrogate therapeutic responses to naked MV. However, successful 
delivery and therapeutic efficacy of BM-MSC-delivered oncolytic MV was 
demonstrated in this setting, suggesting successful MSC homing, virus hand-off, and 
ultimately therapeutic protection from repeated infusions of anti-MV antibody 
designed to model an anamnestic response. This is in contrast to the lack of 
abrogation of MV anti-tumor responses that we have previously described when anti-
viral antibodies are delivered locally to MV-treated subcutaneous human B cell 
lymphoma xenografts
14
, further highlighting the central importance of shielding the 
virus from anti-MV antibodies during systemic delivery to a disseminated 
malignancy. Unexpectedly, delivering MV within BM-MSC carriers also improved 
anti-ALL efficacy beyond that seen with naked MV. Since BM-MSCs administered 
alone granted no survival benefit, we hypothesize that the continuing MV replication 
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and production within the BM-MSCs, enhances the virus payload reaching distant 
tumor targets.  
 
As previously stated, the ability to be able to detect MRD in the vast majority of 
patients with ALL provides a basis for early intervention with novel therapeutics such 
as oncolytic MV, prior to overt disease relapse. Bringing this novel delivery approach 
to the clinic would require clarity surrounding the virus quantification methodology, 
and how it can be accurately and reliably assessed so that the ultimate delivery dose 
of virus is reproducible. It is also worth noting that in the NALM 6 SCID mouse 
model of pre-B ALL, a common primary endpoint is hind limb paralysis – thought to 
be related to infiltration of disease within the spinal canal and CNS. Whilst the CNS 
was not directly examined at post-mortem to assess the presence of virus in these 
experiments outlined here, this would be an important finding in the context of the 
known MV-related CNS complications that can occur in heavily 
immunocompromised individuals post MV vaccination.  
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Chapter 4:  Manipulating the MV genome to enhance 
localization of infected carrier cells 
4.1 Background 
4.1.1 MSC homing 
Whilst many investigators have demonstrated that site-directed administration of 
MSCs can result in cellular localization, integration and engraftment – most often in 
injured tissues - such targeted administration is only practicable in a limited number 
of applications. For this strategy to be effectively utilized in the treatment of a 
disseminated haematological malignancy such as ALL, the localization of 
systemically administered MSCs to appropriate tissues such as BM and lymphoid 
organs should be demonstrated. Although the homing mechanisms of other cell types 
such as leucocytes and haematopoietic stem cells are well characterized, the 
mechanisms by which MSCs migrate to, engraft in, and exert local functional effects 
at the target tissue site are less well defined. Homing is thought to be a multi-step 
process involving numerous adhesion molecules and chemokines (see Figure 4-1). 
SDF-1α is a chemotactic cytokine that is known to play a major role in the homing 
and engraftment of haematopoietic stem cells and progenitor cells to the BM
240
. A 
number of studies have confirmed the interaction of SDF-1α and its receptor CXCR4 
as central in mediating MSC homing to areas of tumour growth as well as normal BM 
stroma
241-243
. Levels of both SDF-1α and CXCR4 have been shown to be upregulated 
in stressed or injured tissues
244-246
. Whilst CXCR4 is expressed only at low levels (1-
3%) on the surface of human BM-MSCs
243
, in-vitro migration assays have repeatedly 
demonstrated the importance of this signaling pathway in the migration of MSCs, and 
it has been postulated that this is due to upregulation of functional intracellular 
CXCR4 to the cell surface in appropriate conditions
242,243,247
. Whether or not we can 
assume that the ‘signals’ provided by malignant haematopoietic cells are sufficient to 
stimulate the process of homing and tumour localization for MV-infected BM-MSCs 
remains to be determined.  
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4.2 Purpose of this chapter 
Whilst numerous groups have demonstrated the migratory capacity of MSCs, low 
surface expression levels of CXCR4 on MSCs and downregulation of chemokine 
receptor expression during ex-vivo culture with concomitant decrease in chemotactic 
responses
248
, present potential limitations to the therapeutic utility of these cells. 
Other groups have demonstrated that CXCR4 overexpression by retroviral vector 
transduction produces enhanced MSC homing and stromal engraftment
249
. Thus, in 
anticipation of potential limitations of using heavily manipulated MSCs to deliver 
vaccine MV to distant tumour targets, and as a means of improving the use of MSCs 
as vectors for viral delivery, this chapter explores the generation of a novel strain of 
MV expressing the human chemokine receptor hCXCR4 gene as an additional 
transcription unit within the viral genome. The aim of this approach was to promote 
hCXCR4 surface expression on infected cell carriers, thereby enhancing trafficking, 
and ultimately improving therapeutic outcomes of the MSC cell carrier approach to 
virus delivery. As there is a high level of homology between murine and human 
CXCR4 (>90%), the generation of a novel strain of MV expressing the hCXCR4 gene 
was thought unlikely to be a hindrance to the application of this virus in murine 
models of pre-B ALL. The work carried out in this chapter was performed in parallel 
to early ex-vivo MSC virus loading experiments detailed in Chapter 3, using standard 
vaccine strains of MV. Successful localization of MV-NSe-Luc-infected MSCs to the 
BM in pre-clinical SCID mouse models of disseminated precursor-B lineage ALL had 
not been demonstrated prior to commencement of the work outlined in this chapter. 
Furthermore, pre-clinical therapeutic efficacy of the BM-MSC carrier approach to 
systemic delivery of unmanipulated MV-NSe strains had not been demonstrated at the 
time this work was initiated.  
4.3 Hypotheses 
a. MV-infected BM-MSCs will show sub-optimal localization to tumour targets 
within the murine BM, due to downregulation of chemokine receptors during 
ex-vivo culture.  
b. MSCs infected with a hCXCR4-expressing oncolytic MV may upregulate 
trafficking to tumour sites and enhance tumour killing.  
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Figure 4-1: Mechanisms of MSC trafficking (adapted from Fox et al. 2007). VCAM-1: vascular cell adhesion 
protein 1; VLA-4: very late antigen 4 (integrin alpha4beta1); GAGs: glycosaminoglycans; TNF-α: tumour necrosis 
factor alpha.  
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4.4 Methods 
4.4.1 TOPO TA cloning 
The hCXCR4 gene was PCR amplified from a human CXCR4 cDNA containing 
vector (Cambridge Bioscience Ltd, Cambridge, UK) using the following primers 
tailed with MluI and AatII restriction sites at the 5’ and 3’ flanks respectively 
(underlined):  
 
CXCR4 s 5’-atgctgacgcgtgATGTCCATTCCTTTGCC-3’  
CXCR4 a 5’-tgaccagacgtccTTAGCTGGAGTGAAAAC-3’  
 
The PCR product was ligated into pCRII-TOPO cloning kit and the insert verified by 
sequence analysis. Both pCRII-TOPO-CXCR4 and a previously generated plasmid 
encoding a GFP expressing NSe strain of MV (p(+)MV-NSe-GFP) were restriction 
digested using MluI and AatII restriction enzymes, and the CXCR4 insert and MV 
backbone obtained by QIAex II gel purification of DNA unexposed to UV light, prior 
to ligation to produce p(+)MV-NSe-CXCR4. Bacterial transformation was performed 
using One shot® TOP10 competent cells, by adding 1 to 5ul ligation reaction directly 
to a vial of competent cells and incubating on ice for 30 minutes, heat-shocked at 
42°C for 30 seconds, and then adding 250μl of pre-warmed SOC medium to each 
vial. Vials were then placed in a shaking incubator at 37°C for 1 hour at 225 rpm. LB 
agar plates containing 100μg/ml ampicillin were spread with 20-200μl of each 
transformation reaction, inverted and stored in a bacterial incubator at 37°C overnight. 
Colonies were picked with a sterile pipette tip and transferred to 2mls LB broth to 
form a starter culture, and placed in the shaking incubator at 37°C for 3-4 hours, 
before being transferred to 50mls of liquid culture medium and left in the shaking 
incubator overnight. The following morning, liquid culture medium was decanted and 
centrifuged at 4000rpm for 20 minutes at 4°C (no brake). Supernatant was discarded 
and bacterial pellet was used for DNA extraction using the HiSpeed Plasmid Midi 
Kit. 
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4.4.2 Rescue of MV from cloned cDNA 
Using Lipofectamine (Invitrogen, Paisley, UK), Vero-SLAM cells infected with a T7 
RNA polymerase-expressing modified vaccinia ankara virus were co-transfected with 
full-length cloned MV p(+) cDNA with plasmids encoding the MV polymerase 
complex (pCG-L, -N and -P)
150,250
 in OptiMEM® GlutaMAX (Invitrogen, Paisley, 
UK). After 72 hours, the supernatant was overlaid onto fresh Vero-SLAM cells. 
Individual syncytia typical of MV mediated cytopathology were transferred to wells 
containing Vero cells and MV constructs were subsequently harvested in 
OptiMEM®. 
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Figure 4-2: Rescue of MV from cloned cDNA. Schematic representation of methodology, using a multiple plasmid transfection approach, with 
recombinant Vaccinia Ankara virus to provide T7 RNA polymerase. RNP: ribonucleoprotein complex.  
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4.4.3 Transwell experiments 
24 well Transwell® plates with polycarbonate membrane-containing inserts (8.0μm 
pore size; 10μm membrane thickness) (Corning, NY, USA) were used for the 
purposes of the transwell experiments. On day 0, inserts were pre-coated with 
fibronectin (R&D systems, MN, USA) at a concentration of 1μg/ml for 3 hours at 
37°C. MSCs were plated on day 0 in separate tissue culture flasks. On day 1, cells 
were infected at MOI 1.0 with MV-NSe-GFP, MV-NSe-hCXCR4 or mock infected 
under standard conditions. Post infection, cells were cultured in the presence of FIP at 
a concentration of 40μg/ml. On day 2 (24 hours post infection), cells were harvested, 
washed once with serum free DMEM (+ penicillin and streptomycin as previous; + 
0.1% BSA) and counted. Cell suspension was made at 4x10
5
 cells/ml, and 100μl cell 
suspension was aliquoted per well to the appropriate transwell insert. For CXCR4 
inhibition, AMD3100/Plerixafor (Sigma Aldrich, Poole, UK) was used to pre-treat the 
cells where appropriate at a concentration of 100μm for 1 hour at 4°C before being 
added to the appropriate transwell insert. In the lower chamber of the transwell plate, 
600μl of DMEM/0.1% BSA (negative control); DMEM/30% FBS (positive control) 
or DMEM/0.1% BSA plus SDF-1α at the desired concentration were added on day 2 
prior to positioning the loaded insert. Plates were cultured in a tissue culture incubator 
at 37°C and 5% CO2 for 24 hours before removing the insert and fixing cells in 70% 
ice cold methanol for 10 minutes. Inserts were then washed once with PBS and 
stained with crystal violet (Sigma Aldrich, Poole, UK) solution at a concentration of 
0.5% in 20% methanol for 1 hour at room temperature. Inserts were then washed with 
DI H20 until water was running clear, and un-migrated cells were gently removed 
from the upper surface of the transwell insert using a cotton bud. Inserts were then 
air-dried and membranes removed and mounted onto microscope slides before 
enumerating number of migrated MSCs per 5 x high-powered fields (hpf).   
4.5 Results 
4.5.1 Human CXCR4 can be successfully cloned into the MV genome 
Efficient replication of MV requires the viral genome to have a total number of 
nucleotides divisible by 6 (the “rule of six”)251. Therefore changes to the total number 
of nucleotides in MV-NSe-GFP during insertion of hCXCR4 were required to be 
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divisible by six. Following confirmation of the gene sequence of the hCXCR4 gene 
(transcript variant 1), forward and reverse primers were designed for PCR 
amplification of the gene and insertion of MluI and AatII restriction enzyme sites 
respectively. To enhance restriction enzyme efficiency, primers were designed with 6 
additional nucleotides adjacent to each restriction enzyme site. Using MluI and AatII, 
removal of the GFP gene from p(+)MV-NSe-GFP (753 nucleotides), and insertion of 
hCXCR4 with the addition of MluI and AatII (1081 nucleotides) requires that a further 
addition of 2 extra nucleotides (along with the hCXCR4 construct) takes place in order 
to adhere with the ‘rule of six’. As detailed in chapter specific methods, the hCXCR4 
gene was PCR amplified with the appropriate primers. Site of hCXCR4 insertion is 
shown in Figure 4-3, and the success of this approach was confirmed by restriction 
digest of the product (see Figure 4-4) and sequence analysis. 
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Figure 4-3: Plasmid construct of p(+)MV-NSe-hCXCR4. The hCXCR4 gene is cloned downstream of the MV-P gene, in place of GFP, 
within the multiple cloning site (MCS) of the MV genome, using MluI and AatII restriction sites. 
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Figure 4-4: Diagnostic digest of p(+)MV-NSe-hCXCR4. hCXCR4 tailed with Mlu1 and AatII restriction sites was transferred from pCRII-
TOPO-CXCR4 to p(+)MV-NSe by restriction/ligation. Successful transfer was confirmed by diagnostic digest with Mlu1/AatII of pCRII-TOPO-
CXCR4 (lane 1), p(+)MV-NSe-GFP (lane 2) and p(+)MV-NSe-hCXCR4 (lane 3). The sizes of the bands obtained are represented on the left of 
the figure (Kb) with the identities of the bands indicated on the right.  
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4.5.2 MV-NSe-hCXCR4 can be rescued by reverse genetics from the full length 
cDNA construct 
MV-NSe-hCXCR4 was rescued from p(+)MV-NSe-hCXCR4 by Lipofectamine 
(Invitrogen, Paisley, UK) co-transfection of Vero-SLAM cells infected with a T7 
RNA polymerase expressing modified Vaccinia Ankara virus with the full length MV 
plasmid along with plasmids encoding the MV ribonucleoprotein complex (pCG-L, -
N and -P) (see Methods Chapter 2.4.4). Three days post transfection, the supernatant 
was overlaid onto fresh Vero-SLAM cells, and typical cytopathic effects of MV 
infection were observed after 72 hours. Individual syncytia typical of MV-mediated 
cytopathology were transferred to wells containing Vero cells and MV-NSe-hCXCR4 
was subsequently harvested in Opti-MEM (Gibco), titrated, and stored at -80°C until 
required.  
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Figure 4-5: Rescue of p(+)MV-NSe-hCXCR4 from cloned cDNA. (A) Schematic representation of the p(+)MV-NSe-hCXCR4 plasmid. (B) 
Evidence of successful MV-NSe-hCXCR4 rescue from p(+)MV-NSe-hCXCR4 with giant multinucleate syncytia formation observed in Vero-
SLAM cells at 72 hours. 
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4.5.3 Phenotypic and functional characterization of MV-NSe-hCXCR4 
Following successful rescue and propagation of the hCXCR4-modified virus, one-
step growth curves were performed on both Vero cells and BM-MSCs, using MV-
NSe-GFP as the comparator virus. Using Vero cells, MV-NSe-hCXCR4 showed 
similar growth kinetics to MV-NSe-GFP. However, peak virus productivity was 
delayed by 24-36 hours, and viral titres were a log less than with the comparator virus 
– possibly as a result of the size and complexity of the transgene insert (see Figure 4-
6A). Replication in BM-MSCs was retained, but again one-step growth curves 
confirmed a delayed and one log-reduced peak in productivity (see Figure 4-6B). 
Following this, confirmation of transgene expression in MV-NSe-hCXCR4-infected 
cells was performed. Initially, Vero cells were infected (or mock-infected) with MV-
NSe-hCXCR4 at an MOI of 1.0 under standard conditions. At 48 hours post infection, 
cells were harvested, and stained for flow cytometric analysis. Whilst uninfected Vero 
cells did not express detectible hCXCR4 on the cell surface, those cells infected with 
the novel virus demonstrated a significant increase in the amount of cell surface 
hCXCR4 expression, with the chemokine receptor detectable in >85% of cells (see 
Figure 4-7A). For confirmation of cellular transgene expression, Vero cells and BM-
MSCs were infected with MV-NSe-hCXCR4 at MOI 1.0, and chemokine receptor 
expression was sought by immunohistochemical staining. Whilst uninfected BM-
MSCs and Vero cells showed no demonstrable hCXCR4 surface expression, both 
infected BM-MSCs and Vero cell populations showed syncytia formation and high 
levels of cell surface hCXCR4 expression localized to areas of syncytia (see Figure 4-
7B). 
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Figure 4-6: One-step growth curves for MV-NSe-hCXCR4. (A) Growth curves for MV-NSe-hCXCR4 (black) as compared to standard MV-
NSe-GFP (red) on Vero cells and (B) BM-MSCs. In all cases, MOI 1.0 was used, and cells incubated in 37°C/5% CO2 incubator. For Vero cells, 
N=1; for MSCs N=3 independent experiments. Data shown is mean +/- SEM.  
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Figure 4-7: Cell surface hCXCR4 expression on MV-NSe-hCXCR4-infected 
cells. (A) Representative flow cytometry plots of MV-NSe-hCXCR4-infected (MOI 
1.0) or uninfected Vero cells at 48 hours. Live cells were gated according to FSC and 
SSC characteristics. Corresponding isotypes were used as negative controls. (B) 
Representative photographs of MV-NSe-hCXCR4-infected (MOI 1.0) or uninfected 
BM-MSCs or Vero cells at 48 hours, following fixation and immunohistochemical 
staining for surface hCXCR4.
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4.5.4 Migratory capacity of MV-NSe-hCXCR4-infected MSCs 
To assess the effect of MV-NSe-hCXCR4 on MSC trafficking, BM-MSCs were 
infected with either the novel virus, or MV-NSe-GFP as a comparator at MOI 1.0, and 
assessment of in vitro cellular migratory capacity towards the CXCR4 ligand SDF-1α 
was performed using a transwell system (see Figure 4-8A-B). There was a clear 
enhancement in MSC migratory capacity towards an SDF-1α positive gradient, for 
those cells infected with the hCXCR4-expressing virus, as compared to the standard 
GFP-expressing virus, although for both percentage of cell migration and absolute 
numbers of migrated cells, differences between values failed to reach statistical 
significance when the two viruses were directly compared. Increasing the 
concentration of SDF-1α in the lower chamber promoted migration of cells infected 
with MV-NSe-hCXCR4, but no statistically significant difference was seen for the 
different chemokine concentrations. To assess the role of surface hCXCR4 expression 
in the migration of infected MSCs, MV-infected cells (at 24 hours) were pretreated 
with a non-peptide competitive antagonist of the CXCR4 receptor – 
AMD3100/Plerixafor, known to reversibly inhibit binding and function of SDF-1α 
with high affinity and potency
252-254
, before being inserted into the upper transwell 
chamber and assessing migration towards an SDF-1α positive gradient 24 hours later 
(see Figure 4-9). Whilst there was no significant difference seen between the 
migratory capacity of MV-NSe-GFP-infected MSCs receiving pre-treatment or no 
pre-treatment, MSCs infected with MV-NSe-hCXCR4 showed significant abrogation 
in migratory capacity following pre-treatment with AMD3100, suggesting that for 
these cells, hCXCR4 is playing a major role in their migration towards SDF-1α in 
vitro (MV-NSe-GFP-MSCs with no AMD3100: 145.833+/-3.33 cells/5xhpf; with 
AMD3100: 113.13+/-10.67 cells/5xhpf; MV-NSe-hCXCR4-MSCs with no 
AMD3100: 187.50+/-11.77 cells/5xhpf; with AMD3100: 108.13+/-6.72 cells/5xhpf). 
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Figure 4-8: MV-NSe-hCXCR4-infected MSC migration. (A) Percentage of transwell migrated MSCs (x5 high-powered fields (hpf)) at 48 
hours post infection with MV-NSe-hCXCR4 or MV-NSe-GFP (MOI 1.0). Number of migrated cells for the positive control (+) is normalized to 
100%, with all other values expressed as a percentage of the positive control condition, minus background cellular migration (-). (B) Absolute 
numbers of migrated cells (x5 hpf). For each experiment, N=3. Data shown is mean +/- SEM. There is no significant difference in MSC 
migration between MV-NSe-GFP and MV-NSe-hCXCR4-infected cells, or between the amounts of MSC migration of MV-NSe-hCXCR4-
infected cells with different concentrations of SDF-1α, using the unpaired t-test. 
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Figure 4-9: Effect of AMD3100 pre-treatment of MV-NSe-hCXCR4 infected MSCs. Absolute number of transwell migrated MSCs 
following pre-treatment (+) or no pre-treatment  (-) with AMD3100. Data shown is mean +/- SEM for 3 independent experiments. Analysis 
uses the unpaired t-test. For the difference between MV-NSe-hCXCR4-infected MSCs pre-treatment versus no pre-treatment, **p=0.0011.  
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4.6 Discussion 
Reasons for choosing BM-MSCs as biological delivery vehicles for systemically 
delivered oncolytic measles virotherapy have already been outlined in this chapter. Of 
paramount importance in the success of such approach is the ability of the chosen 
carrier cell to migrate to sites of tumour upon intravenous infusion. Whilst there is a 
plethora of data reporting the tumour-homing properties of MSCs, there is also data to 
suggest that following ex-vivo manipulation, MSCs downregulate surface chemokine 
receptors involved in the trafficking process. As a result, MSCs may be less efficient 
at reaching distant tumor targets. With this in mind, I set out to explore mechanisms 
that could be utilized to enhance the homing of BM-MSCs to tumours, whilst keeping 
them ‘fit for purpose’ as virotherapeutic delivery vehicles.  
 
As detailed in Chapter 3, when MV-loaded MSCs were administered to SCID mice 
with established NALM-6 xenografts, early localization of infected carrier cells was 
suboptimal – with passive lung entrapment being evident. Passive lung entrapment is 
a well -recognized phenomenon
237
, and is explained by the size of the cells 
administered and the animal model used. Whilst it is a phenomenon that has not been 
associated with the systemic delivery of MSCs to humans, it can provide an obstacle 
to in vivo murine modeling. Other groups have tackled this by using alternative 
animal models, including larger rodents or primates, or by the pre-administration of 
prostaglandin infusions to mice to promote vasodilatation within the pulmonary 
vasculature
255
. Whilst there were initial concerns here that passive lung entrapment 
would prevent successful carrier cell delivery to distant tumour targets in this model, 
there was a demonstrable re-localisation of infected MSCs to recognized sites of 
leukaemia within the BM of treated animals from as early as day 2 post infusion. 
Using a luciferase-expressing strain of MV-NSe allowed for accurate assessment of 
MV localization, with increasing luciferase activity over time representing MV 
replication within tumour tissue. As previously discussed, attempts to directly 
demonstrate the presence of human MSCs within the murine BM by flow cytometric 
analysis at the time of experiment termination were unsuccessful. This was likely to 
be due to the relatively low input cell doses, the reduced likelihood of MSC survival 
at late timepoints following virus hand-off to tumour targets, and the lack of long-
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term engraftment of systemically delivered MSCs that has been demonstrated by 
others. Whilst bioluminescent imaging supported the finding of tumour localization of 
MV-NSe-Luc-infected MSCs from day 2 post infusion onwards, consideration was 
given to ways in which efficiency of homing mechanisms could be potentiated.  
 
Chemokine receptors are G protein-coupled receptors that in conjunction with their 
ligands, regulate the migration of many cell types. CXCR4 is one of 19 known human 
chemokine receptors, and it is exclusively activated by the chemokine SDF-1α. SDF-
1α is constitutively expressed within the BM, and can be secreted is association with 
tissue damage incuding infarction, ischaemia, toxic liver damage, total body 
irradiation, and post chemotherapy. SDF-1α is also expressed by endothelial cells and 
pericytes of hypoxic, injured or pathological tissues. The CXCR4/SDF-1α signaling 
pathway is thought to provide a number of diverse cellular functions. Of relevance to 
ALL is the stromal cell chemoprotection of leukaemic cells within the BM, which is 
in part mediated by CXCR4 and SDF-1α256. A major role of the CXCR4/SDF-1α axis 
is in the trafficking/chemotaxis of multiple cell types including MSCs. In light of this, 
the generation of a strain of MV-NSe expressing the hCXCR4 gene as an additional 
transcription unit was undertaken, with the aim of enhancing MSC surface CXCR4 
receptor expression, ultimately deriving a comparison between the localization 
capacities, and therapeutic outcomes of standard MV-NSe loaded MSCs versus MV-
NSe-hCXCR4 loaded MSCs in pre-clinical models of pre-B ALL.  
 
MV-NSe-hCXCR4 was successfully cloned and rescued by a process of reverse 
genetics, and growth characteristics were similar to those of MV-NSe-GFP, from 
which the novel strain of MV was generated. Of note, MV-NSe-hCXCR4 reached 
titres that were a log lower than MV-NSe-GFP, peaking approximately 24 hours later 
than the original virus. It is likely that these subtle differences in growth 
characteristics relate to the size and the complexity of the novel insert, with the 
hCXCR4 gene consists of a 1071bp open reading frame (ORF), and encoding for a 
seven-span transmembrane receptor. Whilst both Vero cells and BM-MSCs infected 
with MV-NSe-hCXCR4 showed upregulation of cell surface levels of CXCR4 
expression (both by flow cytometric and immunohistochemical analysis), and 
transwell migration studies showed improved migratory capacities of MV-NSe-
hCXCR4 infected cells as compared to MV-NSe-GFP infected cells towards an SDF-
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1α gradient, the migratory differences seen were not statistically significant. 
Interestingly, inhibition of CXCR4 by the reversible antagonist AMD3100 did result 
in a significant abrogation of migration for MV-NSe-hCXCR4 infected cells which 
was not seen for MV-NSe-GFP infected cells. It is possible that this is due to the 
blocking of both hCXCR4 molecules on the cell surface generated by the novel MV 
strain, as well as the blocking of basal cell surface hCXCR4 present on BM-MSCs 
prior to infection.  
 
Ultimately, in light of the excellent therapeutic outcomes seen when standard MV-
NSe was delivered within BM-MSCs to disseminated pre-B ALL xenografts (Chapter 
3), the novel hCXCR4-expressing virus strain was not taken forward into comparative 
in vivo studies. 
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Chapter 5:  Characterizing MV kinetics in a stromal cell 
model of transformation 
5.1 Background 
Whilst we have an existing understanding of the antiviral mechanisms at play within 
normal cells that can halt the progression of cellular MV infection, thus far we have a 
limited knowledge of the significance of these mechanisms in relation to the oncolytic 
capabilities of vaccine strain MV. In order to facilitate rational design and ultimate 
success of oncolytic MV in future clinical trials, a detailed understanding of the 
cellular mechanisms conferring this promising new virotherapeutic its tumour 
specificity and ultimate anticancer efficacy is required. 
 
As discussed in Chapter 1, in vitro studies have shown that high levels of CD46 
receptor density on tumour cells leads to enhanced cell fusion, viral gene expression, 
and ultimate virus-induced cell death by oncolytic MV
166,167
, as compared to cells 
with low CD46 levels. Whilst widely expressed on human nucleated cells, CD46 
overexpression is not a recognized feature of adult pre-B ALL (although SLAM is 
known to be expressed), a tumour type which we have demonstrated is exquisitely 
sensitive to MV-mediated oncolysis. A further hypothesis is that antiviral immune 
responses may be suppressed in certain cancer cells
257-259
, resulting in their inability to 
mount an effective immune response against infection, whilst surrounding normal 
tissues (or virus resistant cancer cell lines) are protected by intact innate immune 
systems. As detailed previously, defects in cytoplasmic PRRs and ISGs have been 
shown to contribute to the differential susceptibility of sarcoma cell lines to vaccine 
MV-mediated killing
168
. Recently whole transcriptome analysis has been used to 
identify gene expression profiles that determine resistance to oncolytic MV in GBM 
models. Looking at both resistant (GBM39) and permissive (GBM12) tumour types, 
several ISGs were identified as being highly expressed prior to infection, in the MV-
resistant relative to the MV-permissive cell line. Furthermore, in primary patient 
material high basal levels of ISG expression were seen in newly diagnosed GBM 
patient brains and correlated with resistance to MV infection when treated upon 
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recurrence, whereas low basal levels of ISG supported infection by oncolytic MV. 
These findings suggest that tumour cells can be in a pre-existing antiviral state that 
can limit viral infection and response to virotherapy. A subset of ISGs correlating 
with MV resistance were identified, and when the ISG, RSAD2 was used to transduce 
HEK-293T cells, inhibition of the release of MV particles was demonstrated in 
vitro
260
. The significance of this mechanism in relation to the efficacy of measles 
virotherapy remains to be determined. Although such studies provide vital 
mechanistic insights, studies directly comparing responses to MV infection in cancer 
cells and healthy normal cells are lacking.   
5.1.1 A stromal cell model of oncogenesis 
A broad range of both haematological and non-haematological malignancies have 
been shown in both pre-clinical and early clinical studies to be susceptible to the 
oncolytic effects of vaccine MV. However, finding appropriate models that can be 
effectively utilized to probe the differential cellular responses to MV between healthy 
and transformed cells represents a challenge. Whilst we can illustrate malignant cell 
permissiveness, viral replication, and ultimate MV-specific cell killing in models of 
pre-B ALL, we are unable to accurately compare intricate intracellular processes with 
those that occur when MV targets their normal healthy B cell counterparts, as we 
would be reliant on a comparison between cellular populations at different stages of 
differentiation. Furthermore, paediatric data suggests that pre-B ALL is a ‘multi-hit’ 
model of oncogenesis, with the initial cellular insult taking place in utero
261
. It is 
therefore impossible to conceive of ever being able to compare ‘like with like’ when 
it comes to looking at differences between healthy versus transformed cells in this 
disorder. With this in mind, I set out to validate a previously characterized stromal 
cell model of cellular transformation, as a useful biological tool with which the 
oncolytic mechanisms of vaccine MV could be further elucidated.  
 
The majority of experimental models of cellular transformation utilize differentiated 
cells. Evidence suggests that certain types of cancer, including many haematological 
malignancies, are likely to be derived from mutations accumulating in normal tissue 
specific precursors or stem cells. In the context of lymphoid leukaemogenesis, stem 
cells are thought to be a target for pre-leukaemic events or leukaemic transformation, 
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with clonotypic leukaemia-associated chromosomal rearrangements having been 
identified in putative haematopoietic stem cell-enriched (CD34+CD38-) 
populations
262
. By their nature, stem cells already have the capacity for longevity and 
self-renewal. It is therefore possible, that fewer mutations or ‘hits’ are required for the 
transformation of a normal stem cell - with the effects of such transforming events 
being expressed downstream - than to ‘turn on’ the capacity to self renew in a 
committed progenitor or terminally differentiated cell
263
. To explore this hypothesis, 
Funes et al. created a model of cellular transformation using primary human BM-
derived mesenchymal ‘stem’ cells, by the sequential disruption of a number of 
pathways that have been described as being involved in the in vitro transformation of 
differentiated cells
223
. Whilst elegantly demonstrating that disruption of the same 
regulatory pathways is required to generate MSCs with a fully transformed 
phenotype, the model of transformation generated allows the direct in vitro 
comparison of primary healthy untransformed MSCs alongside their malignant 
counterparts, and provides a potentially excellent opportunity to examine oncolytic 
MV kinetics.  
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Figure 5-1: Schematic diagram of MSC stepwise transformation (adapted from Funes et al. 2007). MSCs 
have been named according to the oncogene, or number of oncogenes inserted by retroviral vector transduction. 
hTERT encodes for the catalytic subunit of human telomerase - conferring lifespan extension; HPV-16 E6 and E7 
disrupt pRB and p53 tumour suppressor pathways; SV40 small T antigen inactivates protein phosphatase 2A 
leading to C-Myc stabilization; H-RAS
V12 
provides acquisition of a constitutive mitogenic signal. 
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5.2 Purpose of this chapter 
This chapter uses the MSC model of cellular transformation to gain insight into 
mechanisms of MV-mediated oncolysis. I initially set out to confirm that MV 
infection kinetics differed according to transformational stage. I have examined 
permissiveness to MV infection, determined cellular MV productivity, and 
investigated rates of MV-specific cell death. I also initiated preliminary studies to 
investigate intracellular antiviral and metabolic responses to MV infection, with the 
aim of generating new hypotheses by which future investigations into the mechanisms 
of MV-mediated oncolysis could be guided.  
5.3 Hypotheses 
a. There will be a difference in the permissiveness of fully transformed MSCs to 
oncolytic MV, versus that of primary MSCs.  
b. Differences in infectivity, productivity, and cytotoxicity will not be accounted 
for solely by MV receptor expression profile.  
c. Transformation of BM-MSCs will result in cellular functional defects in 
innate immune signaling or translational regulation in response to MV 
infection, which may contribute to differential viral kinetics.  
5.4 Methods 
5.4.1 IFN α/β quantification by ELISA 
MSCs (5x10
5
 cells per well) were cultured in MesenCult MSC basal medium 
supplemented with MesenCult stimulatory supplements (StemCell Technologies, 
Grenoble, France), 100 units/ml penicillin G + 100 μg/ml streptomycin, 2mM L-
glutamine, and 1ng/ml bFGF (R&D systems, Minneapolis, MN), and infected with 
MV-NSe under specified experimental conditions. At 24 and 48 hours post infection, 
tissue culture supernatants for each experimental condition were collected and stored 
in separate falcon tubes at minus 80°C until all samples had been collected. 
Quantification of IFN α and β was performed using Verikine™ Human IFN alpha 
Multi-Subtype ELISA (PBL Assay Science, NJ) and VeriKine™ Human IFN Beta 
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ELISA (PBL Assay Science, NJ) kits respectively. 50-100μl supernatant or standard 
solution was added in duplicate to each well of the provided microplates pre-coated 
with the appropriate monoclonal antibody. After 1-hour incubation at room 
temperature, plates were emptied and washed 3 times with the appropriate wash 
buffer, and 100μl polyclonal antibody was added to each well followed by a further 1-
hour incubation at room temperature. Plates were then emptied and washed x 3 before 
adding 100μl horseradish peroxidase (HRP) solution and incubating again for 1 hour 
at RT. Following a further empty and 3 x wash step, microplates were incubated for 
15 minutes at room temperature in the dark with 100μl of TMB substrate before 
adding 100μl of stop solution to each well and reading optical absorbance using a 
microplate reader (Tecan, Männedorf, Switzerland). The wavelength was set 
according to instructions provided by the manufacturer. Background absorbance was 
assessed in wells using culture media alone, and average background readings were 
subtracted from data values. For each experiment, cubic spline analysis was 
performed on standard curve values, and used to interpolate experimental values.   
5.4.2 RIG-I, MDA-5 and IPS-1 mRNA quantification by RQ-PCR 
For RIG-I, MDA-5 and IPS-1 mRNA relative quantification, QuantiTect® Primer 
assay (Qiagen, Crawley, UK) was used in 25μl reactions. cDNA was mixed with 
0.3μM forward and reverse primers, and 12.5μl of 2x QuantiTect® SYBR Green PCR 
Master Mix (Qiagen). Dissociation curves were generated for each QuantiTect® 
SYBR Green gene expression assay to confirm amplification of the desired product. 
The PCR conditions for the assay are as follows: 
 50°C for 2 minutes 
 95°C for 10 minutes 
40 cycles of: 
 94°C for 15 seconds; 55°C for 30 seconds; 72°C for 35 seconds 
 
Primer sequences are shown below: 
RIG-I s  5’- ACCAGAGCACTTGTGGACGCT-3’ 
RIG-I a  5’- TGCCGGGAGGGTCATTCCTGT-3’ 
MDA-5 s 5’- GGCACCATGGGAAGTGATT-3’ 
MDA-5 a 5’- ATTTGGTAAGGCCTGAGCTG-3’ 
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IPS-1 s 5’- GAGACCAGGATCGACTGCGGGC-3’ 
IPS-1 a 5’- AGAGGCCACTTCGTCCGCGA-3’ 
 
GAPDH was used as the housekeeping gene for all assays. PCR reactions were 
carried out on an ABI 7500 system (Applied Biosystems). Samples were run in 
triplicate for each gene. Non-template control (NTC) using RNase/DNase free water 
was included in each plate. PCR cycle number at threshold is represented as Ct. 
Relative expression of level of gene of interest was calculated using the RQ=2
(-ΔΔCt) 
formula
226
 (see Chapter 2: Methods) 
5.4.3 ATP and cellular metabolism assays 
For ATP assay, 7.5 x 10
4 
cells per well were infected or mock infected under standard 
conditions with MV-NSe at MOI 1.0. At 24 hour intervals post infection, cells were 
trypsinized, washed once with PBS, and then enumerated by trypan blue. For each 
condition, 1 x 10
4 
cells were collected and subject to 2 x freeze-thaw cycles before 
centrifugation at 14000 rpm for 5 mins at 4°C. Cell lysates were then re-suspended in 
standard reaction buffer containing luciferase and luciferin according to the 
manufacturer’s instructions (ATP Determination Kit; Invitrogen), and luminescence 
read at 560nm in a Mithras LB 940 Multimode Microplate Reader (Berthold 
Technologies, Germany). Protein quantification on cell lysates was performed using a 
Bicinchoninic Acid (BCA) Protein Assay kit (Sigma).  This is based on the method of 
Lowry
264
 and relies on the formation of a Cu
2+
-protein complex under alkaline 
conditions, with subsequent reduction of Cu
2+ 
to Cu
1+
.  The amount of reduction is 
proportional to the amount of protein present.  BCA forms a purple-blue complex 
with Cu
1+
 under alkaline conditions with an absorbance of 560nm. 
The assay was performed in a 96 well plate.  A BSA standard supplied in the kit was 
used to construct a standard curve across the linear range of the assay (0-1000μg/ml).  
25μl of test or standard samples were added to wells in duplicate.  BCA working 
reagent was made up by mixing 1 part of 4% copper (II) sulphate pentahydrate 
solution with 50 parts of BCA solution (BCA, sodium carbonate, sodium tartrate and 
sodium bicarbonate in 0.1N NaOH, pH 11.25).  200μl of working solution was added 
to each sample well and the plate incubated at 37°C for 30 minutes.  Absorbance was 
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read at 560nm and the test sample protein concentrations read off the standard curve. 
ATP levels were derived from ATP standard curve, and expressed per g protein.  
 
For cellular metabolism assays, an XF24 extracellular flux analyzer (Seahorse 
Bioscience, MA, USA) was used to determine OCR and ECAR. Viable MSCs were 
seeded (5 x 10
4 
per well) and infected with MV-NSe (MOI 1.0) for 24 or 48 hours. 
Before measurement, cells were changed to unbuffered XF assay media, with 5mM 
glucose, 2mM L-glutamine, and 0.5mM pyruvate (pH 7.4 at 37°C) for 60 minutes in a 
non-CO2 incubator. The cartridge was hydrated with unbuffered XF assay media (as 
above) overnight. On the flux analyser, the protocol included calibration, and 4 
readings to establish basal OCR/ECAR rates in both infected and uninfected cells.  
5.4.4 Reactive oxygen species (ROS) production 
Viable MSCs were plated out (3.75 x 10
4 
per well) and infected (or mock infected) 
with MV-NSe (MOI 1.0). At 24 hours post infection, cells were trypsinised, washed 
and and stained with 5mM CellROX® Green reagent (LifeTechnologies) according to 
manufacturer’s instructions, before washing x 3 with PBS and performing flow 
cytometric analysis. Viable cells were gated according to FSC and SSC 
characteristics. ROS levels in infected cells were compared to basal levels in 
uninfected cells.  
5.4.5 Caspase 3/7 activation 
Caspase 3 and 7 activation were assessed using a luciferase-based assay (Caspase-
Glo® 3/7 Assay, Promega). MSCs were plated (3.75 x 10
4 
per well) and infected with 
MV-NSe (MOI 0.01, 0.1, 1.0) or mock infected for 24 and 48 hours. Cells were 
harvested at the appropriate time point by trypsinisation, washed and enumerated 
using trypan blue. Following this, 5000 cells per well were plated in triplicate for each 
condition into a white 96-well microplate. Caspase-Glo® buffer and substrate were 
allowed to equilibrate to room temperature, and following mixing of buffer and 
substrate, 100μl of reagent was added to each well. Following 30 seconds of agitation 
on a plate shaker, and incubation at room temperature for 30 minutes, the plate was 
read on a Mithras LB 940 Multimode Microplate Reader (Berthold Technologies). 
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Average background values (reagent plus culture medium only) were subtracted from 
all data values.   
5.5 Results 
5.5.1 Transformed MSC in-vitro growth characteristics 
In order to accurately evaluate cell-to-cell differences in MV infectivity and virus 
productivity between primary MSCs and serially transformed MSCs, I initially sought 
to characterize cell growth kinetics. Data demonstrate an increase in cellular growth 
rates (see Figure 5-2A), with a reciprocal decrease in doubling time (82 hours versus 
22.3 hours for primary MSCs and 5H cells respectively) as MSCs become 
progressively transformed (see Figure 5-2B). This needs to be taken into 
consideration when assessing for differences in level of infection and virus 
propagation in vitro.
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Figure 5-2: Growth characteristics of MSCs following stepwise transformation. (A) Growth curves of MSCs showing the total number of 
cells at 1, 3 and 5 days in culture, following initial seeding of 2x10
5 
cells. (B) Calculated cell doubling times.  
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5.5.2 Effect of transformation on MV-infectivity and virus production 
Primary MSCs or sequentially transformed MSCs were infected with MV-NSe-GFP 
using an MOI of 1.0. Observing syncytia formation, GFP expression, and MV-H 
glycoprotein immunostaining at 48 hours post infection permitted assessment of the 
cellular permissiveness to MV infection. As demonstrated, cellular infection using a 
recombinant virus expressing GFP leads to increased numbers of large, multinucleate, 
GFP positive syncytia in 5H cells as compared to primary untransformed MSCs - 
where permissiveness is markedly reduced (as evidenced by smaller syncytia size and 
lower levels of GFP expression).  Furthermore, MV-NSe infection of 5H cells results 
in stronger surface MV-H glycoprotein expression than is seen in primary cells – 
which in conjunction with surface expression of MV-F glycoprotein is likely to 
facilitate cell to cell fusion and virus spread.  
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Figure 5-3: Transformation of BM-MSCs leads to enhanced cellular infectivity by MV-NSe in vitro.  Primary MSCs or fully transformed 
MSCs (5H cells) were infected with MV-NSe-GFP using an MOI of 1.0 under standard tissue culture conditions. At 48 hours post infection, 
cells were assessed for the extent of MV infection as evidenced by MV-H glycoprotein expression by immunostaining, and GFP expression by 
fluorescence microscopy. To ensure the specificity of MV-H immunostaining, anti-human IgG1 isotype antibody was used as a negative control. 
All cells were counter stained with Carrazi’s haematoxylin. All photographs were taken with a Nikon eclipse TS3100 using x 20 objective. 
5H 
1° MSC 
Anti- 
MV-H GFP 
IgG1 isotype 
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To assess MV productivity post infection, cell lysates and tissue culture supernatants 
were harvested and TCID50 virus titrations were performed on hTERT, 3H, 4+V and 
5H cells at 24, 48 and 72 hours post infection (see Figure 5-4) In keeping with 
previously generated data using primary MSCs, virus productivity in hTERT cells 
was only detectable intracellularly, and at low levels, peaking at 48-72 hours post 
infection. Similar levels of productivity were seen in 3H cells, with minimal 
detectable virus in culture supernatants. For 4+V and 5H MSCs there is a 2 to 3-log 
increase in intracellular virus productivity at 48 hours post infection, as compared to 
their less transformed counterparts (2.2x10
2
 +/- 65.4 for 3H versus 1.2x10
5
 +/- 
1.2x10
4
 for 4+V MSC p=0.0006; as previous for 3H versus 1.1x10
4
 +/- 1.8x10
3
 for 
5H MSC p=0.004; see Figure 5-4B). Furthermore, there is a 3-log enhancement in the 
amount of released virus produced in 4+V MSCs when compared to cells at earlier 
stages of immortalization (39.3 +/- 19.7 for 3H versus 1.7x10
4
 +/- 8.7x10
3
 for 4+V 
MSC p=0.0432; see Figure 5-4C). Taken together, these data provide evidence that 
immortalization of healthy BM-MSCs can significantly enhance the ability of MSCs 
to support MV infection and replication. 
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Figure 5-4: Cellular immortalisation leads to phenotypic alterations in the ability 
of MSCs to support and sustain productive MV infection. (A) hTERT, 3H, 4+V 
and 5H cells were infected with MV-NSe at MOI 1.0 under standard tissue culture 
conditions, and TCID50 quantification was performed at 24, 48 and 72 hours post 
infection on cell lysates and tissue culture supernatants. (B) Titres at 48 hours post 
infection are shown for cell lysates and (C) supernatants. Data shown are mean and 
SEM for 3 independent experiments. Statistical analysis was performed using the 
unpaired t-test. For figure B, 3H vs. 5H **p=0.004; 3H vs. 4+V ***p=0.0006; 4+V 
vs. 5H ***p=0.0009. For figure C, 3H vs. 4+V *p=0.0432.    
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5.5.3 Stage of immortalization and extent of MV-specific cell death  
In order to assess the consequences of MV infection and spread in the stromal cell 
model of transformation, hTERT-immortalised, 3H, 4+V and 5H cells were infected 
with MV-NSe at an MOI of 1.0 under standard conditions, and viability was assessed 
using trypan blue staining at 24, 48 and 72 hours post infection. The percentage of 
MV-specific cell death was calculated in relation to cell death in uninfected control 
wells. Data clearly demonstrates a progressive enhancement in the percentage of MV-
specific cell death that parallels the development of a fully immortalized cellular 
phenotype. Whilst the earlier stages of transformation (hTERT-immortalisation, and 
abrogation of tumour suppressor genes p53 and pRB) have little significant effect on 
the extent of cell killing here, there is a 3-fold increase in MV-mediated cell killing at 
both 48 and 72 hours post infection with stabilization of the c-Myc oncogene (48 hpi: 
15.865 +/- 2.795% for 3H versus 44.867 +/- 14.675% for 4+V; 72 hpi: 17.290 +/- 
4.266% for 3H versus 58.2 +/- 12.9% for 4+V), and a further ~1.5-fold increase with 
oncogenic H-Ras activation (48 hpi: 67.942 +/- 5.219%; 72 hpi: 71.450 +/- 10.294% 
for 5H). These data clearly illustrate the relationship between immortalization stage 
and potential efficacy of vaccine MV-mediated cell killing (see Figure 5-5). 
Interestingly, the addition of FIP to cell culture media minimizes the differential 
effect upon cell killing that is conferred by progressive transformational stage at later 
timepoints (48 hpi: 7.27 +/- 2.496% for 3H; 7.8 +/- 2.485% for 4+V; 14.350 +/- 
5.421% for 5H; 72 hpi: 6.793 +/- 6.503% for 3H; 12.3 +/- 1.453% for 4+V; 10.755 
+/- 3.125% for 5H), with only 2-fold increases seen between 3H and 4+V cells at 72 
hours, and between 3H and 5H cells at 48 and 72 hours post infection. This suggests 
that the formation of cell-cell syncytia plays a critical role in MV-mediated cell death 
in vitro. 
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Figure 5-5: Extent of MV-mediated cell killing is proportional to stage of cellular 
immortalisation. (A) MSCs were infected with MV-NSe at an MOI of 1.0 under 
standard conditions. Cells were cultured in the presence or absence of FIP, harvested 
daily for 3 days post infection, and viability assessed by trypan blue assay to 
enumerate % cell killing by MV relative to uninfected controls. (B) % MV specific 
cell death shown for each cell type with and without FIP. Data is expressed as mean 
+/- SEM. N=3 independent experiments, with data collected in triplicate. Statistical 
analysis is performed using an unpaired t-test.  For 4+V, *p=0.0242; for 5H 48 hours, 
***p=0.0001; for 5H 72 hours, ***p=0.0001. Viability data at 48 hours post infection 
in the absence of FIP is shown in figure B. *p=0.0274; ***p<0.0001.  
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To further assess the effect of transformational stage on the ability of vaccine MV to 
induce cell death, infected or uninfected MSCs (MOI 1.0) were assessed at 48 hours 
to determine their differential ability to promote MTS reduction in vitro. Due to 
differences in cellular growth rates in vitro, MV-specific cell death appears to be 
offset by the metabolic activity of surviving cells, making it difficult to interpret the 
extent of oncolytic activity using this method (see Figure 5-6A). However, when 
results are corrected for cell doubling time, it is clear that primary MSCs demonstrate 
little metabolic consequence in relation to MV infection, but there is a stepwise 
decrease in the ability of cells to perform MTS reduction to formazan product 
paralleling the stepwise increase in cellular immortalization (see Figure 5-6B).  
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Figure 5-6: MSC transformational stage impacts on cellular proliferation and viability post-MV-NSe infection. MSCs were infected with 
MV-NSe (or mock infected) at MOI 1.0. At 48 hours post infection, CellTiter 96® AQueous One Solution Reagent was directly added to each of 
the wells, and following a 4 hour incubation, absorbance was recorded at 490nm with a 96-well plate reader. Graphs represent data uncorrected 
(A) and corrected (B) for cell doubling time. Data was collected in triplicate. N=2 independent experiments.  
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5.5.4 MV receptor expression profile 
As existing literature suggests, differences in MV receptor expression profile is a 
potential mechanism by which MV-permissiveness could be altered. I determined cell 
surface expression patterns of the MV receptors CD46, SLAM and Nectin 4 for each 
MSC type, by flow cytometric methods (see Figure 5-7). Overall, there was no 
significant difference in either the level of expression (see Figure 5-7B), or the 
density of expression (see Figure 5-7C) of MV receptors for MSCs at all 
transformational stages. All cells were negative for the presence of SLAM and Nectin 
4, whilst CD46 was detected in all cases. Percentage expression ranged from 82.6% 
+/- 4.3 for primary MSCs to a peak of 92.4% +/- 5.1 for 3H cells, with 4+V and 5H 
cells falling within this range despite phenotypically being the most permissive to MV 
infection. Similarly, MFI was highest for 3H cells (20.4 +/- 3.8) with 4+V cells 
exhibiting the lowest CD46 receptor densities (15.1 +/- 1.2). Taken together, these 
data suggest that additional mechanisms, occurring as a result of cellular 
immortalization, are influencing MV-permissiveness here. It is worth stating, 
however, that the data shown in Figure 5-7B and C demonstrates marked variability 
as compared to the minimal variability in expression that we would expect to see with 
standard MV permissive cell lines (eg. Vero). As previously detailed, cells used for 
these experiments were derived via the stepwise introduction of oncogenes by 
retroviral transduction. During the initial generation of these cells, selection was 
performed by culturing each sequential cell type in the appropriate antibiotics as 
determined by the drug resistance genes carried on the relevant retroviral vectors. It is 
possible, that within each cell culture, heterogenous expression of oncogenes exists, 
giving rise to the variability in the data seen here, and potentially reducing the 
sensitivity of the experiment. 
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Figure 5-7: Cellular MV receptor expression profiles. (A) MSCs were subject to flow cytometric analysis of surface CD46, CD150/SLAM 
and Nectin 4 MV receptors. Analysis was performed on live cell population (determined according to FSC and SSC characteristics), with 
isotype-stained cells as negative controls. Representative flow cytometry plots are shown. (B) Cumulative CD46 expression data and (C) 
corresponding MFI for MSCs, with Raji cells used as CD46 positive control. Data shown is mean +/- SEM for 5 independent experiments.  
1°
 M
SC
hT
ER
T 3H 4+
V 5H
Ra
ji 
(+
)
0
50
100
150
Cell type
C
D
46
 (
%
 e
xp
re
ss
io
n)
1°
 M
SC
hT
ER
T 3H 4+
V 5H
Ra
ji 
(+
)
0
10
20
30
40
CD46 FITC
Isotype
Cell Type
M
ea
n 
F
lu
or
es
ce
nc
e 
In
te
ns
it
y 
(M
F
I)B C 
  
      159
Overall, there was no significant difference in either the level of expression or the 
density of expression of MV receptors for MSCs at all transformational stages. All 
cells were negative for the presence of CD150/SLAM and Nectin 4, whilst CD46 was 
detected in all cases. Percentage expression ranged from 82.6% +/- 4.3 for primary 
MSCs to a peak of 92.4% +/- 5.1 for 3H cells, with 4+V and 5H cells falling within 
this range despite phenotypically being the most permissive to MV infection. 
Similarly, MFI was highest for 3H cells (20.4 +/- 3.8) with 4+V cells exhibiting the 
lowest CD46 receptor densities (15.1 +/- 1.2). Taken together, these data suggest that 
additional mechanisms, occurring as a result of cellular immortalization, are 
influencing MV-permissiveness here.  
5.5.5 The role of the type I IFN antiviral response pathway in MV oncolytic 
activity 
Next I sought to examine the integrity of the type 1 IFN response pathway to MSCs 
following viral infection, as a potential mechanism by which cellular permissiveness 
to viral production is limited. The sensing of PAMPs is an essential function of the 
innate immune system. PRRs expressed by a variety of different cells are responsible 
for sensing the presence of microbial invasion and up regulating the transcription of 
genes involved in inflammatory responses. Production of type 1 IFNs plays a central 
role in the induction of antiviral responses, as the trigger for transcription of many 
ISGs that influence protein synthesis, growth regulation and apoptosis. RLRs were 
described as cytoplasmic sensors of viral RNA following early reports of TLR-
independent mechanisms of viral sensing. These PRRs are now known to be integral 
to inducing cellular immune responses to MV, upon detection of ssRNA (or dsRNA) 
within the cytoplasm of an infected cell (see Figure 5-8). 
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Figure 5-8: The RLR signaling pathway (adapted from Jensen et al. 2012). Schematic representation of 
signaling pathway following detection of viral RNA by RIG-I and MDA-5. IPS-1 serves as a platform to co-
ordinate the activation of signaling pathways also utilized by the TLRs. Activation of the receptor-interacting 
serine-threonine kinase 1 (RIP-1) cascade results in nuclear translocation of NF-κB. Activation of inhibitors of 
NF- κB kinase (IKKs) leads to phosphorylation of IRF3, nuclear translocation, and the production of IFNβ, which 
up regulates IRF7 and subsequently leads to IFNα production.  
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To determine cellular production of type 1 IFNs, tissue culture supernatants taken 24 
and 48 hours post cell infection by MV (MOI 1.0) were used to perform ELISA for 
IFNα and β. Whilst primary cells showed detectable levels of IFNα and β at 24 and 48 
hours, hTERT, 3H, 4+V and 5H cells produced no detectable levels of IFNα, and 
IFNβ production was inversely proportional to stage of transformation, with minimal 
production seen in 5H cells as compared to primary untransformed cells (see Figure 
5-9A-B). To assess the integrity of RLR signaling pathways, expression levels of 
RIG-I, MDA-5 and IPS-1 were determined upon cellular stimulation with MV by 
performing RNA extraction on MSCs at 24 and 48 hours post infection, and relative 
quantification of RIG-I, MDA-5 and IPS-1 mRNA using real-time PCR. Data was 
normalized to baseline levels of RIG-I, MDA-5 and IPS-1 mRNA at equivalent time 
points in uninfected cells. As anticipated, levels of RIG-I and MDA-5 mRNA 
paralleled the cellular production of IFNβ, with hTERT cells showing highest 
expression and 5H cells showing minimal expression levels at both 24 and 48 hours 
(see Figure 5-10A-B). Interestingly, this relationship is not borne out for IPS-1, where 
expression levels were negligible in all cell types at all time points post infection (see 
Figure 5-10C). Looking at earlier timepoints post infection may be informative here. 
Whilst there is an apparent defect in IFNβ (and IFNα) production that parallels 
progressive MSC immortalization, it is unclear whether or not these differences in 
cytokine profile, and the resultant consequences upon RLR signaling, are sufficient to 
induce the cellular phenotypic differences in MV permissiveness. 
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Figure 5-9: Cellular type 1 IFN responses to MV infection are influenced by stage of immortalization. (A) IFNα and (B) IFNβ levels as 
assessed by ELISA on tissue culture supernatants from infected cells at 24 hours and 48 hours post infection. N=2 independent experiments, 
with samples performed in duplicate. For all experiments, data shown is mean +/- SEM. 
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Figure 5-10: Activation of the RLR signaling pathway in response to MV infection. (A) RIG-I (B) MDA-5 and (C) IPS-1 mRNA levels as assessed 
by RQ-PCR for each cell type. N=3 independent experiments, with samples performed in triplicate. For all experiments, data shown are mean +/- SEM. 
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5.5.6 Bioenergetics of MV oncolysis and the role of syncytia formation 
As data previously demonstrated, there is a significant abrogation in the amount of 
MV-specific cell killing in MSCs at later stages of transformation (4+V and 5H), 
which occurs when cells are cultured post infection in the presence of FIP (see Figure 
5-5), suggesting that syncytia are playing a role in the extent of MV-mediated cell 
death in vitro in this model. To further assess the cellular processes occurring 
following MV challenge, and the role of syncytia, bioenergetics studies were 
performed on both hTERT and 5H MSCs, post MV infection, +/- FIP, using the 
Seahorse XF
e
24 analyzer. There was a significant increase in the rate of oxygen 
consumption (OCR) at 24 hours post infection in both hTERT and 5H cells (see 
Figure 5-11A). Average increases in OCR seen for 5H cells were ~3-fold from 
baseline, whereas for hTERT cells less than 2-fold increases were seen. This is 
followed by a rapid fall off in OCR at 48 hours post infection, particularly for 5H 
cells, as cell death ensues (0 hours: 5H 315.6 +/- 14.08 pMoles/min and hTERT 115.6 
+/- 2.66 pMoles/min; 24 hours: 5H 871.0 +/- 79.35 pMoles/min and hTERT 174.3 +/- 
8.78 pMoles/min; 48 hours: 5H 17.75 +/- 1.81 pMoles/min and hTERT 78.3 +/- 2.82 
pMoles/min). The initial increase in OCR seen post MV infection was clearly 
abrogated with the addition of FIP to tissue culture media (see Figure 5-11B) (0 
hours: 5H 315.6 +/- 14.08 pMoles/min and hTERT 115.6 +/- 2.66 pMoles/min; 24 
hours: 5H 315.3 +/- 4.059 pMoles/min and hTERT 128.5 +/- 7.801 pMoles/min; 48 
hours: 5H 316.6 +/- 13.50 pMoles/min and hTERT 134.6 +/- 6.029 pMoles/min), 
with inhibition of syncytia formation being confirmed by direct observation using 
light microscopy. In contrast, the effect of MV infection on extracellular acidification 
rate (ECAR) in both 5H and hTERT cells in the absence of FIP is less marked (see 
Figure 5-12A) (0 hours: 5H 22.3 +/- 2.206 mpH/min and hTERT 3.5 +/- 0.256 
mpH/min; 24 hours: 5H 24.56 +/- 2.215 mpH/min and hTERT 4.875 +/- 0.4795 
mpH/min; 48 hours: 5H 2.08 +/- 0.5825 mpH/min and hTERT 4.33 +/- 0.189 
mpH/min). As with OCR, the addition of FIP post infection results in a marked 
abrogation of the dramatic fall-off in ECAR seen at 48 hours (see Figure 5-12B) (0 
hours: 5H 22.3 +/- 2.206 mpH/min and hTERT 3.5 +/- 0.258 mpH/min; 24 hours: 5H 
26.27 +/- 0.58 mpH/min and hTERT 4.857 +/- 0.595 mpH/min; 48 hours: 5H 26.86 
+/- 1.725 mpH/min and hTERT 4.64 +/- 0.364 mpH/min). These data suggest that 
MV infection is impacting on cellular bioenergetics, in particular on mitochondrial 
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respiration. The extent of impact parallels stage of immortalization, and is not evident 
when syncytia formation is inhibited.  
  
      
1
6
6
 
 
Figure 5-11: Cellular mitochondrial respiration post MV infection. (A) Seahorse XF
e 
24 analyzer was used to assess oxygen consumption 
rate (OCR) of hTERT and 5H cells at 0, 24 and 48 hours post infection with MV-NSe in the absence of and (B) in the presence of FIP. Data 
shown is mean +/- SEM of 3 independent experiments, with 5 replicates for each data point. Statistical analysis is performed using an unpaired t 
test. For hTERT and 5H minus FIP ***p<0.0001. For hTERT plus FIP *p=0.0127. 
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Figure 5-12: Cellular glycolytic activity post MV infection. (A) Seahorse XF
e 
24 analyzer was used to assess extracellular acidification rate 
(ECAR) of hTERT and 5H cells at 0, 24 and 48 hours post infection with MV-NSe in the absence of and (B) in the presence of FIP. Data shown 
is mean +/- SEM of 3 independent experiments, with 5 replicates for each data point. Statistical analysis is performed using an unpaired t test. 
For hTERT minus FIP 24 hours *p0.0111 and 48 hours *p=0.0150; for 5H minus FIP 48 hours ***p<0.0001. For hTERT plus FIP 24 hours 
*p=0.0221 and 48 hours *p=0.0146. 
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In light of the dramatic differences in OCR post MV infection, cellular ATP 
quantification and oxygen radical quantification were performed at 24 hourly 
intervals post infection. Preliminary data shows a ~3-fold increase in the amount of 
ATP production primarily in 4+V and 5H cells at 24 hours post infection (see Figure 
5-13), coinciding with the increase in OCR demonstrated with bioenergetics studies in 
5H cells. ATP production is dramatically reduced at 48 hours, correlating with the 
fall-off in OCR and ECAR seen in bioenergetics studies. Furthermore, flow 
cytometric analysis of ROS production in hTERT and 5H cells demonstrates a ~10 
fold increase in the amount of ROS production by fully transformed cells at 24 hours 
post infection in comparison to ROS production in minimally transformed cells (see 
Figure 5-14).
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Figure 5-13: Effect of MV infection on cellular ATP production. Differentially transformed MSCs, either uninfected, or post infection with 
MV-NSe (MOI 1.0) were assessed at 24 hourly intervals post infection for the amount of intracellular ATP production. ATP concentration was 
quantified using a luciferase-based assay, and represented as values per gram of protein. Data shown is for a single experiment, performed in 
triplicate.
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Figure 5-14: Assessment of cellular ROS production following MV infection. 
hTERT and 5H cells were infected (or mock infected) with MV-NSe at MOI 1.0 
under standard tissue culture conditions. At 24 hours, cells were harvested and subject 
to flow cytometric analysis for the amount of ROS production. Representative plots 
from a single experiment are shown. Viable cells were gated according to FSC and 
SSC characteristics. Red line: baseline ROS expression in uninfected cells. Blue line: 
ROS expression in infected cells. 
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To investigate apoptosis triggering following MV infection, caspase 3/7 activation 
was assessed in hTERT and 5H cells at 24 and 48 hours post MV-NSe infection for a 
range of MOIs, using a luciferase based assay (see Figure 5-15). Whilst caspase 3/7 
activation is minimal in hTERT cells post MV-infection (hTERT 48 hrs uninfected 
5208.5 +/- 222.5; MOI 0.01 3167.0 +/- 69.0; MOI 0.1 2750.0 +/- 82.0; MOI 1.0 
3957.0 +/- 65.0), there is a marked increase in caspase 3/7 activation for 5H cells at 
48 hours post infection, which increases in parallel with an increasing MOI (5H 48 
hrs uninfected 3362.5 +/- 1028.5; MOI 0.01 2355.0 +/- 166; MOI 0.1 9866.0 +/- 
1225; MOI 1.0 50034.0 +/- 2054.0).  
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Figure 5-15: Caspase 3/7 activation following cellular infection by MV. Levels of caspase 3/7 activation post MV-NSe 
infection at a range of MOIs was performed on hTERT and 5H cells using a luciferase based assay. Data represented is 
mean +/- SEM from 2 independent experiments performed in triplicate.  
  
      173
5.6 Discussion 
Tumorigenesis is a multistep process involving the combined accumulation of 
oncogenic pathway activations and the inactivation of tumor suppressor genes. Whilst 
a handful of studies have attempted to investigate the mechanisms underlying tumour 
specificity demonstrated by live, attenuated vaccine MV strains by looking at MV-
permissive versus resistant models of the same tumour type, no studies have been 
performed directly comparing cellular responses of transformed and untransformed 
cells for this virus. Wang et al. used an alternative oncolytic virus – myxoma virus – 
to look at the effect of immortalization on permissiveness and susceptibility to killing 
of mouse embryonic fibroblasts (MEFs). Whilst primary MEFs were non-permissive 
to myxoma virus replication, corresponding immortalized MEFs supported a highly 
productive viral infection, with permissiveness being related to an immortalization-
associated selective block to the cellular αβ IFN induction machinery normally 
triggered in response to virus infection
265
.  
 
Here, a stromal cell model of oncogenesis was utilized to probe mechanisms of 
tumour selectivity known to be a defining feature of oncolytic MV. Proof of principle 
was achieved, with demonstration of enhanced infectivity, improved virus 
productivity (both intracellular and released virus) and improved rates of MV-specific 
cell death with progressive cellular transformation, that was not solely related to 
enhanced cell turnover. Whilst hTERT-immortalised MSCs, or MSCs with additional 
disruption of tumour suppressor gene pathways showed limited MV cytopathy, those 
cells with disrupted proto-oncogenes such as c-Myc and H-Ras were highly 
susceptible to MV-mediated killing, (even following experimental correction for 
cellular doubling time). Whilst examination of cellular MV receptor profiles did not 
demonstrate significant differences that would suggest virus discrimination between 
normal versus cancer cells on a cell entry level, there was marked variability in the 
receptor profile data. The possibility remains that subtle but significant differences in 
receptor profile could be influencing virus entry into normal versus transformed cells, 
and this requires clarification. Cell-to-cell spread via fusion mechanisms appears to be 
vital to dissemination of virus and propagation of cell killing in vitro. This interesting 
finding is in contrast to in vivo pre-clinical models, where therapeutic effect of 
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oncolytic MV is evident with little MV cytopathy demonstrable within treated 
tumours
14
. It is likely that anti-MV or anti-tumour immune responses are involved in 
perpetuating or amplifying anti-tumour efficacy in vivo.  
 
Examination of cellular type 1 IFN responses to MV stimulation in this model 
demonstrated a robust induction of IFNβ (and to a lesser extent IFNα) in primary 
MSCs, that was lost with progressive cellular transformation, suggesting that IFN 
response pathways are affected by immortalization, and potentially implicating this as 
a mechanism for the enhanced MV permissiveness seen here. This could be further 
confirmed by the pre-treatment of fully immortalized MSCs with exogenous IFNβ 
with subsequent re-evalualtion of the extent of cellular virus productivity, and 
induced cell death.  
 
As cytoplasmic RLR signaling mechanisms are known to play a significant role in the 
triggering of IFN responses by MV, activation of RLRs was investigated by 
examining relative levels of RIG-I, MDA-5 and their common signaling adapter IPS-
1 mRNA post MV-infection. Along with the blunted type 1 IFN responses seen in 
fully immortalized, MV permissive MSCs, reduced levels of RIG-I and MDA-5 
mRNA are seen in these cells, suggesting that defective RLR-mediated signaling may 
result from immortalization, and contribute to the impaired antiviral responses seen. 
However, whilst RIG-I and MDA-5 levels parallel those of the type 1 IFNs, it is 
interesting to note that levels of IPS-1 mRNA were negligible, being effectively 
indistinguishable at different stages of transformation. It would be expected that IPS-1 
mRNA levels would reflect those of the upstream RLR family members, with 
signaling via IPS-1 being intact in untransformed/normal MSCs and impaired in 
immortalized MSCs. Whether or not defects in RLR-mediated signaling are 
responsible for abrogating the antiviral responses in MV permissive cells is unclear 
from this data. It is possible that additional interacting pathways, known to play a role 
in IFN-mediated cellular responses (such as STING signaling or TLR-mediated 
signaling) may be contributing to the altered type 1 IFN profile, and the phenotypic 
differences in MV-permissiveness seen in here. It is worth noting, however, that TLR-
2 (the well recognized TLR utilized by MV) has been shown only to be activated by 
wild-type but not vaccine virus strains
110
.  
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In addition to examining innate immune responses of MV-stimulated healthy and 
transformed MSCs, to gain understanding of how MV can discriminate between these 
conditions, I was interested to examine the metabolic consequences resultant upon 
cellular MV infection, with the aim of understanding the specific bioenergetic 
processes and cell death mechanisms consequent upon MV infection. When 
considering mode of cell death implicated in models of MV oncolysis, mechanisms 
usually refer to the observation of apoptotic phenomena
25,266
, although this has 
recently been contested. In relation to another oncolytic virus, Whilding et al.
267
 
evaluated cell death pathways following thymidine kinase-deleted (dTK) vaccinia 
virus infection of ovarian cancer cells. They were able to demonstrate a significant 
increase after 24 hours of infection, in both OCR and ECAR, followed by a steep 
decline to below baseline. In addition there was a reduction in intracellular ATP 
levels in all cell lines infected with dTK vaccinia strain. These bioenergetics events 
were ultimately linked to the occurance of necrotic cell death mediated through a 
programmed series of events. Recent work looking at the effect of MV-Edm infection 
on cell death mechanisms in non-small cell lung cancer (NSCLC) cell lines 
demonstrated an induction of autophagy and sequestosome 1-mediated mitophagy 
(intracellular degradation of mitochondria) leading to decreased cytochrome c release, 
and early blocking of the pro-apoptotic cascade in order to favour viral replication, 
before ultimate necrotic cell death due to ATP depletion. When autophagy was 
impaired, MV-Edm-induced cell death was abrogated despite increased induction of 
apoptotic pathways
268
. Furthermore, the same group was able to demonstrate in this 
model, that MV-Edm exploits autophagy to mitigate the innate immune response 
mediated by RLRs, by the mitophagy-targeted reduction of IPS-1
269
.  
 
Data presented here suggests a role for syncytia formation in the potentiation of MV-
mediated cell killing in vitro. Previous studies have demonstrated mitochondrial 
dysfunction in gibbon ape leukaemia virus hyperfusogenic envelope protein (GALV-
FMG) induced syncytia, prior to loss of mitochondrial membrane potential and 
syncytial viability, cellular ATP depletion and cell death with necrosis
270
. Preliminary 
bioenergetics data here shows a marked increase in OCR (with less of an effect on 
ECAR) in response to MV infection that is clearly abrogated in the presence of FIP. 
Increases in OCR were reflected by modest increases in ATP levels at early 
timepoints post infection in 4+V and 5H transformed MSCs, with ATP levels 
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subsequently demonstrating a dramatic fall off at 48 hours post infection. It is 
possible therefore, that the increases in OCR seen in MV-permissive fully 
transformed MSCs post infection are not related to increased ATP generation, but 
relate to mitochondrial dysfunction and production of oxygen radicals post MV 
infection. Flow cytometric analysis of ROS production in the less-permissive hTERT 
cells versus the fully permissive 5H cells demonstrated an increase in ROS production 
in transformed cells at 24 hours post infection that supports this theory, however 
further evaluation of the effect of antioxidants on cell killing is warranted, along with 
investigation of the direct effects of MV-infection on cellular mitochondria (including 
mitochondrial stress tests, evalualtion of mitochondrial mass and mitochondrial 
membrane potential studies pre and post infection with MV).  
 
The presence of oxygen radicals has been implicated in several aspects of RNA virus 
disease pathogenesis including triggering of apoptosis pathways
271
, and it is notable 
therefore, that post-MV infection there is clear activation of caspases 3 and 7 in the 
MV-permissive MSCs here. Activation of caspases seen in this model is in keeping 
with existing literature, where both vaccine and (to a greater extent) wild-type MV 
have been shown to induce caspase 3 activation and widespread apoptosis via 
induction of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)
272
. 
Further confirmation of the role of apoptosis pathways in cell death mechanisms in 
this model should be sought (including examination of the effect of the pan-caspase 
inhibitor, Z-VAD-fmk, on extent of cell death, and by seeking evidence of poly ADP 
ribose polymerase (PARP) cleavage). In addition, evaluation of the potential roles of 
autophagy and primary necrosis in MV-mediated killing in this model is warranted. 
Although it is clear that apoptosis pathways are being triggered here, it is likely that 
mechanisms of cell death may not be universal for all pre-clinical models. It is also 
probable that mechanisms of virally-mediated cell killing in vitro may be distinct 
from those seen in vivo.  
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Chapter 6:  General discussion 
Whilst the appropriateness of using oncolytic measles virotherapy as a novel 
treatment strategy in precursor B-lineage ALL has previously been addressed, this 
project has established the importance of understanding the intricate interactions that 
take place between oncolytic virus and host. Understanding host responses to mode of 
virotherapy delivery and the impact that this will have on therapeutic outcomes, and 
furthermore understanding cellular factors that allow MV to discriminate between 
host healthy and cancer cells are of paramount importance if MV is to be taken 
forward into rationally designed, safe and effective clinical trials. This chapter will 
address the overall findings of the project in the broader context of research in the 
oncolytic virotherapy field, discussing new insights into the complex biological 
interactions between MV and host, and considering future investigative directions, 
whilst also taking into account the limitations of methodological approaches.  
6.1 Criteria for selection of oncolytic viruses for cancer therapy 
In order for successful oncolytic application, viruses have to meet stringent selection 
criteria for safety and efficacy. As previously discussed (Chapter 1), vaccine strain 
MV has demonstrated selectivity and specificity for cancer cells in a range of 
malignancies. The negative sense, single stranded unsegmented viral RNA genome 
does not lend itself to recombination, limiting the possibility of the vaccine virus 
regaining pathogenicity. Safety of live, attenuated MV strains has been demonstrated 
in worldwide vaccination programmes, with only select cases of atypical measles 
infection occurring in severely immunocompromised individuals (CD4 <200)
273,274
. 
There have been no cases of transmission of measles infection following vaccination, 
to healthy individuals, and early phase clinical trials have demonstrated little in the 
way of virus shedding. Furthermore, early phase trial data shows minimal undesirable 
side effects, with the recent myeloma trial detailing only transient and reversible 
systemic symptoms upon infusion of the highest doses of product (10
11 
TCID50)
30
. 
Whilst these features make MV a sensible choice as an oncolytic agent, there are two 
significant issues harbouring uptake of this promising virus into advanced phase 
trials. Firstly, pre-existing immunity to MV in vaccinated individuals has been shown 
in pre-clinical studies to harbor the systemic delivery of virus to tumour targets, limit 
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intratumoural spread and have an adverse impact on therapeutic efficacy. Secondly, 
we have a limited mechanistic understanding of the factors that confer MV the ability 
to be able to preferentially target malignant cells over healthy cells.  
6.2 Using BM-MSCs as biological delivery vehicles for oncolytic MV 
Whilst pre-existing neutralizing anti-MV antibodies are implicated as a likely 
mechanism that will limit the ultimate clinical applicability of this virus as an 
oncotherapeutic agent, the scope of the problem has not previously been defined for 
patients with ALL. Data in Chapter 3 demonstrates the issue with clarity, with the 
significant majority of a cohort of adult ALL patients having clinically significant 
levels of anti-measles antibodies present despite prior treatment with extensive 
immunosuppressive chemotherapeutic regimens. In relation to another haematological 
disorder, the ongoing phase 1 clinical trial using MV in heavily pre-treated myeloma 
patients has provisional data suggesting that responders at the highest dose level were 
restricted to those patients who were deemed measles non-immune by their low or 
undetectable levels of anti-MV antibody prior to therapy. Furthermore, single 
intravenously delivered doses of oncolytic MV administered to patients triggered 
strong anamnestic responses
30
. Enhancing efficacy of oncolytic measles virotherapy 
by developing strategies for efficient virus delivery in the face of host antiviral 
immune mechanisms is clearly required. Here, BM-MSCs were utilized as effective 
cellular delivery vehicles for oncolytic MV to distant pre-B ALL cell targets. The 
initial rational for choosing MSCs for this purpose has been discussed elsewhere in 
this document. Chapter 3 demonstrates the ability of BM-MSCs to be infected by 
MV, act as miniature virus producing units (retaining virus intracellularly), retain 
viability long enough to be delivered intravenously to distant tumour targets within 
the murine BM, and hand-off virus to ALL cell targets in the presence of passive 
immunity. Furthermore, enhanced therapeutic outcomes were achieved by using this 
approach to MV-delivery, as compared to control groups where naked MV was 
administered. This is the first demonstration of the use of cellular carriers such as 
BM-MSCs to effectively deliver oncolytic MV to a disseminated malignancy such as 
ALL in the presence of humoral immunity. It is of interest that survival data 
demonstrated enhanced therapeutic outcomes for animals treated with MSC-delivered 
MV as compared to controls even in the absence of humoral immunity. It is likely that 
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MSCs are acting as biological factories within which MV can be amplified, enhancing 
the oncolytic payload delivered to distant tumour targets. It may also be the case that 
MSCs are enhancing targeting of MV to ALL, potentially due to their lack of immune 
recognition. On a more general level, the data firmly establishes the concept of 
targeting distant leukaemia sites using MSCs, which could be extrapolated to the 
delivery of novel treatments other than oncolytic viruses.  
6.3 Enhancing MSC tumour trafficking 
Whilst both DNA and RNA viruses have been used in oncolytic virotherapy, DNA 
viruses were initially thought to be more amenable to genetic manipulation. However, 
the advent of a robust reverse genetics system for the rescue of negative sense RNA 
viruses from cDNA has opened the doors to genetic engineering of MV in order to 
improve cellular targeting, virus traceability and therapeutic efficacy. Chapter 4 
demonstrates the successful cloning and rescue of a novel strain of MV-NSe encoding 
for the human chemokine receptor gene hCXCR4 as an additional transcription unit 
within the MV genome. Whilst proof of principle was established with enhanced 
MSC cell surface expression of hCXCR4 detectable post infection, and improved 
migratory capacity towards a SDF-1α gradient demonstrable in vitro, the migratory 
benefit gained from using this novel virus strain was not significantly superior to use 
of the standard MV-NSe strain for MSC infection. Furthermore, in light of the 
excellent therapeutic responses seen in this project when standard MV-NSe was 
delivered to distant ALL cell targets in vivo, use of the hCXCR4-expressing vaccine 
MV strain was not taken forward into animal modeling.    
6.4 Differentiating between normal and cancer cells 
Whilst other investigators have used MV-permissive and non-permissive cancer cell 
lines to probe mechanisms of virus specificity, this study is the first to utilize a model 
of progressive transformation, allowing the direct comparison of cellular processes 
resultant upon MV infection, in primary normal cells alongside their malignant 
counterparts. Whilst an artificially induced model of cellular immortalisation, MSCs 
deemed ‘fully transformed’ here have previously been shown to possess phenotypic 
characteristics of transformation including anchorage-independent growth and 
tumourigenicity in vivo
223
. Chapter 5 demonstrates enhanced permissiveness, 
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productivity, and susceptibility to MV-mediated killing of fully immortalized, 
tumorigenic MSCs in comparison to healthy MSCs, that is not resultant upon MV 
receptor-mediated entry. In response to MV infection, an upregulation of the 
intracellular sensing molecules RIG-I and MDA-5 was identified in MSCs at earlier 
stages of transformation (previously shown to be less permissive to MV infection and 
replication) indicating a potential role of the innate immune system in preventing 
MV-induced oncolysis in this model. Whilst levels of IPS-1 mRNA did not appear to 
follow the same pattern, it is notable that levels of cellular type 1 IFN production 
were enhanced in primary and hTERT MSCs, with a progressive decline in 
stimulation of IFN responses as MSCs become immortalized. It is likely that defects 
in innate immune responses in immortalized cells are playing a role in MV-
permissiveness here. In addition to looking at other PRRs known to be involved in 
induction of type 1 IFN responses (including TLRs), examining modulation of 
STAT1 phosphorylation and profiling of ISGs in permissive and ‘resistant’ stromal 
cells before and after infection with MV will help to identify downstream candidates 
that may potentially inhibit or enhance cellular virus infectivity
275,276
.  
6.5 MV-induced modes of cell death 
Whilst bioenergetics studies were able to demonstrate a marked effect of MV-
infection on cellular OCR, only subtle differences in intracellular levels of ATP were 
seen in the MV-permissive MSCs. The detection of ROS in infected 5H cells could 
provide an explanation for the increased oxygen requirements seen. Whilst triggering 
of caspases 3 and 7 was evident in transformed MSCs post infection, whether or not 
oxygen radical production is playing a role in the triggering of apoptosis pathways 
requires further investigation. Induction of apoptosis provides a mechanism whereby 
viruses can evade host cell immune responses. During apoptosis, progeny virions 
along with the cellular contents of a cell are packaged into membrane enclosed 
vesicles, which are rapidly taken up by neighbouring cells and allow for undetected 
virus propagation in the host. Apoptotic pathways utilized, and the targets that viruses 
strike, are varied between different viruses and between different cell types. An 
example of this is with adenovirus. Whilst E1A gene of adenovirus associates with the 
pRB/p300 family of histone acetyltransferases and induces p53 dependent apoptosis 
in many cancer cells
277
, adenovirus early region 4 open reading frame (E4orf4) 
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induced apoptosis is p53 independent in mouse embryo fibroblast derived cells
278
. A 
recent study examining cell death processes in melanoma cell cultures infected with 
oncolytic Newcastle-disease-virus (NDV), demonstrated the ability of this oncolytic 
virus to overcome cellular resistance to apoptosis by triggering the activation of 
caspases that can cleave the inhibitor of apoptosis protein (IAP) family member Livin 
(highly expressed in melanoma cells) to create a truncated pro-apoptotic protein
279
 
and potentiate NDV-induced oncolysis. Data in Chapter 5 demonstrates triggering of 
caspases 3 and 7 in 5H transformed MSCs post MV infection, despite lack of 
functional p53 in these cells. Like the related avian Paramyxovirus NDV, the 
possiblity that MV can overcome resistance to apoptosis by modulating inhibitors of 
apoptotic pathways remains.    
6.6 Study limitations 
6.6.1 Using MV in murine xenografts models  
As previously discussed, humans are the only natural host for sustaining MV 
transmission. Historically, the lack of suitable animal models has greatly hindered the 
progress of oncolytic MV research. Whilst transgenic animal models have been 
developed in order to humanize mice and allow for cellular MV infection and the 
study of virus-host interaction, these models are not without limitation. In order to 
mimic the cellular distribution and amount of CD46 found in humans, several 
transgenic models have been generated. In addition to generating murine models 
where CD46 gene expression levels are comparable to that found in humans, 
additional immune defects are required to overcome intracellular factors in murine 
cells that limit MV replication. Resultant murine strains (eg. CD46Ge x IFNAR-
KO
176
; YAC-CD46 x RAG-1
280
) although useful as models of pathogenicity, cannot 
sustain human tumour xenografts. Therefore in order to study the therapeutic effects 
of oncolytic MV in vivo, immunocompromised SCID mice engrafted with human 
xenografts are utilized. Whilst helpful in demonstrating tumour susceptibilities, virus 
replication is limited in these models to human tumour cells, and therefore questions 
regarding virus toxicity or off-target effects cannot be addressed. As 
immunocompromised models are required, modeling the immune responses to virus 
administration is challenging, and humoral immune responses must be re-capitulated 
by passive immunization of animals. Mader et al. demonstrated that at 3 hours post 
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intraperitoneal injection of human serum containing 80EU of anti-measles antibody to 
immunocompromised mice, animals were confirmed to be measles immune with a 
gradual decrease in plaque reduction neutralization (PRN) titres over the following 
week, and an anti-MV antibody t/2 of 19.2 hours
183
. Whilst passive immunization 
allows for effective modeling of pre-existing humoral immune responses, anamnestic 
responses cannot be assessed, nor does this model address the impact of cell-mediated 
immunity on systemic delivery of oncolytic measles virus. Looking at novel ways to 
model the impact of cell-mediated immune responses (eg. by adoptive transfer of anti-
MV specific T cells) could be informative here, and should be explored. 
6.6.2 Models of transformation 
As previously addressed, the stromal cell model of transformation utilized here allows 
for the direct in vitro comparison of primary healthy untransformed MSCs alongside 
their malignant counterparts, and provides a potentially excellent opportunity to 
examine oncolytic MV kinetics. However, it is important to note that although 
providing insight into potential mechanisms of cellular virus sensitivity or resistance, 
and modes of cell killing, the findings here may be specific to the model in question. 
Whether or not similar results can be re-capitulated in other cell-types remains to be 
determined.  
6.7 Conclusions and future research areas 
Whilst, in general it is fair to say that efforts of the oncolytic virotherapy community 
have been directed more towards the use of viruses in the treatment of solid tumours, 
than in disseminated haematological malignancies, the work presented in this project 
has cemented the case for using oncolytic MV as a novel treatment strategy for 
disseminated leukaemias such as pre-B ALL. Furthermore, this work has addressed 
the important issue of how treatment can be delivered successfully in the face of pre-
existing immunity in order to maximize therapeutic benefit. Clinical validation of the 
use of oncolytic MV in ALL is now required. An initial phase I trial of oncolytic MV 
in adult ALL is planned. Alongside efforts to determine the safety of intravenously 
administered oncolytic MV in this disease, secondary goals will include the careful 
monitoring of humoral and cellular responses to injected virus, to set a baseline for 
evaluation of ‘immune shielding’ approaches.  
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In addition, the work presented here has begun to explore the mechanisms that MV 
can exploit to differentiate between healthy and transformed cells. Future work will 
be focused on probing antiviral response pathways further, where possible in a range 
of tissue types, to gain a comprehensive mechanistic understanding of how MV acts 
to kill cancer cells whilst leaving normal cells unharmed. Such work is essential to the 
future progression of this promising novel anticancer agent in the clinical arena.
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Appendix 1: Ethics approval and consent form 
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CONFIDENTIAL 
Patient Information Sheet 
 
Title: Bone Marrow Derived Mesenchymal Stem Cells As 
Cellular Carriers 
 
Investigators:  
Dr Adele Fielding 
Consultant in Haematology 
UCL Cancer Institute 
0207 7940500 x 34970 
 
REC reference: 11/NW/0216 
 
 
 
Dear Patient, 
 
You are being invited to take part in a research study. Before you decide, it is 
important that you understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask your doctor if there is anything that is not clear or 
if you would like more information. 
 
 
What is the purpose of the study? 
The bone marrow contains cells that can multiply and grow to form many 
different types of tissue, including blood, bone, liver, brain and blood vessels. 
These ‘multipurpose’ cells are called stem cells. Different types of stem cells can 
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be used for different purposes according to their nature. For instance, blood 
stem cells can be used for stem cell transplantation to treat cancers such as 
leukaemia. Other stem cells found in the bone marrow can make different types 
of tissues in the body.  We are interested in a particular type of stem cell – the 
mesenchymal stem cell – that can make tissues that help support the structure of 
the bone marrow, and can play a role in supporting bone marrow cell growth. 
The purpose of our research is to learn how to grow these stem cells in the 
laboratory, and to see if we can use them to deliver cancer-killing viruses to the 
bone marrow to treat leukaemia.  
 
Why have I been chosen? 
You have been chosen because you are donating blood stem cells for 
transplantation, by donating your bone marrow.  
 
 
 
Do I have to take part? 
No. It is up to you whether or not to take part. If you decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without 
giving a reason. A decision to withdraw at any time, or a decision not to take part 
will not affect the standard of your medical care. 
 
What does this study involve? 
If you agree to take part in this study, when you have your bone marrow 
harvested, a very small proportion (1-4mls, which is a teaspoon) will be set aside 
for this research. You will not have to undergo any additional tests or 
procedures.  
 
What are the risks of this study? 
There are no risks involved, over and above those related to your bone marrow 
harvest.  
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What are the possible benefits of taking part? 
There are no foreseeable direct benefits to you. However, the knowledge and 
information gained from this research may help us to develop new therapies for 
patients with leukaemia in the future.   
 
Will it affect me? 
It will not have any effect on you at all. 
 
What information about me will be held? 
All bone marrow stem cell samples used in this research are anonymised. That means 
that any information attached to the sample you donate for research will have your 
name, address, date of birth and all identifiable information removed so that you 
cannot be recognised from it.  
 
Will any part of my stem cell sample be retained for future research? 
The sample of bone marrow that you donate as a gift may be retained for future 
research. An ethics committee will review any new research.  
 
Will I be informed of the results? 
The results of this research will be published in the medical literature. You will not be 
identified in any way in these publications or at any stage of the research. 
 
Withdrawal from the study. 
Your participation in this study is entirely voluntary. You are free to decline to enter 
or to withdraw from the study at any time without having to give a reason. If you 
chose not to enter the study, this will in no way affect your future medical care. All 
information regarding your medical records will be treated as strictly confidential and 
will only be used for medical purposes. 
 
 
 
 
Who has reviewed the study? 
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The Multi-Centre Research Ethics Committee for Scotland and the Ethics 
Committee in your local area has also reviewed the study from an ethics 
standpoint. 
 
Contacts for further information. 
If you require any further information regarding the study, we can be contacted 
at the address/telephone numbers at the top of this paper.  
 
What do I have to do if I agree to take part? 
Please read and sign the accompanying consent form that goes with this sheet.  
 
 
Thank you for taking the time to read this information sheet. 
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PATIENT CONSENT FORM 
 
Bone Marrow Derived Mesenchymal Stem Cells as Cellular 
Carriers 
 
  The patient should complete this sheet him/herself. (Please circle one) 
 
 
1. I confirm that I have read and understood the information contained in the information 
sheet version 1 dated December 2006 for the above study. 
 
YES/NO 
   
2.  I have had the opportunity to ask questions and had satisfactory answers to them YES/NO 
   
3. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason and without my medical care or legal rights being affected. 
 
YES/NO 
   
4. Do you give permission for your information to be collected, stored, and used for 
research in a database held at the Royal Free Laboratory? 
YES/NO 
   
5. Do you give permission for your left-over samples to be stored and used for future 
ethically approved studies? 
YES/NO 
   
6. I understand that some study documentation collected during the study may be looked at by 
responsible individuals from the sponsor (UCL) for the purpose of monitoring or auditing for 
good research practice. I give permission for these individuals to have access to this data. 
 
YES/NO 
   
7. I agree to take part in the above study. 
 
YES/NO 
                              
PATIENT 
 
Name (block letters) ………………………………………….. 
 
Signed ………………………………………………………Date …………………… 
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INVESTIGATOR TAKING CONSENT (please delete) 
 
Name (block letters) …………………………………………… 
 
Signed ………………………………………………………Date …………………… 
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Appendix 2: Live cell confocal imaging 
Supplementary Video (CD-ROM): MV-infected BM-MSC to ALL cell 
heterofusion. Representative live cell confocal video demonstrating heterofusion 
events between NALM-6 cell (red) and MV-NSe-GFP-infected BM-MSCs (green) 
over 60 minutes of co-culture.  
 
